BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Cho Y, Gorina S, Jeffrey PD, Pavletich NP. Crystal structure of a p53 tumor suppressor-DNA complex: understanding tumorigenic mutations. Science. 1994;265:346-355. [PMID: 8023157 DOI: 10.1126/science.8023157] [Cited by in Crossref: 1586] [Cited by in F6Publishing: 1591] [Article Influence: 56.6] [Reference Citation Analysis]
Number Citing Articles
1 Vaughan C, Pearsall I, Yeudall A, Deb SP, Deb S. p53: its mutations and their impact on transcription. Subcell Biochem 2014;85:71-90. [PMID: 25201189 DOI: 10.1007/978-94-017-9211-0_4] [Cited by in Crossref: 19] [Cited by in F6Publishing: 20] [Article Influence: 2.4] [Reference Citation Analysis]
2 Gieldon A, Mori M, Del Conte R. Theoretical study on binding of S100B protein. J Mol Model 2007;13:1123-31. [PMID: 17713798 DOI: 10.1007/s00894-007-0231-6] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 0.4] [Reference Citation Analysis]
3 Koduru PR, Raju K, Vadmal V, Menezes G, Shah S, Susin M, Kolitz J, Broome JD. Correlation Between Mutation in P53, p53 Expression, Cytogenetics, Histologic Type, and Survival in Patients With B-Cell Non-Hodgkin's Lymphoma. Blood 1997;90:4078-91. [DOI: 10.1182/blood.v90.10.4078] [Cited by in Crossref: 104] [Article Influence: 4.2] [Reference Citation Analysis]
4 Augello C, Gregorio V, Bazan V, Cammareri P, Agnese V, Cascio S, Corsale S, Calò V, Gullo A, Passantino R, Gargano G, Bruno L, Rinaldi G, Morello V, Gerbino A, Tomasino RM, Macaluso M, Surmacz E, Russo A. TP53 and p16INK4A, but not H-KI-Ras, are involved in tumorigenesis and progression of pleomorphic adenomas. J Cell Physiol 2006;207:654-9. [PMID: 16447252 DOI: 10.1002/jcp.20601] [Cited by in Crossref: 16] [Cited by in F6Publishing: 16] [Article Influence: 1.0] [Reference Citation Analysis]
5 Ang HC, Joerger AC, Mayer S, Fersht AR. Effects of Common Cancer Mutations on Stability and DNA Binding of Full-length p53 Compared with Isolated Core Domains. Journal of Biological Chemistry 2006;281:21934-41. [DOI: 10.1074/jbc.m604209200] [Cited by in Crossref: 101] [Cited by in F6Publishing: 60] [Article Influence: 6.3] [Reference Citation Analysis]
6 Suad O, Rozenberg H, Brosh R, Diskin-Posner Y, Kessler N, Shimon LJ, Frolow F, Liran A, Rotter V, Shakked Z. Structural basis of restoring sequence-specific DNA binding and transactivation to mutant p53 by suppressor mutations. J Mol Biol. 2009;385:249-265. [PMID: 18996393 DOI: 10.1016/j.jmb.2008.10.063] [Cited by in Crossref: 33] [Cited by in F6Publishing: 36] [Article Influence: 2.4] [Reference Citation Analysis]
7 Furuta S, Ortiz F, Zhu Sun X, Wu HH, Mason A, Momand J. Copper uptake is required for pyrrolidine dithiocarbamate-mediated oxidation and protein level increase of p53 in cells. Biochem J 2002;365:639-48. [PMID: 11964141 DOI: 10.1042/BJ20011251] [Cited by in Crossref: 31] [Cited by in F6Publishing: 29] [Article Influence: 1.6] [Reference Citation Analysis]
8 Sun XZ, Vinci C, Makmura L, Han S, Tran D, Nguyen J, Hamann M, Grazziani S, Sheppard S, Gutova M, Zhou F, Thomas J, Momand J. Formation of disulfide bond in p53 correlates with inhibition of DNA binding and tetramerization. Antioxid Redox Signal 2003;5:655-65. [PMID: 14580323 DOI: 10.1089/152308603770310338] [Cited by in Crossref: 65] [Cited by in F6Publishing: 61] [Article Influence: 3.6] [Reference Citation Analysis]
9 Lamoureux JS, Stuart D, Tsang R, Wu C, Glover JN. Structure of the sporulation-specific transcription factor Ndt80 bound to DNA. EMBO J 2002;21:5721-32. [PMID: 12411490 DOI: 10.1093/emboj/cdf572] [Cited by in Crossref: 48] [Cited by in F6Publishing: 45] [Article Influence: 2.4] [Reference Citation Analysis]
10 Gomes AS, Trovão F, Andrade Pinheiro B, Freire F, Gomes S, Oliveira C, Domingues L, Romão MJ, Saraiva L, Carvalho AL. The Crystal Structure of the R280K Mutant of Human p53 Explains the Loss of DNA Binding. Int J Mol Sci 2018;19:E1184. [PMID: 29652801 DOI: 10.3390/ijms19041184] [Cited by in Crossref: 11] [Cited by in F6Publishing: 9] [Article Influence: 2.8] [Reference Citation Analysis]
11 Roth J, Koch P, Contente A, Dobbelstein M. Tumor-derived mutations within the DNA-binding domain of p53 that phenotypically resemble the deletion of the proline-rich domain. Oncogene 2000;19:1834-42. [PMID: 10777217 DOI: 10.1038/sj.onc.1203500] [Cited by in Crossref: 24] [Cited by in F6Publishing: 26] [Article Influence: 1.1] [Reference Citation Analysis]
12 Yang DS, Saeedi A, Davtyan A, Fathi M, Sherman MB, Safari MS, Klindziuk A, Barton MC, Varadarajan N, Kolomeisky AB, Vekilov PG. Mesoscopic protein-rich clusters host the nucleation of mutant p53 amyloid fibrils. Proc Natl Acad Sci U S A 2021;118:e2015618118. [PMID: 33653952 DOI: 10.1073/pnas.2015618118] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 3.0] [Reference Citation Analysis]
13 Inoue T, Wu L, Stuart J, Maki CG. Control of p53 nuclear accumulation in stressed cells. FEBS Lett 2005;579:4978-84. [PMID: 16115632 DOI: 10.1016/j.febslet.2005.08.006] [Cited by in Crossref: 22] [Cited by in F6Publishing: 23] [Article Influence: 1.3] [Reference Citation Analysis]
14 Lindh U. Cell biology, trace elements and nuclear microscopy. Nuclear Instruments and Methods in Physics Research Section B: Beam Interactions with Materials and Atoms 1995;104:285-91. [DOI: 10.1016/0168-583x(95)00389-4] [Cited by in Crossref: 8] [Article Influence: 0.3] [Reference Citation Analysis]
15 Shivakumar CV, Brown DR, Deb S, Deb SP. Wild-type human p53 transactivates the human proliferating cell nuclear antigen promoter. Mol Cell Biol 1995;15:6785-93. [PMID: 8524244 DOI: 10.1128/MCB.15.12.6785] [Cited by in Crossref: 83] [Cited by in F6Publishing: 21] [Article Influence: 3.2] [Reference Citation Analysis]
16 Johnson RA, Ince TA, Scotto KW. Transcriptional repression by p53 through direct binding to a novel DNA element. J Biol Chem. 2001;276:27716-27720. [PMID: 11350951 DOI: 10.1074/jbc.c100121200] [Cited by in Crossref: 112] [Cited by in F6Publishing: 43] [Article Influence: 5.3] [Reference Citation Analysis]
17 Zhou H, Zhang Y, Ou-Yang Z, Lindsay SM, Feng XZ, Balagurumoorthy P, Harrington RE. Conformation and rigidity of DNA microcircles containing waf1 response element for p53 regulatory protein. J Mol Biol 2001;306:227-38. [PMID: 11237596 DOI: 10.1006/jmbi.2000.4370] [Cited by in Crossref: 10] [Cited by in F6Publishing: 10] [Article Influence: 0.5] [Reference Citation Analysis]
18 Seeliger MA, Moll UM. p73 - constitutively open for business. Cell Death Differ 2013;20:972-3. [PMID: 23832148 DOI: 10.1038/cdd.2013.56] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 0.5] [Reference Citation Analysis]
19 Kelley ML, Winge P, Heaney JD, Stephens RE, Farell JH, Van Beneden RJ, Reinisch CL, Lesser MP, Walker CW. Expression of homologues for p53 and p73 in the softshell clam (Mya arenaria), a naturally-occurring model for human cancer. Oncogene 2001;20:748-58. [PMID: 11314008 DOI: 10.1038/sj.onc.1204144] [Cited by in Crossref: 68] [Cited by in F6Publishing: 63] [Article Influence: 3.2] [Reference Citation Analysis]
20 Gao W, Mady HH, Melhem MF, Keohavong P. Analysis of p53 mutations in histologically normal lung tissues and lung tumors from non-small cell lung cancer patients: p53 MUTATIONS IN NORMAL-APPEARING LUNG TISSUE. Mol Carcinog 2009;48:633-41. [DOI: 10.1002/mc.20505] [Cited by in Crossref: 15] [Cited by in F6Publishing: 14] [Article Influence: 1.1] [Reference Citation Analysis]
21 Nataraj AJ, Trent JC 2nd, Ananthaswamy HN. p53 gene mutations and photocarcinogenesis. Photochem Photobiol 1995;62:218-30. [PMID: 7480131 DOI: 10.1111/j.1751-1097.1995.tb05262.x] [Cited by in Crossref: 106] [Cited by in F6Publishing: 97] [Article Influence: 3.9] [Reference Citation Analysis]
22 Végran F, Boidot R, Oudin C, Defrain C, Rebucci M, Lizard-Nacol S. Association of p53 gene alterations with the expression of antiapoptotic survivin splice variants in breast cancer. Oncogene 2007;26:290-7. [PMID: 16847456 DOI: 10.1038/sj.onc.1209784] [Cited by in Crossref: 44] [Cited by in F6Publishing: 39] [Article Influence: 2.8] [Reference Citation Analysis]
23 Mandriani B, Castellana S, Rinaldi C, Manzoni M, Venuto S, Rodriguez-Aznar E, Galceran J, Nieto MA, Borsani G, Monti E, Mazza T, Merla G, Micale L. Identification of p53-target genes in Danio rerio. Sci Rep 2016;6:32474. [PMID: 27581768 DOI: 10.1038/srep32474] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 0.8] [Reference Citation Analysis]
24 Shaw PH. The Role of p53 in Cell Cycle Regulation. Pathology - Research and Practice 1996;192:669-75. [DOI: 10.1016/s0344-0338(96)80088-4] [Cited by in Crossref: 73] [Cited by in F6Publishing: 31] [Article Influence: 2.8] [Reference Citation Analysis]
25 Hara T, Arai K, Koike K. Form of Human p53 Protein during Nuclear Transport in Xenopus laevis Embryos. Experimental Cell Research 2000;258:152-61. [DOI: 10.1006/excr.2000.4926] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 0.2] [Reference Citation Analysis]
26 Ch�ne P, Ory K, R�edi D, Soussi T, Hegi ME. Functional analyses of a uniquep53 germline mutant (y236?) associated with a familial brain tumor syndrome. Int J Cancer 1999;82:17-22. [DOI: 10.1002/(sici)1097-0215(19990702)82:1<17::aid-ijc4>3.0.co;2-6] [Cited by in Crossref: 4] [Article Influence: 0.2] [Reference Citation Analysis]
27 Weirauch MT, Hughes TR. A catalogue of eukaryotic transcription factor types, their evolutionary origin, and species distribution. Subcell Biochem 2011;52:25-73. [PMID: 21557078 DOI: 10.1007/978-90-481-9069-0_3] [Cited by in Crossref: 70] [Cited by in F6Publishing: 67] [Article Influence: 11.7] [Reference Citation Analysis]
28 Tisné C, Delepierre M, Hartmann B. How NF-κB can be attracted by its cognate DNA. Journal of Molecular Biology 1999;293:139-50. [DOI: 10.1006/jmbi.1999.3157] [Cited by in Crossref: 44] [Cited by in F6Publishing: 43] [Article Influence: 1.9] [Reference Citation Analysis]
29 Aurelio ON, Kong XT, Gupta S, Stanbridge EJ. p53 mutants have selective dominant-negative effects on apoptosis but not growth arrest in human cancer cell lines. Mol Cell Biol 2000;20:770-8. [PMID: 10629033 DOI: 10.1128/MCB.20.3.770-778.2000] [Cited by in Crossref: 44] [Cited by in F6Publishing: 15] [Article Influence: 2.0] [Reference Citation Analysis]
30 Bech-Otschir D, Kraft R, Huang X, Henklein P, Kapelari B, Pollmann C, Dubiel W. COP9 signalosome-specific phosphorylation targets p53 to degradation by the ubiquitin system. EMBO J 2001;20:1630-9. [PMID: 11285227 DOI: 10.1093/emboj/20.7.1630] [Cited by in Crossref: 271] [Cited by in F6Publishing: 273] [Article Influence: 12.9] [Reference Citation Analysis]
31 Wang G, Fersht AR. Mechanism of initiation of aggregation of p53 revealed by Φ-value analysis. Proc Natl Acad Sci U S A 2015;112:2437-42. [PMID: 25675526 DOI: 10.1073/pnas.1500243112] [Cited by in Crossref: 23] [Cited by in F6Publishing: 22] [Article Influence: 3.3] [Reference Citation Analysis]
32 Bergh J, Norberg T, Sjögren S, Lindgren A, Holmberg L. Complete sequencing of the p53 gene provides prognostic information in breast cancer patients, particularly in relation to adjuvant systemic therapy and radiotherapy. Nat Med 1995;1:1029-34. [PMID: 7489358 DOI: 10.1038/nm1095-1029] [Cited by in Crossref: 277] [Cited by in F6Publishing: 252] [Article Influence: 10.7] [Reference Citation Analysis]
33 Scotcher J, Clarke DJ, Mackay CL, Hupp T, Sadler PJ, Langridge-smith PRR. Redox regulation of tumour suppressor protein p53: identification of the sites of hydrogen peroxide oxidation and glutathionylation. Chem Sci 2013;4:1257. [DOI: 10.1039/c2sc21702c] [Cited by in Crossref: 16] [Cited by in F6Publishing: 9] [Article Influence: 1.8] [Reference Citation Analysis]
34 Uberti D, Lanni C, Carsana T, Francisconi S, Missale C, Racchi M, Govoni S, Memo M. Identification of a mutant-like conformation of p53 in fibroblasts from sporadic Alzheimer's disease patients. Neurobiol Aging 2006;27:1193-201. [PMID: 16165254 DOI: 10.1016/j.neurobiolaging.2005.06.013] [Cited by in Crossref: 33] [Cited by in F6Publishing: 30] [Article Influence: 1.9] [Reference Citation Analysis]
35 Karamychev VN, Wang D, Mazur SJ, Appella E, Neumann RD, Zhurkin VB, Panyutin IG. Radioprobing the conformation of DNA in a p53-DNA complex. Int J Radiat Biol 2012;88:1039-45. [PMID: 22640875 DOI: 10.3109/09553002.2012.698030] [Cited by in Crossref: 1] [Article Influence: 0.1] [Reference Citation Analysis]
36 Ho WC, Fitzgerald MX, Marmorstein R. Structure of the p53 core domain dimer bound to DNA. J Biol Chem 2006;281:20494-502. [PMID: 16717092 DOI: 10.1074/jbc.M603634200] [Cited by in Crossref: 90] [Cited by in F6Publishing: 53] [Article Influence: 5.6] [Reference Citation Analysis]
37 Kim E, Deppert W. The versatile interactions of p53 with DNA: when flexibility serves specificity. Cell Death Differ 2006;13:885-9. [PMID: 16543936 DOI: 10.1038/sj.cdd.4401909] [Cited by in Crossref: 30] [Cited by in F6Publishing: 28] [Article Influence: 2.0] [Reference Citation Analysis]
38 Webley KM, Shorthouse AJ, Royds JA. Effect of mutation and conformation on the function of p53 in colorectal cancer. J Pathol 2000;191:361-7. [DOI: 10.1002/1096-9896(2000)9999:9999<::aid-path660>3.0.co;2-2] [Cited by in Crossref: 16] [Cited by in F6Publishing: 6] [Article Influence: 0.7] [Reference Citation Analysis]
39 van Hest LP, Ruijs MW, Wagner A, van der Meer CA, Verhoef S, van't Veer LJ, Meijers-Heijboer H. Two TP53 germline mutations in a classical Li-Fraumeni syndrome family. Fam Cancer 2007;6:311-6. [PMID: 17318340 DOI: 10.1007/s10689-006-9115-7] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 0.3] [Reference Citation Analysis]
40 Slattery ML, Wolff RK, Herrick JS, Caan BJ, Samowitz W. Calcium, vitamin D, VDR genotypes, and epigenetic and genetic changes in rectal tumors. Nutr Cancer 2010;62:436-42. [PMID: 20432164 DOI: 10.1080/01635580903441204] [Cited by in Crossref: 15] [Cited by in F6Publishing: 14] [Article Influence: 1.3] [Reference Citation Analysis]
41 Ahn J, Poyurovsky MV, Baptiste N, Beckerman R, Cain C, Mattia M, McKinney K, Zhou J, Zupnick A, Gottifredi V, Prives C. Dissection of the sequence-specific DNA binding and exonuclease activities reveals a superactive yet apoptotically impaired mutant p53 protein. Cell Cycle 2009;8:1603-15. [PMID: 19462533 DOI: 10.4161/cc.8.10.8548] [Cited by in Crossref: 20] [Cited by in F6Publishing: 16] [Article Influence: 1.5] [Reference Citation Analysis]
42 Kanada R, Terakawa T, Kenzaki H, Takada S. Nucleosome Crowding in Chromatin Slows the Diffusion but Can Promote Target Search of Proteins. Biophys J 2019;116:2285-95. [PMID: 31151739 DOI: 10.1016/j.bpj.2019.05.007] [Cited by in Crossref: 11] [Cited by in F6Publishing: 8] [Article Influence: 3.7] [Reference Citation Analysis]
43 Otsuka K, Kato S, Kakudo Y, Mashiko S, Shibata H, Ishioka C. The screening of the second-site suppressor mutations of the common p53 mutants. Int J Cancer 2007;121:559-66. [DOI: 10.1002/ijc.22724] [Cited by in Crossref: 20] [Cited by in F6Publishing: 16] [Article Influence: 1.3] [Reference Citation Analysis]
44 Chen GD, Chou CM, Hwang SP, Wang FF, Chen YC, Hung CC, Chen JY, Huang CJ. Requirement of nuclear localization and transcriptional activity of p53 for its targeting to the yolk syncytial layer (YSL) nuclei in zebrafish embryo and its use for apoptosis assay. Biochem Biophys Res Commun 2006;344:272-82. [PMID: 16616005 DOI: 10.1016/j.bbrc.2006.03.136] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 0.3] [Reference Citation Analysis]
45 Herzog G, Joerger AC, Shmueli MD, Fersht AR, Gazit E, Segal D. Evaluating Drosophila p53 as a model system for studying cancer mutations. J Biol Chem 2012;287:44330-7. [PMID: 23135266 DOI: 10.1074/jbc.M112.417980] [Cited by in Crossref: 10] [Cited by in F6Publishing: 10] [Article Influence: 1.0] [Reference Citation Analysis]
46 Santiago A, Li D, Zhao LY, Godsey A, Liao D. p53 SUMOylation promotes its nuclear export by facilitating its release from the nuclear export receptor CRM1. Mol Biol Cell. 2013;24:2739-2752. [PMID: 23825024 DOI: 10.1091/mbc.e12-10-0771] [Cited by in Crossref: 45] [Cited by in F6Publishing: 35] [Article Influence: 5.0] [Reference Citation Analysis]
47 Sobhani N, D'Angelo A, Wang X, Young KH, Generali D, Li Y. Mutant p53 as an Antigen in Cancer Immunotherapy. Int J Mol Sci 2020;21:E4087. [PMID: 32521648 DOI: 10.3390/ijms21114087] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
48 Stavridi ES, Huyen Y, Sheston EA, Halazonetis TD. The Three-Dimensional Structure of p53. In: Zambetti GP, editor. The p53 Tumor Suppressor Pathway and Cancer. Boston: Springer US; 2005. pp. 25-52. [DOI: 10.1007/0-387-30127-5_2] [Cited by in Crossref: 4] [Cited by in F6Publishing: 2] [Reference Citation Analysis]
49 Le Roux E, Gormally E, Hainaut P. Somatic mutations in human cancer: applications in molecular epidemiology. Revue d'Épidémiologie et de Santé Publique 2005;53:257-66. [DOI: 10.1016/s0398-7620(05)84603-6] [Cited by in Crossref: 7] [Article Influence: 0.4] [Reference Citation Analysis]
50 Carethers JM. THE CELLULAR AND MOLECULAR PATHOGENESIS OF COLORECTAL CANCER. Gastroenterology Clinics of North America 1996;25:737-54. [DOI: 10.1016/s0889-8553(05)70272-7] [Cited by in Crossref: 29] [Cited by in F6Publishing: 10] [Article Influence: 1.1] [Reference Citation Analysis]
51 Muller PA, Vousden KH, Norman JC. p53 and its mutants in tumor cell migration and invasion. J Cell Biol 2011;192:209-18. [PMID: 21263025 DOI: 10.1083/jcb.201009059] [Cited by in Crossref: 306] [Cited by in F6Publishing: 292] [Article Influence: 27.8] [Reference Citation Analysis]
52 Krause MK, Rhodes LD, Van Beneden RJ. Cloning of the p53 tumor suppressor gene from the Japanese medaka (Oryzias latipes) and evaluation of mutational hotspots in MNNG-exposed fish. Gene 1997;189:101-6. [DOI: 10.1016/s0378-1119(96)00841-4] [Cited by in Crossref: 49] [Cited by in F6Publishing: 3] [Article Influence: 2.0] [Reference Citation Analysis]
53 Derbyshire DJ, Basu BP, Serpell LC, Joo WS, Date T, Iwabuchi K, Doherty AJ. Crystal structure of human 53BP1 BRCT domains bound to p53 tumour suppressor. EMBO J 2002;21:3863-72. [PMID: 12110597 DOI: 10.1093/emboj/cdf383] [Cited by in Crossref: 124] [Cited by in F6Publishing: 123] [Article Influence: 6.2] [Reference Citation Analysis]
54 Ohiro Y, Usheva A, Kobayashi S, Duffy SL, Nantz R, Gius D, Horikoshi N. Inhibition of stress-inducible kinase pathways by tumorigenic mutant p53. Mol Cell Biol 2003;23:322-34. [PMID: 12482984 DOI: 10.1128/MCB.23.1.322-334.2003] [Cited by in Crossref: 20] [Cited by in F6Publishing: 9] [Article Influence: 1.1] [Reference Citation Analysis]
55 Götz C, Montenarh M. p53: DNA damage, DNA repair, and apoptosis. Reviews of Physiology, Biochemistry and Pharmacology, Volume 94. Berlin: Springer Berlin Heidelberg; 1982. pp. 65-95. [DOI: 10.1007/bfb0048265] [Cited by in Crossref: 29] [Cited by in F6Publishing: 10] [Article Influence: 1.8] [Reference Citation Analysis]
56 Walker KK, Levine AJ. Identification of a novel p53 functional domain that is necessary for efficient growth suppression. PNAS. 1996;93:15335-15340. [PMID: 8986812 DOI: 10.1073/pnas.93.26.15335] [Cited by in Crossref: 291] [Cited by in F6Publishing: 303] [Article Influence: 11.6] [Reference Citation Analysis]
57 Wahl GM, Stommel JM, Krummel K, Wade M. Gatekeepers of the Guardian: p53 Regulation by Post-Translational Modification, MDM2 and MDMX. In: Hainaut P, Wiman KG, editors. 25 Years of p53 Research. Dordrecht: Springer Netherlands; 2007. pp. 73-113. [DOI: 10.1007/978-1-4020-2922-6_4] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 0.2] [Reference Citation Analysis]
58 Fulci G, Van Meir EG. p53 and the CNS: Tumors and developmental abnormalities. Mol Neurobiol 1999;19:61-77. [DOI: 10.1007/bf02741378] [Cited by in Crossref: 15] [Cited by in F6Publishing: 6] [Article Influence: 0.7] [Reference Citation Analysis]
59 Lefrou L, Godart B, Muret AD, Scotto B, Dorval E. Néomutation germinale du gène p53 chez une malade présentant un syndrome de Li-Fraumeni et un adénocarcinome du pancréas. Gastroentérologie Clinique et Biologique 2006;30:484-6. [DOI: 10.1016/s0399-8320(06)73212-2] [Cited by in Crossref: 4] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
60 Grasso L, Mercer WE. Pathways of p53-Dependent Apoptosis. Elsevier; 1997. pp. 139-73. [DOI: 10.1016/s0083-6729(08)60706-2] [Cited by in Crossref: 5] [Cited by in F6Publishing: 1] [Article Influence: 0.2] [Reference Citation Analysis]
61 Mclure KG, Kastan MB. 20 Years of DNA Damage Signaling to p53. In: Hainaut P, Wiman KG, editors. 25 Years of p53 Research. Dordrecht: Springer Netherlands; 2007. pp. 53-71. [DOI: 10.1007/978-1-4020-2922-6_3] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
62 Ma X, Hu J, Lindner DJ, Kalvakolanu DV. Mutational analysis of human thioredoxin reductase 1. Effects on p53-mediated gene expression and interferon and retinoic acid-induced cell death. J Biol Chem 2002;277:22460-8. [PMID: 11953436 DOI: 10.1074/jbc.M202286200] [Cited by in Crossref: 15] [Cited by in F6Publishing: 3] [Article Influence: 0.8] [Reference Citation Analysis]
63 Devi K, Awasthi P. Sulfonamide phenylalanine (SPA) series of analogues as an antibacterial, antifungal, anticancer agents along with p53 tumor suppressor-DNA complex inhibitor - part 1. J Biomol Struct Dyn 2020;38:4081-97. [PMID: 31547774 DOI: 10.1080/07391102.2019.1671229] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
64 Soond SM, Savvateeva LV, Makarov VA, Gorokhovets NV, Townsend PA, Zamyatnin AA Jr. Making Connections: p53 and the Cathepsin Proteases as Co-Regulators of Cancer and Apoptosis. Cancers (Basel) 2020;12:E3476. [PMID: 33266503 DOI: 10.3390/cancers12113476] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 3.5] [Reference Citation Analysis]
65 Sugikawa E, Yazaki N, Tsunoda S, Nakanishi N, Ohashi M. Inhibition of mutant p53 phosphorylation at serine 15 or serine 315 partially restores the function of wild-type p53. Biochem Biophys Res Commun 1999;261:256-63. [PMID: 10425175 DOI: 10.1006/bbrc.1999.1019] [Cited by in Crossref: 9] [Cited by in F6Publishing: 8] [Article Influence: 0.4] [Reference Citation Analysis]
66 Varley JM, Evans DG, Birch JM. Li-Fraumeni syndrome--a molecular and clinical review. Br J Cancer 1997;76:1-14. [PMID: 9218725 DOI: 10.1038/bjc.1997.328] [Cited by in Crossref: 222] [Cited by in F6Publishing: 179] [Article Influence: 8.9] [Reference Citation Analysis]
67 Maret W. Zinc Coordination Environments in Proteins as Redox Sensors and Signal Transducers. Antioxidants & Redox Signaling 2006;8:1419-41. [DOI: 10.1089/ars.2006.8.1419] [Cited by in Crossref: 208] [Cited by in F6Publishing: 184] [Article Influence: 13.0] [Reference Citation Analysis]
68 Hieken TJ, Ronan SG, Farolan M, Shilkaitis AL, Das Gupta TK. Molecular prognostic markers in intermediate-thickness cutaneous malignant melanoma. Cancer 1999;85:375-82. [PMID: 10023705 DOI: 10.1002/(sici)1097-0142(19990115)85:2<375::aid-cncr15>3.0.co;2-1] [Cited by in Crossref: 55] [Cited by in F6Publishing: 17] [Article Influence: 2.4] [Reference Citation Analysis]
69 Li X, Zhang XX, Lin YX, Xu XM, Li L, Yang JB. Virtual Screening Based on Ensemble Docking Targeting Wild-Type p53 for Anticancer Drug Discovery. Chem Biodivers 2019;16:e1900170. [PMID: 31134745 DOI: 10.1002/cbdv.201900170] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
70 Bakalkin G, Selivanova G, Yakovleva T, Kiseleva E, Kashuba E, Magnusson KP, Szekely L, Klein G, Terenius L, Wiman KG. p53 binds single-stranded DNA ends through the C-terminal domain and internal DNA segments via the middle domain. Nucleic Acids Res 1995;23:362-9. [PMID: 7885831 DOI: 10.1093/nar/23.3.362] [Cited by in Crossref: 98] [Cited by in F6Publishing: 100] [Article Influence: 3.6] [Reference Citation Analysis]
71 Zupnick A, Prives C. Mutational analysis of the p53 core domain L1 loop. J Biol Chem 2006;281:20464-73. [PMID: 16687402 DOI: 10.1074/jbc.M603387200] [Cited by in Crossref: 42] [Cited by in F6Publishing: 23] [Article Influence: 2.6] [Reference Citation Analysis]
72 Keohavong P, Gao W, Zheng K, Mady H, Lan Q, Melhem M, Mumford J. Detection of K-ras and p53 mutations in sputum samples of lung cancer patients using laser capture microdissection microscope and mutation analysis. Analytical Biochemistry 2004;324:92-9. [DOI: 10.1016/j.ab.2003.09.030] [Cited by in Crossref: 23] [Cited by in F6Publishing: 17] [Article Influence: 1.3] [Reference Citation Analysis]
73 Luciani MG, Hutchins JR, Zheleva D, Hupp TR. The C-terminal regulatory domain of p53 contains a functional docking site for cyclin A. J Mol Biol 2000;300:503-18. [PMID: 10884347 DOI: 10.1006/jmbi.2000.3830] [Cited by in Crossref: 48] [Cited by in F6Publishing: 47] [Article Influence: 2.2] [Reference Citation Analysis]
74 Brooks G, La Thangue NB. The cell cycle and drug discovery: the promise and the hope. Drug Discovery Today 1999;4:455-64. [DOI: 10.1016/s1359-6446(99)01400-2] [Cited by in Crossref: 25] [Cited by in F6Publishing: 7] [Article Influence: 1.1] [Reference Citation Analysis]
75 Miller M. The importance of being flexible: the case of basic region leucine zipper transcriptional regulators. Curr Protein Pept Sci 2009;10:244-69. [PMID: 19519454 DOI: 10.2174/138920309788452164] [Cited by in Crossref: 67] [Cited by in F6Publishing: 64] [Article Influence: 5.2] [Reference Citation Analysis]
76 Yu X, Blanden AR, Narayanan S, Jayakumar L, Lubin D, Augeri D, Kimball SD, Loh SN, Carpizo DR. Small molecule restoration of wildtype structure and function of mutant p53 using a novel zinc-metallochaperone based mechanism. Oncotarget 2014;5:8879-92. [PMID: 25294809 DOI: 10.18632/oncotarget.2432] [Cited by in Crossref: 54] [Cited by in F6Publishing: 53] [Article Influence: 7.7] [Reference Citation Analysis]
77 North S, Pluquet O, Maurici D, El-Ghissassi F, Hainaut P. Restoration of wild-type conformation and activity of a temperature-sensitive mutant of p53 (p53(V272M)) by the cytoprotective aminothiol WR1065 in the esophageal cancer cell line TE-1. Mol Carcinog 2002;33:181-8. [PMID: 11870884 DOI: 10.1002/mc.10038] [Cited by in Crossref: 59] [Cited by in F6Publishing: 57] [Article Influence: 3.0] [Reference Citation Analysis]
78 Tang M, Wahl GM, Nistér M. Explaining the biological activity of transactivation-deficient p53 variants. Nat Genet 2006;38:395-6; author reply 396-7. [PMID: 16570054 DOI: 10.1038/ng0406-395] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 0.4] [Reference Citation Analysis]
79 Mathe E, Olivier M, Kato S, Ishioka C, Vaisman I, Hainaut P. Predicting the transactivation activity of p53 missense mutants using a four-body potential score derived from Delaunay tessellations. Hum Mutat 2006;27:163-72. [PMID: 16395672 DOI: 10.1002/humu.20284] [Cited by in Crossref: 18] [Cited by in F6Publishing: 12] [Article Influence: 1.1] [Reference Citation Analysis]
80 Low L, Goh A, Koh J, Lim S, Wang CI. Targeting mutant p53-expressing tumours with a T cell receptor-like antibody specific for a wild-type antigen. Nat Commun 2019;10:5382. [PMID: 31772160 DOI: 10.1038/s41467-019-13305-z] [Cited by in Crossref: 8] [Cited by in F6Publishing: 9] [Article Influence: 2.7] [Reference Citation Analysis]
81 D'erchia A, Pesole G, Tullo A, Saccone C, Sbisà E. Guinea Pig p53 mRNA: Identification of New Elements in Coding and Untranslated Regions and Their Functional and Evolutionary Implications. Genomics 1999;58:50-64. [DOI: 10.1006/geno.1999.5794] [Cited by in Crossref: 10] [Cited by in F6Publishing: 12] [Article Influence: 0.4] [Reference Citation Analysis]
82 Yue X, Zhao Y, Xu Y, Zheng M, Feng Z, Hu W. Mutant p53 in Cancer: Accumulation, Gain-of-Function, and Therapy. J Mol Biol. 2017;429:1595-1606. [PMID: 28390900 DOI: 10.1016/j.jmb.2017.03.030] [Cited by in Crossref: 118] [Cited by in F6Publishing: 118] [Article Influence: 23.6] [Reference Citation Analysis]
83 Honda K, Sbisà E, Tullo A, Papeo PA, Saccone C, Poole S, Pignatelli M, Mitry RR, Ding S, Isla A. p53 mutation is a poor prognostic indicator for survival in patients with hepatocellular carcinoma undergoing surgical tumour ablation. Br J Cancer. 1998;77:776-782. [PMID: 9514057 DOI: 10.1038/bjc.1998.126] [Cited by in Crossref: 73] [Cited by in F6Publishing: 75] [Article Influence: 3.0] [Reference Citation Analysis]
84 Lyakhov IG, Krishnamachari A, Schneider TD. Discovery of novel tumor suppressor p53 response elements using information theory. Nucleic Acids Res 2008;36:3828-33. [PMID: 18495754 DOI: 10.1093/nar/gkn189] [Cited by in Crossref: 23] [Cited by in F6Publishing: 24] [Article Influence: 1.6] [Reference Citation Analysis]
85 Huang W, Bateman E. Cloning, Expression, and Characterization of the TATA-binding Protein (TBP) Promoter Binding Factor, a Transcription Activator of the Acanthamoeba TBP Gene. Journal of Biological Chemistry 1995;270:28839-47. [DOI: 10.1074/jbc.270.48.28839] [Cited by in Crossref: 9] [Cited by in F6Publishing: 11] [Article Influence: 0.3] [Reference Citation Analysis]
86 Weinberg RL, Freund SM, Veprintsev DB, Bycroft M, Fersht AR. Regulation of DNA binding of p53 by its C-terminal domain. J Mol Biol 2004;342:801-11. [PMID: 15342238 DOI: 10.1016/j.jmb.2004.07.042] [Cited by in Crossref: 74] [Cited by in F6Publishing: 71] [Article Influence: 4.1] [Reference Citation Analysis]
87 Saffari M, Dinehkabodi OS, Ghaffari SH, Modarressi MH, Mansouri F, Heidari M. Identification of novel p53 target genes by cDNA AFLP in glioblastoma cells. Cancer Lett 2009;273:316-22. [PMID: 18814959 DOI: 10.1016/j.canlet.2008.08.020] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 0.5] [Reference Citation Analysis]
88 Park KJ, Choi HJ, Suh SP, Ki CS, Kim JW. Germline TP53 Mutation and Clinical Characteristics of Korean Patients With Li-Fraumeni Syndrome. Ann Lab Med 2016;36:463-8. [PMID: 27374712 DOI: 10.3343/alm.2016.36.5.463] [Cited by in Crossref: 11] [Cited by in F6Publishing: 11] [Article Influence: 2.2] [Reference Citation Analysis]
89 Terakawa T, Kenzaki H, Takada S. p53 Searches on DNA by Rotation-Uncoupled Sliding at C-Terminal Tails and Restricted Hopping of Core Domains. J Am Chem Soc 2012;134:14555-62. [DOI: 10.1021/ja305369u] [Cited by in Crossref: 71] [Cited by in F6Publishing: 62] [Article Influence: 7.1] [Reference Citation Analysis]
90 Dehner A, Kessler H. Diffusion NMR spectroscopy: folding and aggregation of domains in p53. Chembiochem 2005;6:1550-65. [PMID: 16138303 DOI: 10.1002/cbic.200500093] [Cited by in Crossref: 55] [Cited by in F6Publishing: 49] [Article Influence: 3.4] [Reference Citation Analysis]
91 Zhang Y, Yan W, Chen X. Mutant p53 disrupts MCF-10A cell polarity in three-dimensional culture via epithelial-to-mesenchymal transitions. J Biol Chem 2011;286:16218-28. [PMID: 21454711 DOI: 10.1074/jbc.M110.214585] [Cited by in Crossref: 63] [Cited by in F6Publishing: 46] [Article Influence: 5.7] [Reference Citation Analysis]
92 Dedecker BS. Allosteric drugs: thinking outside the active-site box. Chemistry & Biology 2000;7:R103-7. [DOI: 10.1016/s1074-5521(00)00115-0] [Cited by in Crossref: 28] [Cited by in F6Publishing: 9] [Article Influence: 1.3] [Reference Citation Analysis]
93 Chrisanthar R, Knappskog S, Løkkevik E, Anker G, Ostenstad B, Lundgren S, Risberg T, Mjaaland I, Skjønsberg G, Aas T, Schlichting E, Fjösne HE, Nysted A, Lillehaug JR, Lønning PE. Predictive and prognostic impact of TP53 mutations and MDM2 promoter genotype in primary breast cancer patients treated with epirubicin or paclitaxel. PLoS One 2011;6:e19249. [PMID: 21556366 DOI: 10.1371/journal.pone.0019249] [Cited by in Crossref: 49] [Cited by in F6Publishing: 44] [Article Influence: 4.5] [Reference Citation Analysis]
94 Doyle B, Morton JP, Delaney DW, Ridgway RA, Wilkins JA, Sansom OJ. p53 mutation and loss have different effects on tumourigenesis in a novel mouse model of pleomorphic rhabdomyosarcoma. J Pathol 2010;222:129-37. [PMID: 20662002 DOI: 10.1002/path.2748] [Cited by in Crossref: 63] [Cited by in F6Publishing: 63] [Article Influence: 5.3] [Reference Citation Analysis]
95 Merabet A, Houlleberghs H, Maclagan K, Akanho E, Bui T, Pagano B, Drake A, Fraternali F, Nikolova P. Mutants of the tumour suppressor p53 L1 loop as second-site suppressors for restoring DNA binding to oncogenic p53 mutations: structural and biochemical insights. Biochemical Journal 2010;427:225-36. [DOI: 10.1042/bj20091888] [Cited by in Crossref: 25] [Cited by in F6Publishing: 11] [Article Influence: 2.1] [Reference Citation Analysis]
96 Timsit Y. DNA Structure and Polymerase Fidelity: A New Role for A-DNA. J Biomol Struct Dyn 2000;17 Suppl 1:169-76. [PMID: 22607420 DOI: 10.1080/07391102.2000.10506617] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.3] [Reference Citation Analysis]
97 Grønbæk K, de Nully Brown P, Møller M, Nedergaard T, Ralfkiaer E, Møller P, Zeuthen J, Guldberg P. Concurrent disruption of p16INK4a and the ARF-p53 pathway predicts poor prognosis in aggressive non-Hodgkin's lymphoma. Leukemia 2000;14:1727-35. [DOI: 10.1038/sj.leu.2401901] [Cited by in Crossref: 62] [Cited by in F6Publishing: 55] [Article Influence: 2.8] [Reference Citation Analysis]
98 Chytil M, Verdine GL. The Rel family of eukaryotic transcription factors. Curr Opin Struct Biol 1996;6:91-100. [PMID: 8696978 DOI: 10.1016/s0959-440x(96)80100-x] [Cited by in Crossref: 38] [Cited by in F6Publishing: 12] [Article Influence: 1.5] [Reference Citation Analysis]
99 Yacoubi-Hadj Amor I, Smaoui K, Belguith H, Djemal L, Dardouri M, Mokdad-Gargouri R, Gargouri A. Selection of cell death-deficient p53 mutants in Saccharomyces cerevisiae. Yeast 2009;26:441-50. [PMID: 19579214 DOI: 10.1002/yea.1677] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 0.4] [Reference Citation Analysis]
100 Hsu Y, Tang F, Liu W, Chuang J, Lai M, Lin Y. Transcriptional Regulation by p53. Journal of Biological Chemistry 1995;270:6966-74. [DOI: 10.1074/jbc.270.12.6966] [Cited by in Crossref: 23] [Cited by in F6Publishing: 25] [Article Influence: 0.9] [Reference Citation Analysis]
101 Keen JC, Davidson NE. The biology of breast carcinoma. Cancer 2003;97:825-33. [PMID: 12548582 DOI: 10.1002/cncr.11126] [Cited by in Crossref: 127] [Cited by in F6Publishing: 105] [Article Influence: 6.7] [Reference Citation Analysis]
102 Ishida A, Sasaguri T, Miwa Y, Kosaka C, Taba Y, Abumiya T. Tumor suppressor p53 but not cGMP mediates NO-induced expression of p21(Waf1/Cip1/Sdi1) in vascular smooth muscle cells. Mol Pharmacol 1999;56:938-46. [PMID: 10531398 DOI: 10.1124/mol.56.5.938] [Cited by in Crossref: 22] [Cited by in F6Publishing: 24] [Article Influence: 1.0] [Reference Citation Analysis]
103 Danziger SA, Swamidass SJ, Zeng J, Dearth LR, Lu Q, Chen JH, Cheng J, Hoang VP, Saigo H, Luo R, Baldi P, Brachmann RK, Lathrop RH. Functional census of mutation sequence spaces: the example of p53 cancer rescue mutants. IEEE/ACM Trans Comput Biol Bioinform 2006;3:114-25. [PMID: 17048398 DOI: 10.1109/TCBB.2006.22] [Cited by in Crossref: 24] [Cited by in F6Publishing: 7] [Article Influence: 1.5] [Reference Citation Analysis]
104 Pan Y, Ma B, Venkataraghavan RB, Levine AJ, Nussinov R. In the quest for stable rescuing mutants of p53: computational mutagenesis of flexible loop L1. Biochemistry 2005;44:1423-32. [PMID: 15683227 DOI: 10.1021/bi047845y] [Cited by in Crossref: 21] [Cited by in F6Publishing: 19] [Article Influence: 1.2] [Reference Citation Analysis]
105 Béroud C, Verdier F, Soussi T. p53 gene mutation: software and database. Nucleic Acids Res 1996;24:147-50. [PMID: 8594565 DOI: 10.1093/nar/24.1.147] [Cited by in Crossref: 31] [Cited by in F6Publishing: 37] [Article Influence: 1.2] [Reference Citation Analysis]
106 Lozano G, Zambetti GP. What have animal models taught us about the p53 pathway? J Pathol 2005;205:206-20. [DOI: 10.1002/path.1704] [Cited by in Crossref: 55] [Cited by in F6Publishing: 54] [Article Influence: 3.2] [Reference Citation Analysis]
107 Ludes-Meyers JH, Subler MA, Shivakumar CV, Munoz RM, Jiang P, Bigger JE, Brown DR, Deb SP, Deb S. Transcriptional activation of the human epidermal growth factor receptor promoter by human p53. Mol Cell Biol 1996;16:6009-19. [PMID: 8887630 DOI: 10.1128/MCB.16.11.6009] [Cited by in Crossref: 128] [Cited by in F6Publishing: 59] [Article Influence: 4.9] [Reference Citation Analysis]
108 Friedler A, Hansson LO, Veprintsev DB, Freund SM, Rippin TM, Nikolova PV, Proctor MR, Rüdiger S, Fersht AR. A peptide that binds and stabilizes p53 core domain: chaperone strategy for rescue of oncogenic mutants. Proc Natl Acad Sci U S A 2002;99:937-42. [PMID: 11782540 DOI: 10.1073/pnas.241629998] [Cited by in Crossref: 193] [Cited by in F6Publishing: 177] [Article Influence: 9.7] [Reference Citation Analysis]
109 Maestro R, Gloghini A, Doglioni C, Piccinin S, Vukosavljevic T, Gasparotto D, Carbone A, Boiocchi M. Human Non-Hodgkin's Lymphomas Overexpress a Wild-Type Form of p53 Which Is a Functional Transcriptional Activator of the Cyclin-Dependent Kinase Inhibitor p21. Blood 1997;89:2523-8. [DOI: 10.1182/blood.v89.7.2523] [Cited by in Crossref: 22] [Article Influence: 0.9] [Reference Citation Analysis]
110 Seidl H, Kreimer-erlacher H, Bäck B, Soyer HP, Kerl H, Wolf P, Höfler G. Ultraviolet Exposure as the Main Initiator of p53 Mutations in Basal Cell Carcinomas from Psoralen and Ultraviolet A-Treated Patients with Psoriasis. Journal of Investigative Dermatology 2001;117:365-70. [DOI: 10.1046/j.0022-202x.2001.01413.x] [Cited by in Crossref: 34] [Cited by in F6Publishing: 23] [Article Influence: 1.6] [Reference Citation Analysis]
111 Joerger AC, Ang HC, Fersht AR. Structural basis for understanding oncogenic p53 mutations and designing rescue drugs. Proc Natl Acad Sci U S A 2006;103:15056-61. [PMID: 17015838 DOI: 10.1073/pnas.0607286103] [Cited by in Crossref: 190] [Cited by in F6Publishing: 189] [Article Influence: 11.9] [Reference Citation Analysis]
112 Soussi T, Béroud C. Assessing TP53 status in human tumours to evaluate clinical outcome. Nat Rev Cancer 2001;1:233-40. [PMID: 11902578 DOI: 10.1038/35106009] [Cited by in Crossref: 444] [Cited by in F6Publishing: 404] [Article Influence: 22.2] [Reference Citation Analysis]
113 Miller JJ, Gaiddon C, Storr T. A balancing act: using small molecules for therapeutic intervention of the p53 pathway in cancer. Chem Soc Rev 2020;49:6995-7014. [DOI: 10.1039/d0cs00163e] [Cited by in Crossref: 7] [Cited by in F6Publishing: 5] [Article Influence: 3.5] [Reference Citation Analysis]
114 Bizzarri AR, Cannistraro S. Time-Resolved Fluorescence and Essential Dynamics Study on the Structural Heterogeneity of p53DBD Bound to the Anticancer p28 Peptide. J Phys Chem B 2020;124:9820-8. [PMID: 33103427 DOI: 10.1021/acs.jpcb.0c06778] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
115 Puglisi F, Damante G, Pizzolitto S, Mariuzzi L, Guerra S, Pellizzari L, Binotto F, Beltrami CA. Combined yolk sac tumor and adenocarcinoma in a gastric stump: Molecular evidence of clonality. Cancer 1999;85:1910-6. [DOI: 10.1002/(sici)1097-0142(19990501)85:9<1910::aid-cncr5>3.0.co;2-3] [Cited by in Crossref: 12] [Article Influence: 0.5] [Reference Citation Analysis]
116 Allende-Vega N, Villalba M. Metabolic stress controls mutant p53 R248Q stability in acute myeloid leukemia cells. Sci Rep 2019;9:5637. [PMID: 30948782 DOI: 10.1038/s41598-019-42220-y] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 2.7] [Reference Citation Analysis]
117 Qi JS, Desai-Yajnik V, Yuan Y, Samuels HH. Constitutive activation of gene expression by thyroid hormone receptor results from reversal of p53-mediated repression. Mol Cell Biol 1997;17:7195-207. [PMID: 9372952 DOI: 10.1128/MCB.17.12.7195] [Cited by in Crossref: 21] [Cited by in F6Publishing: 9] [Article Influence: 0.8] [Reference Citation Analysis]
118 Kalvakolanu DV. The GRIMs: a new interface between cell death regulation and interferon/retinoid induced growth suppression. Cytokine Growth Factor Rev. 2004;15:169-194. [PMID: 15110800 DOI: 10.1016/j.cytogfr.2004.01.002] [Cited by in Crossref: 46] [Cited by in F6Publishing: 44] [Article Influence: 2.6] [Reference Citation Analysis]
119 Sailer C, Offensperger F, Julier A, Kammer KM, Walker-Gray R, Gold MG, Scheffner M, Stengel F. Structural dynamics of the E6AP/UBE3A-E6-p53 enzyme-substrate complex. Nat Commun 2018;9:4441. [PMID: 30361475 DOI: 10.1038/s41467-018-06953-0] [Cited by in Crossref: 28] [Cited by in F6Publishing: 24] [Article Influence: 7.0] [Reference Citation Analysis]
120 Haas MJ, Pitot HC. Characterization of rarep53 mutants from carcinogen-treated albumin–simian virus 40 T-antigen transgenic rats. Mol Carcinog 1998;21:128-34. [DOI: 10.1002/(sici)1098-2744(199802)21:2<128::aid-mc7>3.0.co;2-j] [Cited by in Crossref: 9] [Article Influence: 0.4] [Reference Citation Analysis]
121 Emamzadah S, Petty TJ, De Almeida V, Nishimura T, Joly J, Ferrer JL, Halazonetis TD. Cyclic olefin homopolymer-based microfluidics for protein crystallization and in situ X-ray diffraction. Acta Crystallogr D Biol Crystallogr 2009;65:913-20. [PMID: 19690369 DOI: 10.1107/S0907444909021489] [Cited by in Crossref: 19] [Cited by in F6Publishing: 11] [Article Influence: 1.5] [Reference Citation Analysis]
122 Rainwater R, Parks D, Anderson ME, Tegtmeyer P, Mann K. Role of cysteine residues in regulation of p53 function. Mol Cell Biol 1995;15:3892-903. [PMID: 7791795 DOI: 10.1128/MCB.15.7.3892] [Cited by in Crossref: 204] [Cited by in F6Publishing: 74] [Article Influence: 7.6] [Reference Citation Analysis]
123 Montesano R, Hainaut P, Wild CP. Hepatocellular carcinoma: from gene to public health. J Natl Cancer Inst. 1997;89:1844-1851. [PMID: 9414172 DOI: 10.1093/jnci/89.24.1844] [Cited by in Crossref: 168] [Cited by in F6Publishing: 154] [Article Influence: 7.0] [Reference Citation Analysis]
124 Bieging KT, Mello SS, Attardi LD. Unravelling mechanisms of p53-mediated tumour suppression. Nat Rev Cancer. 2014;14:359-370. [PMID: 24739573 DOI: 10.1038/nrc3711] [Cited by in Crossref: 744] [Cited by in F6Publishing: 713] [Article Influence: 93.0] [Reference Citation Analysis]
125 Jayaraman L, Freulich E, Prives C. Functional dissection of p53 tumor suppressor protein. Methods Enzymol 1997;283:245-56. [PMID: 9251024 DOI: 10.1016/s0076-6879(97)83020-0] [Cited by in Crossref: 19] [Cited by in F6Publishing: 7] [Article Influence: 0.8] [Reference Citation Analysis]
126 Powis G, Gasdaska JR, Baker A. Redox signaling and the control of cell growth and death. Adv Pharmacol. 1997;38:329-359. [PMID: 8895815 DOI: 10.1016/s1054-3589(08)60990-4] [Cited by in Crossref: 70] [Cited by in F6Publishing: 13] [Article Influence: 2.8] [Reference Citation Analysis]
127 Luscombe NM, Austin SE, Berman HM, Thornton JM. An overview of the structures of protein-DNA complexes. Genome Biol 2000;1:REVIEWS001. [PMID: 11104519 DOI: 10.1186/gb-2000-1-1-reviews001] [Cited by in Crossref: 355] [Cited by in F6Publishing: 333] [Article Influence: 16.1] [Reference Citation Analysis]
128 Pan Y, Nussinov R. Structural basis for p53 binding-induced DNA bending. J Biol Chem 2007;282:691-9. [PMID: 17085447 DOI: 10.1074/jbc.M605908200] [Cited by in Crossref: 28] [Cited by in F6Publishing: 16] [Article Influence: 1.8] [Reference Citation Analysis]
129 Ariffin H, Chan AS, Oh L, Abd-Ghafar S, Ong GB, Mohamed M, Razali H, Juraida E, Teo SH, Karsa M, Shamsani J, Hainaut P. Frequent occurrence of gastric cancer in Asian kindreds with Li-Fraumeni syndrome. Clin Genet 2015;88:450-5. [PMID: 25318593 DOI: 10.1111/cge.12525] [Cited by in Crossref: 10] [Cited by in F6Publishing: 9] [Article Influence: 1.3] [Reference Citation Analysis]
130 Kadia TM, Jain P, Ravandi F, Garcia-Manero G, Andreef M, Takahashi K, Borthakur G, Jabbour E, Konopleva M, Daver NG, Dinardo C, Pierce S, Kanagal-Shamanna R, Patel K, Estrov Z, Cortes J, Kantarjian HM. TP53 mutations in newly diagnosed acute myeloid leukemia: Clinicomolecular characteristics, response to therapy, and outcomes. Cancer 2016;122:3484-91. [PMID: 27463065 DOI: 10.1002/cncr.30203] [Cited by in Crossref: 99] [Cited by in F6Publishing: 103] [Article Influence: 16.5] [Reference Citation Analysis]
131 Tong X, Xu D, Mishra RK, Jones RD, Sun L, Schiltz GE, Liao J, Yang GY. Identification of a druggable protein-protein interaction site between mutant p53 and its stabilizing chaperone DNAJA1. J Biol Chem 2021;296:100098. [PMID: 33208462 DOI: 10.1074/jbc.RA120.014749] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
132 Liu S, Cao W, Yu L, Zheng W, Li L, Fan C, Chen T. Zinc(ii) complexes containing bis-benzimidazole derivatives as a new class of apoptosis inducers that trigger DNA damage-mediated p53 phosphorylation in cancer cells. Dalton Trans 2013;42:5932. [DOI: 10.1039/c3dt33077j] [Cited by in Crossref: 61] [Cited by in F6Publishing: 54] [Article Influence: 6.8] [Reference Citation Analysis]
133 Wang PL, Sait F, Winter G. The ‘wildtype’ conformation of p53: epitope mapping using hybrid proteins. Oncogene 2001;20:2318-24. [DOI: 10.1038/sj.onc.1204316] [Cited by in Crossref: 24] [Cited by in F6Publishing: 27] [Article Influence: 1.1] [Reference Citation Analysis]
134 Kaeser MD, Iggo RD. Chromatin immunoprecipitation analysis fails to support the latency model for regulation of p53 DNA binding activity in vivo. Proc Natl Acad Sci U S A 2002;99:95-100. [PMID: 11756653 DOI: 10.1073/pnas.012283399] [Cited by in Crossref: 229] [Cited by in F6Publishing: 221] [Article Influence: 10.9] [Reference Citation Analysis]
135 Mummenbrauer T, Janus F, Müller B, Wiesmüller L, Deppert W, Grosse F. p53 Protein Exhibits 3′-to-5′ Exonuclease Activity. Cell 1996;85:1089-99. [DOI: 10.1016/s0092-8674(00)81309-4] [Cited by in Crossref: 158] [Cited by in F6Publishing: 47] [Article Influence: 6.1] [Reference Citation Analysis]
136 Liu C, Liang G, Liu Z, Zu L. Time-Resolved Fluorescence Anisotropy Study of the Interaction Between DNA and a Peptide Truncated from the p53 Protein Core Domain. J Fluoresc 2014;24:533-9. [DOI: 10.1007/s10895-013-1322-7] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.3] [Reference Citation Analysis]
137 Bykov VJ, Zhang Q, Zhang M, Ceder S, Abrahmsen L, Wiman KG. Targeting of Mutant p53 and the Cellular Redox Balance by APR-246 as a Strategy for Efficient Cancer Therapy. Front Oncol 2016;6:21. [PMID: 26870698 DOI: 10.3389/fonc.2016.00021] [Cited by in Crossref: 50] [Cited by in F6Publishing: 53] [Article Influence: 8.3] [Reference Citation Analysis]
138 Lin Zhang, Hui Liu, Yufei Huang, Xuesong Wang, Yidong Chen, Jia Meng. Cancer Progression Prediction Using Gene Interaction Regularized Elastic Net. IEEE/ACM Trans Comput Biol Bioinform 2017;14:145-54. [PMID: 28055897 DOI: 10.1109/TCBB.2015.2511758] [Cited by in Crossref: 12] [Cited by in F6Publishing: 5] [Article Influence: 1.7] [Reference Citation Analysis]
139 Yang J, Bashkenova N, Zang R, Huang X, Wang J. The roles of TET family proteins in development and stem cells. Development 2020;147:dev183129. [PMID: 31941705 DOI: 10.1242/dev.183129] [Cited by in Crossref: 11] [Cited by in F6Publishing: 9] [Article Influence: 5.5] [Reference Citation Analysis]
140 Thapar R. Structure-specific nucleic acid recognition by L-motifs and their diverse roles in expression and regulation of the genome. Biochim Biophys Acta 2015;1849:677-87. [PMID: 25748361 DOI: 10.1016/j.bbagrm.2015.02.006] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 0.7] [Reference Citation Analysis]
141 Van Roey K, Uyar B, Weatheritt RJ, Dinkel H, Seiler M, Budd A, Gibson TJ, Davey NE. Short Linear Motifs: Ubiquitous and Functionally Diverse Protein Interaction Modules Directing Cell Regulation. Chem Rev 2014;114:6733-78. [DOI: 10.1021/cr400585q] [Cited by in Crossref: 227] [Cited by in F6Publishing: 195] [Article Influence: 28.4] [Reference Citation Analysis]
142 Unfried K, Kociok N, Roller M, Friemann J, Pott F, Dehnen W. P53 mutations in tumours induced by intraperitoneal injection of crocidolite asbestos and benzo[a]pyrene in rats. Experimental and Toxicologic Pathology 1997;49:181-7. [DOI: 10.1016/s0940-2993(97)80005-x] [Cited by in Crossref: 7] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
143 Chen JM, Rosal R, Smith S, Pincus MR, Brandt-Rauf PW. Common conformational effects of p53 mutations. J Protein Chem 2001;20:101-5. [PMID: 11563689 DOI: 10.1023/a:1011065022283] [Cited by in Crossref: 7] [Cited by in F6Publishing: 5] [Article Influence: 0.4] [Reference Citation Analysis]
144 Kong XT, Gao H, Stanbridge EJ. Mechanisms of differential activation of target gene promoters by p53 hinge domain mutants with impaired apoptotic function. J Biol Chem. 2001;276:32990-33000. [PMID: 11395510 DOI: 10.1074/jbc.M103681200] [Cited by in Crossref: 16] [Cited by in F6Publishing: 7] [Article Influence: 0.8] [Reference Citation Analysis]
145 Klein C, Georges G, Künkele KP, Huber R, Engh RA, Hansen S. High thermostability and lack of cooperative DNA binding distinguish the p63 core domain from the homologous tumor suppressor p53. J Biol Chem 2001;276:37390-401. [PMID: 11477076 DOI: 10.1074/jbc.M103801200] [Cited by in Crossref: 53] [Cited by in F6Publishing: 24] [Article Influence: 2.5] [Reference Citation Analysis]
146 Gottschalk B, Klein A. Restoration of wild-type p53 in drug-resistant mouse breast cancer cells leads to differential gene expression, but is not sufficient to overcome the malignant phenotype. Mol Cell Biochem 2013;379:213-27. [DOI: 10.1007/s11010-013-1643-5] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.2] [Reference Citation Analysis]
147 Sukhbaatar N, Bachmayr-Heyda A, Auer K, Aust S, Deycmar S, Horvat R, Pils D. Two different, mutually exclusively distributed, TP53 mutations in ovarian and peritoneal tumor tissues of a serous ovarian cancer patient: indicative for tumor origin? Cold Spring Harb Mol Case Stud 2017;3:a001461. [PMID: 28679689 DOI: 10.1101/mcs.a001461] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 0.8] [Reference Citation Analysis]
148 Huang FY, Wong DK, Tsui VW, Seto WK, Mak LY, Cheung TT, Lai KK, Yuen MF. Targeted genomic profiling identifies frequent deleterious mutations in FAT4 and TP53 genes in HBV-associated hepatocellular carcinoma. BMC Cancer 2019;19:789. [PMID: 31395065 DOI: 10.1186/s12885-019-6002-9] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 1.7] [Reference Citation Analysis]
149 Ghosh G, Huang D, Huxford T. Molecular mimicry of the NF-κB DNA target site by a selected RNA aptamer. Current Opinion in Structural Biology 2004;14:21-7. [DOI: 10.1016/j.sbi.2004.01.004] [Cited by in Crossref: 34] [Cited by in F6Publishing: 32] [Article Influence: 1.9] [Reference Citation Analysis]
150 Inoue K, Kurabayashi A, Shuin T, Ohtsuki Y, Furihata M. Overexpression of p53 protein in human tumors. Med Mol Morphol. 2012;45:115-123. [PMID: 23001293 DOI: 10.1007/s00795-012-0575-6] [Cited by in Crossref: 16] [Cited by in F6Publishing: 15] [Article Influence: 1.6] [Reference Citation Analysis]
151 Baroni TE, Wang T, Qian H, Dearth LR, Truong LN, Zeng J, Denes AE, Chen SW, Brachmann RK. A global suppressor motif for p53 cancer mutants. Proc Natl Acad Sci USA. 2004;101:4930-4935. [PMID: 15037740 DOI: 10.1073/pnas.0401162101] [Cited by in Crossref: 62] [Cited by in F6Publishing: 54] [Article Influence: 3.4] [Reference Citation Analysis]
152 Postel EH, Weiss VH, Beneken J, Kirtane A. Mutational analysis of NM23-H2/NDP kinase identifies the structural domains critical to recognition of a c-myc regulatory element. Proc Natl Acad Sci U S A 1996;93:6892-7. [PMID: 8692914 DOI: 10.1073/pnas.93.14.6892] [Cited by in Crossref: 56] [Cited by in F6Publishing: 60] [Article Influence: 2.2] [Reference Citation Analysis]
153 Coutandin D, Ou HD, Löhr F, Dötsch V. Tracing the protectors path from the germ line to the genome. Proc Natl Acad Sci U S A 2010;107:15318-25. [PMID: 20696896 DOI: 10.1073/pnas.1001069107] [Cited by in Crossref: 9] [Cited by in F6Publishing: 9] [Article Influence: 0.8] [Reference Citation Analysis]
154 Hoehner JC, Gestblom C, Olsen L, Påhlman S. Spatial association of apoptosis-related gene expression and cellular death in clinical neuroblastoma. Br J Cancer 1997;75:1185-94. [PMID: 9099968 DOI: 10.1038/bjc.1997.203] [Cited by in Crossref: 31] [Cited by in F6Publishing: 33] [Article Influence: 1.2] [Reference Citation Analysis]
155 Kihara C, Seki T, Furukawa Y, Yamana H, Kimura Y, van Schaardenburgh P, Hirata K, Nakamura Y. Mutations in zinc-binding domains of p53 as a prognostic marker of esophageal-cancer patients. Jpn J Cancer Res. 2000;91:190-198. [PMID: 10761706 DOI: 10.1111/j.1349-7006.2000.tb00931.x] [Cited by in Crossref: 22] [Cited by in F6Publishing: 24] [Article Influence: 1.0] [Reference Citation Analysis]
156 Moscetti I, Cannistraro S, Bizzarri AR. Probing direct interaction of oncomiR-21-3p with the tumor suppressor p53 by fluorescence, FRET and atomic force spectroscopy. Arch Biochem Biophys 2019;671:35-41. [PMID: 31181181 DOI: 10.1016/j.abb.2019.05.026] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 1.7] [Reference Citation Analysis]
157 Sundar D, Yu Y, Katiyar SP, Putri JF, Dhanjal JK, Wang J, Sari AN, Kolettas E, Kaul SC, Wadhwa R. Wild type p53 function in p53Y220C mutant harboring cells by treatment with Ashwagandha derived anticancer withanolides: bioinformatics and experimental evidence. J Exp Clin Cancer Res 2019;38:103. [PMID: 30808373 DOI: 10.1186/s13046-019-1099-x] [Cited by in Crossref: 10] [Cited by in F6Publishing: 9] [Article Influence: 3.3] [Reference Citation Analysis]
158 Hsieh JC, Kuta R, Armour CR, Boehmer PE. Identification of two novel functional p53 responsive elements in the herpes simplex virus-1 genome. Virology 2014;460-461:45-54. [PMID: 25010269 DOI: 10.1016/j.virol.2014.04.019] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 0.6] [Reference Citation Analysis]
159 Trtková K, Plachý J. Deletions in the DNA-binding domain of the TP53 gene in v-src-transformed chicken cells. In Vitro Cell Dev Biol Anim 2004;40:285-92. [PMID: 15723564 DOI: 10.1290/0312091.1] [Reference Citation Analysis]
160 Rohs R, Jin X, West SM, Joshi R, Honig B, Mann RS. Origins of specificity in protein-DNA recognition. Annu Rev Biochem 2010;79:233-69. [PMID: 20334529 DOI: 10.1146/annurev-biochem-060408-091030] [Cited by in Crossref: 588] [Cited by in F6Publishing: 507] [Article Influence: 49.0] [Reference Citation Analysis]
161 El-deiry WS. The role of p53 in chemosensitivity and radiosensitivity. Oncogene 2003;22:7486-95. [DOI: 10.1038/sj.onc.1206949] [Cited by in Crossref: 230] [Cited by in F6Publishing: 199] [Article Influence: 12.1] [Reference Citation Analysis]
162 Pavlakis E, Stiewe T. p53's Extended Reach: The Mutant p53 Secretome. Biomolecules 2020;10:E307. [PMID: 32075247 DOI: 10.3390/biom10020307] [Cited by in Crossref: 18] [Cited by in F6Publishing: 18] [Article Influence: 9.0] [Reference Citation Analysis]
163 Resnick-Silverman L, Manfredi JJ. Gene-specific mechanisms of p53 transcriptional control and prospects for cancer therapy. J Cell Biochem 2006;99:679-89. [PMID: 16676359 DOI: 10.1002/jcb.20925] [Cited by in Crossref: 17] [Cited by in F6Publishing: 16] [Article Influence: 1.1] [Reference Citation Analysis]
164 Yoneda K, Yokoyama T, Yamamoto T, Hatabe T, Osaki T. p53 gene mutations and p21 protein expression induced independently of p53, by TGF-β and γ-rays in squamous cell carcinoma cells. European Journal of Cancer 1999;35:278-83. [DOI: 10.1016/s0959-8049(98)00291-3] [Cited by in Crossref: 10] [Cited by in F6Publishing: 3] [Article Influence: 0.4] [Reference Citation Analysis]
165 Burns TF, El-Deiry WS. The p53 pathway and apoptosis. J Cell Physiol 1999;181:231-9. [PMID: 10497302 DOI: 10.1002/(SICI)1097-4652(199911)181:2<231::AID-JCP5>3.0.CO;2-L] [Cited by in Crossref: 151] [Cited by in F6Publishing: 34] [Article Influence: 6.6] [Reference Citation Analysis]
166 Gañán-Gómez I, Estañ-Omaña MC, Sancho P, Aller P, Boyano-Adánez MC. Mechanisms of resistance to apoptosis in the human acute promyelocytic leukemia cell line NB4. Ann Hematol 2015;94:379-92. [PMID: 25322811 DOI: 10.1007/s00277-014-2237-3] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 0.5] [Reference Citation Analysis]
167 Wilcken R, Wang G, Boeckler FM, Fersht AR. Kinetic mechanism of p53 oncogenic mutant aggregation and its inhibition. Proc Natl Acad Sci U S A 2012;109:13584-9. [PMID: 22869713 DOI: 10.1073/pnas.1211550109] [Cited by in Crossref: 83] [Cited by in F6Publishing: 74] [Article Influence: 8.3] [Reference Citation Analysis]
168 Picksley SM, Spicer JF, Barnes DM, Lane DP. The P53-MDM2 Interaction in a Cancer-Prone Family, and the Identification of a Novel Therapeutic Target. Acta Oncologica 2009;35:429-34. [DOI: 10.3109/02841869609109917] [Cited by in Crossref: 16] [Cited by in F6Publishing: 15] [Article Influence: 1.2] [Reference Citation Analysis]
169 Pascal LE, Wang Y, Zhong M, Wang D, Chakka AB, Yang Z, Li F, Song Q, Rigatti LH, Chaparala S, Chandran U, Parwani AV, Wang Z. EAF2 and p53 Co-Regulate STAT3 Activation in Prostate Cancer. Neoplasia 2018;20:351-63. [PMID: 29518696 DOI: 10.1016/j.neo.2018.01.011] [Cited by in Crossref: 9] [Cited by in F6Publishing: 9] [Article Influence: 2.3] [Reference Citation Analysis]
170 Schilling T, Kairat A, Melino G, Krammer PH, Stremmel W, Oren M, Müller M. Interference with the p53 family network contributes to the gain of oncogenic function of mutant p53 in hepatocellular carcinoma. Biochem Biophys Res Commun 2010;394:817-23. [PMID: 20233581 DOI: 10.1016/j.bbrc.2010.03.082] [Cited by in Crossref: 23] [Cited by in F6Publishing: 22] [Article Influence: 1.9] [Reference Citation Analysis]
171 Simeonova I, Jaber S, Draskovic I, Bardot B, Fang M, Bouarich-Bourimi R, Lejour V, Charbonnier L, Soudais C, Bourdon JC, Huerre M, Londono-Vallejo A, Toledo F. Mutant mice lacking the p53 C-terminal domain model telomere syndromes. Cell Rep 2013;3:2046-58. [PMID: 23770245 DOI: 10.1016/j.celrep.2013.05.028] [Cited by in Crossref: 46] [Cited by in F6Publishing: 44] [Article Influence: 5.1] [Reference Citation Analysis]
172 Wang Y, Yang J, Zheng H, Tomasek GJ, Zhang P, McKeever PE, Lee EY, Zhu Y. Expression of mutant p53 proteins implicates a lineage relationship between neural stem cells and malignant astrocytic glioma in a murine model. Cancer Cell. 2009;15:514-526. [PMID: 19477430 DOI: 10.1016/j.ccr.2009.04.001] [Cited by in Crossref: 167] [Cited by in F6Publishing: 159] [Article Influence: 12.8] [Reference Citation Analysis]
173 Soussi T. The p53 tumour suppressor gene: a model for molecular epidemiology of human cancer. Mol Med Today. 1996;2:32-37. [PMID: 8796849 DOI: 10.1016/1357-4310(96)88756-9] [Cited by in Crossref: 40] [Cited by in F6Publishing: 34] [Article Influence: 1.5] [Reference Citation Analysis]
174 Li Y, Wang Z, Chen Y, Petersen RB, Zheng L, Huang K. Salvation of the fallen angel: Reactivating mutant p53. Br J Pharmacol 2019;176:817-31. [PMID: 30632144 DOI: 10.1111/bph.14572] [Cited by in Crossref: 13] [Cited by in F6Publishing: 14] [Article Influence: 4.3] [Reference Citation Analysis]
175 Augustyn KE, Merino EJ, Barton JK. A role for DNA-mediated charge transport in regulating p53: Oxidation of the DNA-bound protein from a distance. Proc Natl Acad Sci U S A 2007;104:18907-12. [PMID: 18025460 DOI: 10.1073/pnas.0709326104] [Cited by in Crossref: 40] [Cited by in F6Publishing: 39] [Article Influence: 2.7] [Reference Citation Analysis]
176 Jayaraman L, Moorthy NC, Murthy KG, Manley JL, Bustin M, Prives C. High mobility group protein-1 (HMG-1) is a unique activator of p53. Genes Dev. 1998;12:462-472. [PMID: 9472015 DOI: 10.1101/gad.12.4.462] [Cited by in Crossref: 215] [Cited by in F6Publishing: 232] [Article Influence: 9.0] [Reference Citation Analysis]
177 Suhardja A, Kovacs K, Rutka J. Genetic basis of pituitary adenoma invasiveness: a review. J Neurooncol 2001;52:195-204. [PMID: 11519849 DOI: 10.1023/a:1010655419332] [Cited by in Crossref: 25] [Cited by in F6Publishing: 9] [Article Influence: 1.3] [Reference Citation Analysis]
178 Duan W, Gao L, Wu X, Hade EM, Gao JX, Ding H, Barsky SH, Otterson GA, Villalona-Calero MA. Expression of a mutant p53 results in an age-related demographic shift in spontaneous lung tumor formation in transgenic mice. PLoS One 2009;4:e5563. [PMID: 19440353 DOI: 10.1371/journal.pone.0005563] [Cited by in Crossref: 9] [Cited by in F6Publishing: 9] [Article Influence: 0.7] [Reference Citation Analysis]
179 Ota I, Okamoto N, Yane K, Takahashi A, Masui T, Hosoi H, Ohnishi T. Therapeutic strategies for head and neck cancer based on p53 status. Exp Ther Med 2012;3:585-91. [PMID: 22969933 DOI: 10.3892/etm.2012.474] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 0.5] [Reference Citation Analysis]
180 Enemark EJ, Chen G, Vaughn DE, Stenlund A, Joshua-tor L. Crystal Structure of the DNA Binding Domain of the Replication Initiation Protein E1 from Papillomavirus. Molecular Cell 2000;6:149-58. [DOI: 10.1016/s1097-2765(05)00016-x] [Cited by in Crossref: 59] [Article Influence: 2.7] [Reference Citation Analysis]
181 Levrero M, De Laurenzi V, Costanzo A, Gong J, Wang J, Melino G. The p53/p63/p73 family of transcription factors: overlapping and distinct functions. Journal of Cell Science 2000;113:1661-70. [DOI: 10.1242/jcs.113.10.1661] [Cited by in Crossref: 172] [Cited by in F6Publishing: 134] [Article Influence: 7.8] [Reference Citation Analysis]
182 Naka N, Tomita Y, Nakanishi H, Araki N, Hongyo T, Ochi T, Aozasa K. Mutations ofp53 tumor-suppressor gene in angiosarcoma. Int J Cancer 1997;71:952-5. [DOI: 10.1002/(sici)1097-0215(19970611)71:6<952::aid-ijc7>3.0.co;2-x] [Cited by in Crossref: 61] [Cited by in F6Publishing: 20] [Article Influence: 2.4] [Reference Citation Analysis]
183 Jayaraman L, Prives C. Activation of p53 sequence-specific DNA bindingby short single strands of DNA requires the p53 C-terminus. Cell 1995;81:1021-9. [DOI: 10.1016/s0092-8674(05)80007-8] [Cited by in Crossref: 226] [Cited by in F6Publishing: 80] [Article Influence: 8.4] [Reference Citation Analysis]
184 Guynn J, Chan EAW. Zinc and Zinc-Dependent Proteins in Cancer and Chemotherapeutics. In: Mudipalli A, Zelikoff JT, editors. Essential and Non-essential Metals. Cham: Springer International Publishing; 2017. pp. 69-94. [DOI: 10.1007/978-3-319-55448-8_4] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.4] [Reference Citation Analysis]
185 Loriaux PM, Hoffmann A. A protein turnover signaling motif controls the stimulus-sensitivity of stress response pathways. PLoS Comput Biol 2013;9:e1002932. [PMID: 23468615 DOI: 10.1371/journal.pcbi.1002932] [Cited by in Crossref: 11] [Cited by in F6Publishing: 6] [Article Influence: 1.2] [Reference Citation Analysis]
186 Hartwig A. Zinc Finger Proteins as Potential Targets for Toxic Metal Ions: Differential Effects on Structure and Function. Antioxidants & Redox Signaling 2001;3:625-34. [DOI: 10.1089/15230860152542970] [Cited by in Crossref: 191] [Cited by in F6Publishing: 168] [Article Influence: 9.1] [Reference Citation Analysis]
187 Chen S, Wu J, Zhong S, Li Y, Zhang P, Ma J, Ren J, Tan Y, Wang Y, Au KF, Siebold C, Bond GL, Chen Z, Lu M, Jones EY, Lu X. iASPP mediates p53 selectivity through a modular mechanism fine-tuning DNA recognition. Proc Natl Acad Sci U S A 2019;116:17470-9. [PMID: 31395738 DOI: 10.1073/pnas.1909393116] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 2.3] [Reference Citation Analysis]
188 Adámik M, Bažantová P, Navrátilová L, Polášková A, Pečinka P, Holaňová L, Tichý V, Brázdová M. Impact of cadmium, cobalt and nickel on sequence-specific DNA binding of p63 and p73 in vitro and in cells. Biochem Biophys Res Commun 2015;456:29-34. [PMID: 25446071 DOI: 10.1016/j.bbrc.2014.11.027] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 0.5] [Reference Citation Analysis]
189 Zeng X, Li X, Miller A, Yuan Z, Yuan W, Kwok RP, Goodman R, Lu H. The N-terminal domain of p73 interacts with the CH1 domain of p300/CREB binding protein and mediates transcriptional activation and apoptosis. Mol Cell Biol 2000;20:1299-310. [PMID: 10648616 DOI: 10.1128/MCB.20.4.1299-1310.2000] [Cited by in Crossref: 65] [Cited by in F6Publishing: 24] [Article Influence: 3.0] [Reference Citation Analysis]
190 Hou H, Qin K, Liang Y, Zhang C, Liu D, Jiang H, Liu K, Zhu J, Lv H, Li T, Zhang X. Concurrent TP53 mutations predict poor outcomes of EGFR-TKI treatments in Chinese patients with advanced NSCLC. Cancer Manag Res 2019;11:5665-75. [PMID: 31417310 DOI: 10.2147/CMAR.S201513] [Cited by in Crossref: 15] [Cited by in F6Publishing: 11] [Article Influence: 5.0] [Reference Citation Analysis]
191 McLure KG, Lee PW. How p53 binds DNA as a tetramer. EMBO J 1998;17:3342-50. [PMID: 9628871 DOI: 10.1093/emboj/17.12.3342] [Cited by in Crossref: 169] [Cited by in F6Publishing: 171] [Article Influence: 7.0] [Reference Citation Analysis]
192 Koulgi S, Achalere A, Sharma N, Sonavane U, Joshi R. QM-MM simulations on p53-DNA complex: a study of hot spot and rescue mutants. J Mol Model 2013;19:5545-59. [DOI: 10.1007/s00894-013-2042-2] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 0.7] [Reference Citation Analysis]
193 Clore GM, Ernst J, Clubb R, Omichinski JG, Kennedy WM, Sakaguchi K, Appella E, Gronenborn AM. Refined solution structure of the oligomerization domain of the tumour suppressor p53. Nat Struct Biol 1995;2:321-33. [PMID: 7796267 DOI: 10.1038/nsb0495-321] [Cited by in Crossref: 153] [Cited by in F6Publishing: 154] [Article Influence: 5.7] [Reference Citation Analysis]
194 Verhaegh GW, Richard MJ, Hainaut P. Regulation of p53 by metal ions and by antioxidants: dithiocarbamate down-regulates p53 DNA-binding activity by increasing the intracellular level of copper. Mol Cell Biol 1997;17:5699-706. [PMID: 9315628 DOI: 10.1128/MCB.17.10.5699] [Cited by in Crossref: 124] [Cited by in F6Publishing: 33] [Article Influence: 5.0] [Reference Citation Analysis]
195 Qin Q, Baudry M, Liao G, Noniyev A, Galeano J, Bi X. A novel function for p53: regulation of growth cone motility through interaction with Rho kinase. J Neurosci 2009;29:5183-92. [PMID: 19386914 DOI: 10.1523/JNEUROSCI.0420-09.2009] [Cited by in Crossref: 46] [Cited by in F6Publishing: 31] [Article Influence: 3.5] [Reference Citation Analysis]
196 Sauer RT. Lac repressor at last. Structure 1996;4:219-22. [DOI: 10.1016/s0969-2126(96)00025-1] [Cited by in Crossref: 11] [Cited by in F6Publishing: 3] [Article Influence: 0.4] [Reference Citation Analysis]
197 Wells M, Tidow H, Rutherford TJ, Markwick P, Jensen MR, Mylonas E, Svergun DI, Blackledge M, Fersht AR. Structure of tumor suppressor p53 and its intrinsically disordered N-terminal transactivation domain. Proc Natl Acad Sci U S A 2008;105:5762-7. [PMID: 18391200 DOI: 10.1073/pnas.0801353105] [Cited by in Crossref: 287] [Cited by in F6Publishing: 263] [Article Influence: 20.5] [Reference Citation Analysis]
198 Li G, Tolstonog GV, Sabasch M, Traub P. Interaction In Vitro of Type III Intermediate Filament Proteins with Supercoiled Plasmid DNA and Modulation of Eukaryotic DNA Topoisomerase I and II Activities. DNA and Cell Biology 2002;21:743-69. [DOI: 10.1089/104454902760599726] [Cited by in Crossref: 9] [Cited by in F6Publishing: 8] [Article Influence: 0.5] [Reference Citation Analysis]
199 Lübbe J, Ammon K, Watanabe K, Hegi ME, Kleihues P. Familial Brain Tumour Syndrome Associated with a p53 Germline Deletion of Codon 236. Brain Pathology 1995;5:15-23. [DOI: 10.1111/j.1750-3639.1995.tb00572.x] [Cited by in Crossref: 22] [Cited by in F6Publishing: 22] [Article Influence: 0.8] [Reference Citation Analysis]
200 Liou SH, Singh SK, Singer RH, Coleman RA, Liu WL. Structure of the p53/RNA polymerase II assembly. Commun Biol 2021;4:397. [PMID: 33767390 DOI: 10.1038/s42003-021-01934-4] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
201 Farid NR, Zou M, Shi Y. Genetics of Follicular Thyroid Cancer. Endocrinology and Metabolism Clinics of North America 1995;24:865-83. [DOI: 10.1016/s0889-8529(18)30024-0] [Cited by in Crossref: 27] [Article Influence: 1.0] [Reference Citation Analysis]
202 Nakamura T, Pichel JG, Williams-Simons L, Westphal H. An apoptotic defect in lens differentiation caused by human p53 is rescued by a mutant allele. Proc Natl Acad Sci U S A 1995;92:6142-6. [PMID: 7597093 DOI: 10.1073/pnas.92.13.6142] [Cited by in Crossref: 45] [Cited by in F6Publishing: 38] [Article Influence: 1.7] [Reference Citation Analysis]
203 Mee T, Okorokov AL, Metcalfe S, Milner J. Proteolytic cleavage of p53 mutants in response to mismatched DNA. Br J Cancer 1999;81:212-8. [PMID: 10496344 DOI: 10.1038/sj.bjc.6690679] [Cited by in Crossref: 4] [Cited by in F6Publishing: 7] [Article Influence: 0.2] [Reference Citation Analysis]
204 K. Murakami, T. Fujioka, T. Okimoto. Analysis of p53 Gene Mutations in Helicobacter pylori-Associated Gastritis Mucosa in Endoscopic Biopsy Specimens. Scandinavian Journal of Gastroenterology 2009;34:474-7. [DOI: 10.1080/003655299750026191] [Cited by in Crossref: 23] [Cited by in F6Publishing: 25] [Article Influence: 1.8] [Reference Citation Analysis]
205 Holmquist GP, Gao S. Somatic mutation theory, DNA repair rates, and the molecular epidemiology of p53 mutations. Mutation Research/Reviews in Mutation Research 1997;386:69-101. [DOI: 10.1016/s1383-5742(96)00045-2] [Cited by in Crossref: 54] [Cited by in F6Publishing: 8] [Article Influence: 2.2] [Reference Citation Analysis]
206 Li B, Rosen JM, McMenamin-Balano J, Muller WJ, Perkins AS. neu/ERBB2 cooperates with p53-172H during mammary tumorigenesis in transgenic mice. Mol Cell Biol 1997;17:3155-63. [PMID: 9154814 DOI: 10.1128/MCB.17.6.3155] [Cited by in Crossref: 70] [Cited by in F6Publishing: 38] [Article Influence: 2.8] [Reference Citation Analysis]
207 Zhao K, Chai X, Johnston K, Clements A, Marmorstein R. Crystal Structure of the Mouse p53 Core DNA-binding Domain at 2.7 Å Resolution. Journal of Biological Chemistry 2001;276:12120-7. [DOI: 10.1074/jbc.m011644200] [Cited by in Crossref: 65] [Cited by in F6Publishing: 27] [Article Influence: 3.1] [Reference Citation Analysis]
208 Weinberg RL, Veprintsev DB, Bycroft M, Fersht AR. Comparative binding of p53 to its promoter and DNA recognition elements. J Mol Biol 2005;348:589-96. [PMID: 15826656 DOI: 10.1016/j.jmb.2005.03.014] [Cited by in Crossref: 141] [Cited by in F6Publishing: 130] [Article Influence: 8.3] [Reference Citation Analysis]
209 Liu B, Chen Y, St Clair DK. ROS and p53: a versatile partnership. Free Radic Biol Med 2008;44:1529-35. [PMID: 18275858 DOI: 10.1016/j.freeradbiomed.2008.01.011] [Cited by in Crossref: 501] [Cited by in F6Publishing: 482] [Article Influence: 35.8] [Reference Citation Analysis]
210 Lieschke E, Wang Z, Kelly GL, Strasser A. Discussion of some 'knowns' and some 'unknowns' about the tumour suppressor p53. J Mol Cell Biol 2019;11:212-23. [PMID: 30496435 DOI: 10.1093/jmcb/mjy077] [Cited by in Crossref: 10] [Cited by in F6Publishing: 9] [Article Influence: 5.0] [Reference Citation Analysis]
211 Farid NR. P53 mutations in thyroid carcinoma: tidings from an old foe. J Endocrinol Invest. 2001;24:536-545. [PMID: 11508790 DOI: 10.1007/bf03343889] [Cited by in Crossref: 26] [Cited by in F6Publishing: 5] [Article Influence: 1.3] [Reference Citation Analysis]
212 Binkley J, Karra K, Kirby A, Hosobuchi M, Stone EA, Sidow A. ProPhylER: a curated online resource for protein function and structure based on evolutionary constraint analyses. Genome Res 2010;20:142-54. [PMID: 19846609 DOI: 10.1101/gr.097121.109] [Cited by in Crossref: 28] [Cited by in F6Publishing: 28] [Article Influence: 2.2] [Reference Citation Analysis]
213 Retzlaff M, Rohrberg J, Küpper NJ, Lagleder S, Bepperling A, Manzenrieder F, Peschek J, Kessler H, Buchner J. The regulatory domain stabilizes the p53 tetramer by intersubunit contacts with the DNA binding domain. J Mol Biol 2013;425:144-55. [PMID: 23103206 DOI: 10.1016/j.jmb.2012.10.015] [Cited by in Crossref: 14] [Cited by in F6Publishing: 15] [Article Influence: 1.4] [Reference Citation Analysis]
214 Klein C, Hesse F, Dehner A, Engh RA, Schwaiger M, Hansen S. In vitro folding and characterization of the p53 DNA binding domain. Biological Chemistry 2004;385:95-102. [DOI: 10.1515/bc.2004.012] [Cited by in Crossref: 5] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
215 Fleckenstein DS, Uphoff CC, Drexler HG, Quentmeier H. Detection of p53 gene mutations by single strand conformational polymorphism (SSCP) in human acute myeloid leukemia-derived cell lines. Leuk Res 2002;26:207-14. [PMID: 11755471 DOI: 10.1016/s0145-2126(01)00107-2] [Cited by in Crossref: 23] [Cited by in F6Publishing: 10] [Article Influence: 1.2] [Reference Citation Analysis]
216 Willis AC, Pipes T, Zhu J, Chen X. p73 can suppress the proliferation of cells that express mutant p53. Oncogene. 2003;22:5481-5495. [PMID: 12934108 DOI: 10.1038/sj.onc.1206505] [Cited by in Crossref: 20] [Cited by in F6Publishing: 22] [Article Influence: 1.1] [Reference Citation Analysis]
217 Jassem E, Nikliński J, Rosell R, Niklińska W, Jakóbkiewicz J, Monzo M, Chyczewski L, Kobierska G, Skokowski J, Żylicz M, Jassem J. Types and localisation of p53 gene mutations. Lung Cancer 2001;34:S47-51. [DOI: 10.1016/s0169-5002(01)00344-0] [Cited by in Crossref: 13] [Cited by in F6Publishing: 3] [Article Influence: 0.6] [Reference Citation Analysis]
218 Maiyar AC, Huang AJ, Phu PT, Cha HH, Firestone GL. p53 Stimulates Promoter Activity of the sgk Serum/Glucocorticoid-inducible Serine/Threonine Protein Kinase Gene in Rodent Mammary Epithelial Cells. Journal of Biological Chemistry 1996;271:12414-22. [DOI: 10.1074/jbc.271.21.12414] [Cited by in Crossref: 56] [Cited by in F6Publishing: 51] [Article Influence: 2.2] [Reference Citation Analysis]
219 Chitayat S, Arrowsmith CH. Four p(53)s in a pod. Nat Struct Mol Biol 2010;17:390-1. [DOI: 10.1038/nsmb0410-390] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.2] [Reference Citation Analysis]
220 Li L, Li X, Tang Y, Lao Z, Lei J, Wei G. Common cancer mutations R175H and R273H drive the p53 DNA-binding domain towards aggregation-prone conformations. Phys Chem Chem Phys 2020;22:9225-32. [DOI: 10.1039/c9cp06671c] [Cited by in Crossref: 4] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
221 Salomao N, Karakostis K, Hupp T, Vollrath F, Vojtesek B, Fahraeus R. What do we need to know and understand about p53 to improve its clinical value? J Pathol 2021;254:443-53. [DOI: 10.1002/path.5677] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
222 Tan YH, Chen YM, Ye X, Lu Q, Tretyachenko-Ladokhina V, Yang W, Senear DF, Luo R. Molecular mechanisms of functional rescue mediated by P53 tumor suppressor mutations. Biophys Chem 2009;145:37-44. [PMID: 19748724 DOI: 10.1016/j.bpc.2009.08.008] [Cited by in Crossref: 8] [Cited by in F6Publishing: 7] [Article Influence: 0.6] [Reference Citation Analysis]
223 Kucab JE, Phillips DH, Arlt VM. Linking environmental carcinogen exposure to TP53 mutations in human tumours using the human TP53 knock-in (Hupki) mouse model: Cancer aetiology and TP53 mutations. FEBS Journal 2010;277:2567-83. [DOI: 10.1111/j.1742-4658.2010.07676.x] [Cited by in Crossref: 52] [Cited by in F6Publishing: 23] [Article Influence: 4.3] [Reference Citation Analysis]
224 Bizzarri AR, Cannistraro S. Direct Interaction of miRNA and circRNA with the Oncosuppressor p53: An Intriguing Perspective in Cancer Research. Cancers (Basel) 2021;13:6108. [PMID: 34885216 DOI: 10.3390/cancers13236108] [Reference Citation Analysis]
225 Seemann S, Hainaut P. Roles of thioredoxin reductase 1 and APE/Ref-1 in the control of basal p53 stability and activity. Oncogene 2005;24:3853-63. [PMID: 15824742 DOI: 10.1038/sj.onc.1208549] [Cited by in Crossref: 91] [Cited by in F6Publishing: 82] [Article Influence: 5.4] [Reference Citation Analysis]
226 Seagle BL, Eng KH, Dandapani M, Yeh JY, Odunsi K, Shahabi S. Survival of patients with structurally-grouped TP53 mutations in ovarian and breast cancers. Oncotarget 2015;6:18641-52. [PMID: 26215675 DOI: 10.18632/oncotarget.4080] [Cited by in Crossref: 14] [Cited by in F6Publishing: 13] [Article Influence: 2.3] [Reference Citation Analysis]
227 Nagata T, Werner MH. Functional mutagenesis of AML1/RUNX1 and PEBP2β/CBFβ define distinct, non-overlapping sites for DNA recognition and heterodimerization by the runt domain1 1Edited by M. Yaniv. Journal of Molecular Biology 2001;308:191-203. [DOI: 10.1006/jmbi.2001.4596] [Cited by in Crossref: 32] [Cited by in F6Publishing: 32] [Article Influence: 1.5] [Reference Citation Analysis]
228 Ren J, Datta R, Shioya H, Li Y, Oki E, Biedermann V, Bharti A, Kufe D. p73β Is Regulated by Protein Kinase Cδ Catalytic Fragment Generated in the Apoptotic Response to DNA Damage. Journal of Biological Chemistry 2002;277:33758-65. [DOI: 10.1074/jbc.m110667200] [Cited by in Crossref: 89] [Cited by in F6Publishing: 34] [Article Influence: 4.5] [Reference Citation Analysis]
229 Duan J, Nilsson L. Effect of Zn 2+ on DNA Recognition and Stability of the p53 DNA-Binding Domain. Biochemistry 2006;45:7483-92. [DOI: 10.1021/bi0603165] [Cited by in Crossref: 46] [Cited by in F6Publishing: 46] [Article Influence: 2.9] [Reference Citation Analysis]
230 Demma M, Maxwell E, Ramos R, Liang L, Li C, Hesk D, Rossman R, Mallams A, Doll R, Liu M, Seidel-Dugan C, Bishop WR, Dasmahapatra B. SCH529074, a small molecule activator of mutant p53, which binds p53 DNA binding domain (DBD), restores growth-suppressive function to mutant p53 and interrupts HDM2-mediated ubiquitination of wild type p53. J Biol Chem 2010;285:10198-212. [PMID: 20124408 DOI: 10.1074/jbc.M109.083469] [Cited by in Crossref: 63] [Cited by in F6Publishing: 30] [Article Influence: 5.3] [Reference Citation Analysis]
231 Morton DJ, Patel D, Joshi J, Hunt A, Knowell AE, Chaudhary J. ID4 regulates transcriptional activity of wild type and mutant p53 via K373 acetylation. Oncotarget 2017;8:2536-49. [PMID: 27911860 DOI: 10.18632/oncotarget.13701] [Cited by in Crossref: 5] [Cited by in F6Publishing: 6] [Article Influence: 1.3] [Reference Citation Analysis]
232 Pivonková H, Pecinka P, Cesková P, Fojta M. DNA modification with cisplatin affects sequence-specific DNA binding of p53 and p73 proteins in a target site-dependent manner. FEBS J. 2006;273:4693-4706. [PMID: 16981908 DOI: 10.1111/j.1742-4658.2006.05472.x] [Cited by in Crossref: 8] [Cited by in F6Publishing: 9] [Article Influence: 0.5] [Reference Citation Analysis]
233 Solcia E, Klersy C, Mastracci L, Alberizzi P, Candusso ME, Diegoli M, Tava F, Riboni R, Manca R, Luinetti O. A combined histologic and molecular approach identifies three groups of gastric cancer with different prognosis. Virchows Arch. 2009;455:197-211. [PMID: 19672623 DOI: 10.1007/s00428-009-0813-z] [Cited by in Crossref: 25] [Cited by in F6Publishing: 28] [Article Influence: 1.9] [Reference Citation Analysis]
234 Monti P, Menichini P, Speciale A, Cutrona G, Fais F, Taiana E, Neri A, Bomben R, Gentile M, Gattei V, Ferrarini M, Morabito F, Fronza G. Heterogeneity of TP53 Mutations and P53 Protein Residual Function in Cancer: Does It Matter? Front Oncol 2020;10:593383. [PMID: 33194757 DOI: 10.3389/fonc.2020.593383] [Cited by in Crossref: 5] [Cited by in F6Publishing: 6] [Article Influence: 2.5] [Reference Citation Analysis]
235 Adduri R Sr, Kotapalli V, Gupta NA, Gowrishankar S, Srinivasulu M, Ali MM, Rao S, Uppin SG, Nayak UK, Dhagam S, Chigurupati MV, Bashyam MD. P53 nuclear stabilization is associated with FHIT loss and younger age of onset in squamous cell carcinoma of oral tongue. BMC Clin Pathol 2014;14:37. [PMID: 25152695 DOI: 10.1186/1472-6890-14-37] [Cited by in Crossref: 10] [Cited by in F6Publishing: 9] [Article Influence: 1.3] [Reference Citation Analysis]
236 Guimaraes D, Hainaut P. TP53: a key gene in human cancer. Biochimie 2002;84:83-93. [DOI: 10.1016/s0300-9084(01)01356-6] [Cited by in Crossref: 103] [Cited by in F6Publishing: 34] [Article Influence: 5.2] [Reference Citation Analysis]
237 Al-Kashwan TA, Houshmand M, Al-Janabi A, Melconian AK, Al-Abbasi D, Al-Musawi MN, Rostami M, Yasseen AA. Specific-mutational patterns of p53 gene in bladder transitional cell carcinoma among a group of Iraqi patients exposed to war environmental hazards. BMC Res Notes. 2012;5:466. [PMID: 22929185 DOI: 10.1186/1756-0500-5-466] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.2] [Reference Citation Analysis]
238 Phillips H. The Role of the p53 Tumour Suppressor Gene in Human Breast Cancer. Clinical Oncology 1999;11:148-55. [DOI: 10.1053/clon.1999.9032] [Cited by in Crossref: 9] [Cited by in F6Publishing: 9] [Article Influence: 0.4] [Reference Citation Analysis]
239 Ghobashi AH, Kamel MA. Tip60: updates. J Appl Genet 2018;59:161-8. [PMID: 29549519 DOI: 10.1007/s13353-018-0432-y] [Cited by in Crossref: 15] [Cited by in F6Publishing: 15] [Article Influence: 3.8] [Reference Citation Analysis]
240 Schaefer KN, Barton JK. DNA-mediated oxidation of p53. Biochemistry 2014;53:3467-75. [PMID: 24853816 DOI: 10.1021/bi5003184] [Cited by in Crossref: 14] [Cited by in F6Publishing: 12] [Article Influence: 1.8] [Reference Citation Analysis]
241 Joruiz SM, Bourdon JC. p53 Isoforms: Key Regulators of the Cell Fate Decision. Cold Spring Harb Perspect Med 2016;6:a026039. [PMID: 26801896 DOI: 10.1101/cshperspect.a026039] [Cited by in Crossref: 69] [Cited by in F6Publishing: 66] [Article Influence: 11.5] [Reference Citation Analysis]
242 Monti P, Inga A, Scott G, Aprile A, Campomenosi P, Menichini P, Ottaggio L, Viaggi S, Abbondandolo A, Burns PA, Fronza G. 5-Methylcytosine at HpaII sites in p53 is not hypermutable after UVC irradiation. Mutation Research/Fundamental and Molecular Mechanisms of Mutagenesis 1999;431:93-103. [DOI: 10.1016/s0027-5107(99)00187-6] [Cited by in Crossref: 8] [Cited by in F6Publishing: 2] [Article Influence: 0.3] [Reference Citation Analysis]
243 Ko LJ, Shieh SY, Chen X, Jayaraman L, Tamai K, Taya Y, Prives C, Pan ZQ. p53 is phosphorylated by CDK7-cyclin H in a p36MAT1-dependent manner. Mol Cell Biol 1997;17:7220-9. [PMID: 9372954 DOI: 10.1128/MCB.17.12.7220] [Cited by in Crossref: 104] [Cited by in F6Publishing: 40] [Article Influence: 4.2] [Reference Citation Analysis]
244 Haffner R, Oren M. Biochemical properties and biological effects of p53. Curr Opin Genet Dev 1995;5:84-90. [PMID: 7749331 DOI: 10.1016/s0959-437x(95)90058-6] [Cited by in Crossref: 115] [Cited by in F6Publishing: 27] [Article Influence: 4.3] [Reference Citation Analysis]
245 Luwang JW, Natesh R. Phosphomimetic Mutation Destabilizes the Central Core Domain of Human p53: Phosphomimetic mutations compromized p53 stability. IUBMB Life 2018;70:1023-31. [DOI: 10.1002/iub.1914] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
246 Chasov V, Mirgayazova R, Zmievskaya E, Khadiullina R, Valiullina A, Stephenson Clarke J, Rizvanov A, Baud MGJ, Bulatov E. Key Players in the Mutant p53 Team: Small Molecules, Gene Editing, Immunotherapy. Front Oncol 2020;10:1460. [PMID: 32974171 DOI: 10.3389/fonc.2020.01460] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
247 Leng K, Schlien S, Bosch FX. Refined characterization of head and neck squamous cell carcinomas expressing a seemingly wild-type p53 protein. J Oral Pathol Med 2006;35:19-24. [DOI: 10.1111/j.1600-0714.2005.00365.x] [Cited by in Crossref: 6] [Cited by in F6Publishing: 4] [Article Influence: 0.4] [Reference Citation Analysis]
248 Murphy KL, Rosen JM. Mutant p53 and genomic instability in a transgenic mouse model of breast cancer. Oncogene 2000;19:1045-51. [DOI: 10.1038/sj.onc.1203274] [Cited by in Crossref: 26] [Cited by in F6Publishing: 28] [Article Influence: 1.2] [Reference Citation Analysis]
249 Lu Q, Tan YH, Luo R. Molecular dynamics simulations of p53 DNA-binding domain. J Phys Chem B 2007;111:11538-45. [PMID: 17824689 DOI: 10.1021/jp0742261] [Cited by in Crossref: 48] [Cited by in F6Publishing: 43] [Article Influence: 3.2] [Reference Citation Analysis]
250 Hann BC, Lane DP. The dominating effect of mutant p53. Nat Genet 1995;9:221-2. [DOI: 10.1038/ng0395-221] [Cited by in Crossref: 35] [Cited by in F6Publishing: 34] [Article Influence: 1.3] [Reference Citation Analysis]
251 Van Meir EG, Polverini PJ, Chazin VR, Su Huang HJ, de Tribolet N, Cavenee WK. Release of an inhibitor of angiogenesis upon induction of wild type p53 expression in glioblastoma cells. Nat Genet. 1994;8:171-176. [PMID: 7531056 DOI: 10.1038/ng1094-171] [Cited by in Crossref: 219] [Cited by in F6Publishing: 204] [Article Influence: 8.1] [Reference Citation Analysis]
252 Donahue RJ, Razmara M, Hoek JB, Knudsen TB. Direct influence of the p53 tumor suppressor on mitochondrial biogenesis and function. FASEB J 2001;15:635-44. [PMID: 11259382 DOI: 10.1096/fj.00-0262com] [Cited by in Crossref: 46] [Cited by in F6Publishing: 47] [Article Influence: 2.2] [Reference Citation Analysis]
253 Murata A, Itoh Y, Mano E, Kanbayashi S, Igarashi C, Takahashi H, Takahashi S, Kamagata K. One-Dimensional Search Dynamics of Tumor Suppressor p53 Regulated by a Disordered C-Terminal Domain. Biophys J 2017;112:2301-14. [PMID: 28591603 DOI: 10.1016/j.bpj.2017.04.038] [Cited by in Crossref: 16] [Cited by in F6Publishing: 12] [Article Influence: 3.2] [Reference Citation Analysis]
254 Damineni S, Rao VR, Kumar S, Ravuri RR, Kagitha S, Dunna NR, Digumarthi R, Satti V. Germline mutations of TP53 gene in breast cancer. Tumour Biol 2014;35:9219-27. [PMID: 24929325 DOI: 10.1007/s13277-014-2176-6] [Cited by in Crossref: 10] [Cited by in F6Publishing: 8] [Article Influence: 1.3] [Reference Citation Analysis]
255 Seemann S, Maurici D, Olivier M, Caron de Fromentel C, Hainaut P. The tumor suppressor gene TP53: implications for cancer management and therapy. Crit Rev Clin Lab Sci 2004;41:551-83. [PMID: 15603511 DOI: 10.1080/10408360490504952] [Cited by in Crossref: 23] [Cited by in F6Publishing: 21] [Article Influence: 1.4] [Reference Citation Analysis]
256 Solomon H, Buganim Y, Kogan-Sakin I, Pomeraniec L, Assia Y, Madar S, Goldstein I, Brosh R, Kalo E, Beatus T, Goldfinger N, Rotter V. Various p53 mutant proteins differently regulate the Ras circuit to induce a cancer-related gene signature. J Cell Sci 2012;125:3144-52. [PMID: 22427690 DOI: 10.1242/jcs.099663] [Cited by in Crossref: 48] [Cited by in F6Publishing: 48] [Article Influence: 4.8] [Reference Citation Analysis]
257 Pan Y, Nussinov R. Cooperativity dominates the genomic organization of p53-response elements: a mechanistic view. PLoS Comput Biol 2009;5:e1000448. [PMID: 19629163 DOI: 10.1371/journal.pcbi.1000448] [Cited by in Crossref: 16] [Cited by in F6Publishing: 16] [Article Influence: 1.2] [Reference Citation Analysis]
258 Di Como CJ, Gaiddon C, Prives C. p73 function is inhibited by tumor-derived p53 mutants in mammalian cells. Mol Cell Biol 1999;19:1438-49. [PMID: 9891077 DOI: 10.1128/MCB.19.2.1438] [Cited by in Crossref: 285] [Cited by in F6Publishing: 129] [Article Influence: 12.4] [Reference Citation Analysis]
259 Galton DJ. Genetic markers to predict polygenic disease. Curr Atheroscler Rep 1999;1:97-100. [PMID: 11122697 DOI: 10.1007/s11883-999-0004-z] [Cited by in Crossref: 1] [Article Influence: 0.0] [Reference Citation Analysis]
260 Sanseau P. Impact of human genome sequencing for in silico target discovery. Drug Discovery Today 2001;6:316-23. [DOI: 10.1016/s1359-6446(01)01724-x] [Cited by in Crossref: 15] [Cited by in F6Publishing: 2] [Article Influence: 0.7] [Reference Citation Analysis]
261 Timofeev O, Stiewe T. Rely on Each Other: DNA Binding Cooperativity Shapes p53 Functions in Tumor Suppression and Cancer Therapy. Cancers (Basel) 2021;13:2422. [PMID: 34067731 DOI: 10.3390/cancers13102422] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
262 Rippin TM, Bykov VJ, Freund SM, Selivanova G, Wiman KG, Fersht AR. Characterization of the p53-rescue drug CP-31398 in vitro and in living cells. Oncogene 2002;21:2119-29. [PMID: 11948395 DOI: 10.1038/sj.onc.1205362] [Cited by in Crossref: 113] [Cited by in F6Publishing: 108] [Article Influence: 5.7] [Reference Citation Analysis]
263 Stone EA, Sidow A. Physicochemical constraint violation by missense substitutions mediates impairment of protein function and disease severity. Genome Res 2005;15:978-86. [PMID: 15965030 DOI: 10.1101/gr.3804205] [Cited by in Crossref: 240] [Cited by in F6Publishing: 212] [Article Influence: 14.1] [Reference Citation Analysis]
264 Saini H, Hakeem I, Mukherjee S, Chowdhury S, Chowdhury R. Autophagy Regulated by Gain of Function Mutant p53 Enhances Proteasomal Inhibitor-Mediated Cell Death through Induction of ROS and ERK in Lung Cancer Cells. J Oncol 2019;2019:6164807. [PMID: 30723502 DOI: 10.1155/2019/6164807] [Cited by in Crossref: 5] [Cited by in F6Publishing: 6] [Article Influence: 1.7] [Reference Citation Analysis]
265 Suchánková J, Legartová S, Ručková E, Vojtěšek B, Kozubek S, Bártová E. Mutations in the TP53 gene affected recruitment of 53BP1 protein to DNA lesions, but level of 53BP1 was stable after γ-irradiation that depleted MDC1 protein in specific TP53 mutants. Histochem Cell Biol 2017;148:239-55. [PMID: 28397142 DOI: 10.1007/s00418-017-1567-3] [Cited by in Crossref: 8] [Cited by in F6Publishing: 10] [Article Influence: 1.6] [Reference Citation Analysis]
266 Loh SN. The missing zinc: p53 misfolding and cancer. Metallomics 2010;2:442-9. [PMID: 21072344 DOI: 10.1039/c003915b] [Cited by in Crossref: 73] [Cited by in F6Publishing: 65] [Article Influence: 6.1] [Reference Citation Analysis]
267 Olafson LR, Gunawardena M, Nixdorf S, McDonald KL, Rapkins RW. The role of TP53 gain-of-function mutation in multifocal glioblastoma. J Neurooncol 2020;147:37-47. [PMID: 32002804 DOI: 10.1007/s11060-019-03318-5] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 1.5] [Reference Citation Analysis]
268 Li X, Coffino P. Identification of a Region of p53 That Confers Lability. Journal of Biological Chemistry 1996;271:4447-51. [DOI: 10.1074/jbc.271.8.4447] [Cited by in Crossref: 17] [Cited by in F6Publishing: 19] [Article Influence: 0.7] [Reference Citation Analysis]
269 Chryplewicz A, Tienda SM, Nahotko DA, Peters PN, Lengyel E, Eckert MA. Mutant p53 regulates LPA signaling through lysophosphatidic acid phosphatase type 6. Sci Rep 2019;9:5195. [PMID: 30914657 DOI: 10.1038/s41598-019-41352-5] [Cited by in Crossref: 10] [Cited by in F6Publishing: 10] [Article Influence: 3.3] [Reference Citation Analysis]
270 Nasir L, Krasner H, Argyle DJ, Williams A. Immunocytochemical analysis of the tumour suppressor protein (p53) in feline neoplasia. Cancer Letters 2000;155:1-7. [DOI: 10.1016/s0304-3835(00)00337-2] [Cited by in Crossref: 30] [Cited by in F6Publishing: 3] [Article Influence: 1.4] [Reference Citation Analysis]
271 Bosch FX, Ritter D, Enders C, Flechtenmacher C, Abel U, Dietz A, Hergenhahn M, Weidauer H. Head and neck tumor sites differ in prevalence and spectrum ofp53 alterations but these have limited prognostic value. Int J Cancer 2004;111:530-8. [DOI: 10.1002/ijc.11698] [Cited by in Crossref: 55] [Cited by in F6Publishing: 49] [Article Influence: 3.1] [Reference Citation Analysis]
272 Tahirov TH, Inoue-Bungo T, Morii H, Fujikawa A, Sasaki M, Kimura K, Shiina M, Sato K, Kumasaka T, Yamamoto M. Structural analyses of DNA recognition by the AML1/Runx-1 Runt domain and its allosteric control by CBFbeta. Cell. 2001;104:755-767. [PMID: 11257229 DOI: 10.1016/S0092-8674(01)00271-9] [Cited by in Crossref: 212] [Cited by in F6Publishing: 99] [Article Influence: 10.1] [Reference Citation Analysis]
273 Anderson ME, Tegtmeyer P. Giant leap for p53, small step for drug design. Bioessays 1995;17:3-7. [DOI: 10.1002/bies.950170103] [Cited by in Crossref: 9] [Cited by in F6Publishing: 8] [Article Influence: 0.3] [Reference Citation Analysis]
274 Pina S, Canadas RF, Jiménez G, Perán M, Marchal JA, Reis RL, Oliveira JM. Biofunctional Ionic-Doped Calcium Phosphates: Silk Fibroin Composites for Bone Tissue Engineering Scaffolding. Cells Tissues Organs 2017;204:150-63. [PMID: 28803246 DOI: 10.1159/000469703] [Cited by in Crossref: 22] [Cited by in F6Publishing: 18] [Article Influence: 4.4] [Reference Citation Analysis]
275 Regad L, Chéron JB, Triki D, Senac C, Flatters D, Camproux AC. Exploring the potential of a structural alphabet-based tool for mining multiple target conformations and target flexibility insight. PLoS One 2017;12:e0182972. [PMID: 28817602 DOI: 10.1371/journal.pone.0182972] [Cited by in Crossref: 7] [Cited by in F6Publishing: 6] [Article Influence: 1.4] [Reference Citation Analysis]
276 Cantini F, Gianni' P, Savarin P, Bizzarri AR, Sette M. Solution structure of the anticancer p28 peptide in biomimetic medium. J Pept Sci 2021;:e3357. [PMID: 34151482 DOI: 10.1002/psc.3357] [Reference Citation Analysis]
277 Nichols NM, Matthews KS. p53 Unfolding Detected by CD but Not by Tryptophan Fluorescence. Biochemical and Biophysical Research Communications 2001;288:111-5. [DOI: 10.1006/bbrc.2001.5764] [Cited by in Crossref: 10] [Cited by in F6Publishing: 10] [Article Influence: 0.5] [Reference Citation Analysis]
278 Lutzker SG. P53 tumour suppressor gene and germ cell neoplasia. APMIS 1998;106:85-9. [DOI: 10.1111/j.1699-0463.1998.tb01323.x] [Cited by in Crossref: 35] [Cited by in F6Publishing: 35] [Article Influence: 1.5] [Reference Citation Analysis]
279 D'Abramo M, Bešker N, Desideri A, Levine AJ, Melino G, Chillemi G. The p53 tetramer shows an induced-fit interaction of the C-terminal domain with the DNA-binding domain. Oncogene 2016;35:3272-81. [PMID: 26477317 DOI: 10.1038/onc.2015.388] [Cited by in Crossref: 30] [Cited by in F6Publishing: 29] [Article Influence: 4.3] [Reference Citation Analysis]
280 Signorelli S, Cannistraro S, Bizzarri AR. Raman Evidence of p53-DBD Disorder Decrease upon Interaction with the Anticancer Protein Azurin. Int J Mol Sci 2019;20:E3078. [PMID: 31238511 DOI: 10.3390/ijms20123078] [Cited by in Crossref: 8] [Cited by in F6Publishing: 6] [Article Influence: 2.7] [Reference Citation Analysis]
281 Hasegawa M, Ohoka I, Yamazaki K, Hanami K, Sugano I, Nagao T, Asoh A, Wada N, Nagao K, Ishida Y. Expression of p21/WAF-1, status of apoptosis and p53 mutation in esophageal squamous cell carcinoma with HPV infection. Pathol Int. 2002;52:442-450. [PMID: 12167102 DOI: 10.1046/j.1440-1827.2002.01373.x] [Cited by in Crossref: 14] [Cited by in F6Publishing: 15] [Article Influence: 0.7] [Reference Citation Analysis]
282 Menendez D, Inga A, Resnick MA. The biological impact of the human master regulator p53 can be altered by mutations that change the spectrum and expression of its target genes. Mol Cell Biol 2006;26:2297-308. [PMID: 16508005 DOI: 10.1128/MCB.26.6.2297-2308.2006] [Cited by in Crossref: 63] [Cited by in F6Publishing: 31] [Article Influence: 3.9] [Reference Citation Analysis]
283 Monti P, Campomenosi P, Ciribilli Y, Iannone R, Aprile A, Inga A, Tada M, Menichini P, Abbondandolo A, Fronza G. Characterization of the p53 mutants ability to inhibit p73 beta transactivation using a yeast-based functional assay. Oncogene. 2003;22:5252-5260. [PMID: 12917626 DOI: 10.1038/sj.onc.1206511] [Cited by in Crossref: 33] [Cited by in F6Publishing: 31] [Article Influence: 1.7] [Reference Citation Analysis]
284 Xirodimas DP, Lane DP. Molecular evolution of the thermosensitive PAb1620 epitope of human p53 by DNA shuffling. J Biol Chem 1999;274:28042-9. [PMID: 10488156 DOI: 10.1074/jbc.274.39.28042] [Cited by in Crossref: 19] [Cited by in F6Publishing: 18] [Article Influence: 0.8] [Reference Citation Analysis]
285 Hartwig A, Asmuss M, Blessing H, Hoffmann S, Jahnke G, Khandelwal S, Pelzer A, Bürkle A. Interference by toxic metal ions with zinc-dependent proteins involved in maintaining genomic stability. Food and Chemical Toxicology 2002;40:1179-84. [DOI: 10.1016/s0278-6915(02)00043-1] [Cited by in Crossref: 103] [Cited by in F6Publishing: 21] [Article Influence: 5.2] [Reference Citation Analysis]
286 Yang DS, Huang K, Su M, Wang TT, Liu SS, Xu Y, Wang WX. Next-generation sequencing revealed synchronous double primary lung squamous carcinoma: a case report. J Int Med Res 2021;49:3000605211018575. [PMID: 34038210 DOI: 10.1177/03000605211018575] [Reference Citation Analysis]
287 Bizzarri AR, Cannistraro S. Investigation of a Direct Interaction between miR4749 and the Tumor Suppressor p53 by Fluorescence, FRET and Molecular Modeling. Biomolecules 2020;10:E346. [PMID: 32098369 DOI: 10.3390/biom10020346] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 1.5] [Reference Citation Analysis]
288 Russo T, Zambrano N, Esposito F, Ammendola R, Cimino F, Fiscella M, Jackman J, O'Connor PM, Anderson CW, Appella E. A p53-independent pathway for activation of WAF1/CIP1 expression following oxidative stress. J Biol Chem 1995;270:29386-91. [PMID: 7493974 DOI: 10.1074/jbc.270.49.29386] [Cited by in Crossref: 166] [Cited by in F6Publishing: 163] [Article Influence: 6.4] [Reference Citation Analysis]
289 Gorgoulis VG, Zacharatos P, Kotsinas A, Mariatos G, Liloglou T, Vogiatzi T, Foukas P, Rassidakis G, Garinis G, Ioannides T, Zoumpourlis V, Bramis J, Michail PO, Asimacopoulos PJ, Field JK, Kittas C. Altered Expression of the Cell Cycle Regulatory Molecules pRb, p53 and MDM2 Exert a Synergetic Effect on Tumor Growth and Chromosomal Instability in Non-small Cell Lung Carcinomas (NSCLCs). Mol Med 2000;6:208-37. [DOI: 10.1007/bf03402115] [Cited by in Crossref: 27] [Article Influence: 1.2] [Reference Citation Analysis]
290 Tidow H, Veprintsev DB, Freund SM, Fersht AR. Effects of Oncogenic Mutations and DNA Response Elements on the Binding of p53 to p53-binding Protein 2 (53BP2). Journal of Biological Chemistry 2006;281:32526-33. [DOI: 10.1074/jbc.m604725200] [Cited by in Crossref: 36] [Cited by in F6Publishing: 18] [Article Influence: 2.3] [Reference Citation Analysis]
291 Wang G, Zhao Y, Liu X, Wang L, Wu C, Zhang W, Liu W, Zhang P, Cong W, Zhu Y. Allelic loss and gain, but not genomic instability, as the major somatic mutation in primary hepatocellular carcinoma. Genes Chromosomes Cancer. 2001;31:221-227. [PMID: 11391792 DOI: 10.1002/gcc.1138] [Cited by in Crossref: 51] [Cited by in F6Publishing: 53] [Article Influence: 2.4] [Reference Citation Analysis]
292 Gruszka-Westwood AM, Hamoudi RA, Matutes E, Tuset E, Catovsky D. p53 abnormalities in splenic lymphoma with villous lymphocytes. Blood 2001;97:3552-8. [PMID: 11369650 DOI: 10.1182/blood.v97.11.3552] [Cited by in Crossref: 67] [Cited by in F6Publishing: 16] [Article Influence: 3.2] [Reference Citation Analysis]
293 Munsch D, Watanabe-Fukunaga R, Bourdon JC, Nagata S, May E, Yonish-Rouach E, Reisdorf P. Human and mouse Fas (APO-1/CD95) death receptor genes each contain a p53-responsive element that is activated by p53 mutants unable to induce apoptosis. J Biol Chem 2000;275:3867-72. [PMID: 10660538 DOI: 10.1074/jbc.275.6.3867] [Cited by in Crossref: 80] [Cited by in F6Publishing: 81] [Article Influence: 3.6] [Reference Citation Analysis]
294 Prowald A, Cronauer MV, von Klot C, Eilers T, Rinnab L, Herrmann T, Spindler K, Montenarh M, Jonas U, Burchardt M. Modulation of β-catenin-mediated TCF-signalling in prostate cancer cell lines by wild-type and mutant p53. Prostate 2007;67:1751-60. [DOI: 10.1002/pros.20660] [Cited by in Crossref: 9] [Cited by in F6Publishing: 9] [Article Influence: 0.6] [Reference Citation Analysis]
295 Tiberti M, Invernizzi G, Lambrughi M, Inbar Y, Schreiber G, Papaleo E. PyInteraph: a framework for the analysis of interaction networks in structural ensembles of proteins. J Chem Inf Model 2014;54:1537-51. [PMID: 24702124 DOI: 10.1021/ci400639r] [Cited by in Crossref: 67] [Cited by in F6Publishing: 53] [Article Influence: 8.4] [Reference Citation Analysis]
296 Rea S, Xouri G, Akhtar A. Males absent on the first (MOF): from flies to humans. Oncogene 2007;26:5385-94. [DOI: 10.1038/sj.onc.1210607] [Cited by in Crossref: 93] [Cited by in F6Publishing: 96] [Article Influence: 6.2] [Reference Citation Analysis]
297 Temam S, Flahault A, Périé S, Monceaux G, Coulet F, Callard P, Bernaudin JF, St Guily JL, Fouret P. p53 gene status as a predictor of tumor response to induction chemotherapy of patients with locoregionally advanced squamous cell carcinomas of the head and neck. J Clin Oncol 2000;18:385-94. [PMID: 10637254 DOI: 10.1200/JCO.2000.18.2.385] [Cited by in Crossref: 106] [Cited by in F6Publishing: 33] [Article Influence: 4.8] [Reference Citation Analysis]
298 Beno I, Rosenthal K, Levitine M, Shaulov L, Haran TE. Sequence-dependent cooperative binding of p53 to DNA targets and its relationship to the structural properties of the DNA targets. Nucleic Acids Res 2011;39:1919-32. [PMID: 21071400 DOI: 10.1093/nar/gkq1044] [Cited by in Crossref: 39] [Cited by in F6Publishing: 34] [Article Influence: 3.3] [Reference Citation Analysis]
299 Wasielewski M, Hanifi-Moghaddam P, Hollestelle A, Merajver SD, van den Ouweland A, Klijn JG, Ethier SP, Schutte M. Deleterious CHEK2 1100delC and L303X mutants identified among 38 human breast cancer cell lines. Breast Cancer Res Treat 2009;113:285-91. [PMID: 18297428 DOI: 10.1007/s10549-008-9942-3] [Cited by in Crossref: 7] [Cited by in F6Publishing: 6] [Article Influence: 0.5] [Reference Citation Analysis]
300 Shiraishi K, Kato S, Han SY, Liu W, Otsuka K, Sakayori M, Ishida T, Takeda M, Kanamaru R, Ohuchi N. Isolation of temperature-sensitive p53 mutations from a comprehensive missense mutation library. J Biol Chem. 2004;279:348-355. [PMID: 14559903 DOI: 10.1074/jbc.m310815200] [Cited by in Crossref: 57] [Cited by in F6Publishing: 25] [Article Influence: 3.0] [Reference Citation Analysis]
301 Matsumoto M, Furihata M, Ohtsuki Y. Posttranslational phosphorylation of mutant p53 protein in tumor development. Med Mol Morphol 2006;39:79-87. [PMID: 16821145 DOI: 10.1007/s00795-006-0320-0] [Cited by in Crossref: 35] [Cited by in F6Publishing: 34] [Article Influence: 2.2] [Reference Citation Analysis]
302 Jordan JJ, Inga A, Conway K, Edmiston S, Carey LA, Wu L, Resnick MA. Altered-function p53 missense mutations identified in breast cancers can have subtle effects on transactivation. Mol Cancer Res 2010;8:701-16. [PMID: 20407015 DOI: 10.1158/1541-7786.MCR-09-0442] [Cited by in Crossref: 41] [Cited by in F6Publishing: 30] [Article Influence: 3.4] [Reference Citation Analysis]
303 Harris CC. p53 tumor suppressor gene: at the crossroads of molecular carcinogenesis, molecular epidemiology, and cancer risk assessment. Environ Health Perspect 1996;104 Suppl 3:435-9. [PMID: 8781359 DOI: 10.1289/ehp.96104s3435] [Cited by in Crossref: 51] [Cited by in F6Publishing: 45] [Article Influence: 2.0] [Reference Citation Analysis]
304 Perrone F, Bossi P, Cortelazzi B, Locati L, Quattrone P, Pierotti MA, Pilotti S, Licitra L. TP53 Mutations and Pathologic Complete Response to Neoadjuvant Cisplatin and Fluorouracil Chemotherapy in Resected Oral Cavity Squamous Cell Carcinoma. JCO 2010;28:761-6. [DOI: 10.1200/jco.2009.22.4170] [Cited by in Crossref: 79] [Cited by in F6Publishing: 50] [Article Influence: 6.6] [Reference Citation Analysis]
305 Vlaycheva LA, Chambers TJ. Neuroblastoma cell-adapted yellow fever 17D virus: characterization of a viral variant associated with persistent infection and decreased virus spread. J Virol 2002;76:6172-84. [PMID: 12021351 DOI: 10.1128/jvi.76.12.6172-6184.2002] [Cited by in Crossref: 22] [Cited by in F6Publishing: 11] [Article Influence: 1.1] [Reference Citation Analysis]
306 Borah S, Verma SC, Robertson ES. ORF73 of herpesvirus saimiri, a viral homolog of Kaposi's sarcoma-associated herpesvirus, modulates the two cellular tumor suppressor proteins p53 and pRb. J Virol 2004;78:10336-47. [PMID: 15367600 DOI: 10.1128/JVI.78.19.10336-10347.2004] [Cited by in Crossref: 31] [Cited by in F6Publishing: 17] [Article Influence: 1.7] [Reference Citation Analysis]
307 Buzek J, Latonen L, Kurki S, Peltonen K, Laiho M. Redox state of tumor suppressor p53 regulates its sequence-specific DNA binding in DNA-damaged cells by cysteine 277. Nucleic Acids Res 2002;30:2340-8. [PMID: 12034820 DOI: 10.1093/nar/30.11.2340] [Cited by in Crossref: 88] [Cited by in F6Publishing: 80] [Article Influence: 4.4] [Reference Citation Analysis]
308 Koulgi S, Achalere A, Sonavane U, Joshi R. Investigating DNA Binding and Conformational Variation in Temperature Sensitive p53 Cancer Mutants Using QM-MM Simulations. PLoS One 2015;10:e0143065. [PMID: 26579714 DOI: 10.1371/journal.pone.0143065] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 0.9] [Reference Citation Analysis]
309 Lepik D, Ilves I, Kristjuhan A, Maimets T, Ustav M. p53 protein is a suppressor of papillomavirus DNA amplificational replication. J Virol 1998;72:6822-31. [PMID: 9658131 DOI: 10.1128/JVI.72.8.6822-6831.1998] [Cited by in Crossref: 29] [Cited by in F6Publishing: 15] [Article Influence: 1.2] [Reference Citation Analysis]
310 Zhang Y, Coillie SV, Fang JY, Xu J. Gain of function of mutant p53: R282W on the peak? Oncogenesis 2016;5:e196. [PMID: 26878390 DOI: 10.1038/oncsis.2016.8] [Cited by in Crossref: 24] [Cited by in F6Publishing: 19] [Article Influence: 4.0] [Reference Citation Analysis]
311 Arnold AR, Grodick MA, Barton JK. DNA Charge Transport: from Chemical Principles to the Cell. Cell Chem Biol 2016;23:183-97. [PMID: 26933744 DOI: 10.1016/j.chembiol.2015.11.010] [Cited by in Crossref: 89] [Cited by in F6Publishing: 71] [Article Influence: 14.8] [Reference Citation Analysis]
312 Hafsi H, Hainaut P. Redox control and interplay between p53 isoforms: roles in the regulation of basal p53 levels, cell fate, and senescence. Antioxid Redox Signal 2011;15:1655-67. [PMID: 21194382 DOI: 10.1089/ars.2010.3771] [Cited by in Crossref: 36] [Cited by in F6Publishing: 33] [Article Influence: 3.3] [Reference Citation Analysis]
313 Timmerman DM, Remmers TL, Hillenius S, Looijenga LHJ. Mechanisms of TP53 Pathway Inactivation in Embryonic and Somatic Cells-Relevance for Understanding (Germ Cell) Tumorigenesis. Int J Mol Sci 2021;22:5377. [PMID: 34065345 DOI: 10.3390/ijms22105377] [Reference Citation Analysis]
314 Abduljabbar R, Negm OH, Lai CF, Jerjees DA, Al-Kaabi M, Hamed MR, Tighe PJ, Buluwela L, Mukherjee A, Green AR, Ali S, Rakha EA, Ellis IO. Clinical and biological significance of glucocorticoid receptor (GR) expression in breast cancer. Breast Cancer Res Treat 2015;150:335-46. [PMID: 25762479 DOI: 10.1007/s10549-015-3335-1] [Cited by in Crossref: 45] [Cited by in F6Publishing: 44] [Article Influence: 6.4] [Reference Citation Analysis]
315 Amikura T, Sekine M, Hirai Y, Fujimoto S, Hatae M, Kobayashi I, Fujii T, Nagata I, Ushijima K, Obata K, Suzuki M, Yoshinaga M, Umesaki N, Satoh S, Enomoto T, Motoyama S, Nishino K, Haino K, Tanaka K. Mutational analysis of TP53 and p21 in familial and sporadic ovarian cancer in Japan. Gynecologic Oncology 2006;100:365-71. [DOI: 10.1016/j.ygyno.2005.09.010] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 0.4] [Reference Citation Analysis]
316 Tan M, Wang Y, Guan K, Sun Y. PTGF-beta, a type beta transforming growth factor (TGF-beta) superfamily member, is a p53 target gene that inhibits tumor cell growth via TGF-beta signaling pathway. Proc Natl Acad Sci U S A 2000;97:109-14. [PMID: 10618379 DOI: 10.1073/pnas.97.1.109] [Cited by in Crossref: 181] [Cited by in F6Publishing: 168] [Article Influence: 8.2] [Reference Citation Analysis]
317 Yamazaki Y, Chiba I, Hirai A, Sugiura C, Notani K, Kashiwazaki H, Tei K, Totsuka Y, Fukuda H. Specific p53 mutations predict poor prognosis in oral squamous cell carcinoma. Oral Oncology 2003;39:163-9. [DOI: 10.1016/s1368-8375(02)00064-7] [Cited by in Crossref: 34] [Cited by in F6Publishing: 6] [Article Influence: 1.8] [Reference Citation Analysis]
318 Celli J, Duijf P, Hamel BC, Bamshad M, Kramer B, Smits AP, Newbury-ecob R, Hennekam RC, Van Buggenhout G, van Haeringen A, Woods C, van Essen AJ, de Waal R, Vriend G, Haber DA, Yang A, Mckeon F, Brunner HG, van Bokhoven H. Heterozygous Germline Mutations in the p53 Homolog p63 Are the Cause of EEC Syndrome. Cell 1999;99:143-53. [DOI: 10.1016/s0092-8674(00)81646-3] [Cited by in Crossref: 478] [Cited by in F6Publishing: 173] [Article Influence: 20.8] [Reference Citation Analysis]
319 Cox LS, Lane DP. Tumour suppressors, kinases and clamps: How p53 regulates the cell cycle in response to DNA damage. Bioessays 1995;17:501-8. [DOI: 10.1002/bies.950170606] [Cited by in Crossref: 197] [Cited by in F6Publishing: 188] [Article Influence: 7.3] [Reference Citation Analysis]
320 Kang HJ, Chun SM, Kim KR, Sohn I, Sung CO. Clinical relevance of gain-of-function mutations of p53 in high-grade serous ovarian carcinoma. PLoS One 2013;8:e72609. [PMID: 23967324 DOI: 10.1371/journal.pone.0072609] [Cited by in Crossref: 38] [Cited by in F6Publishing: 41] [Article Influence: 4.2] [Reference Citation Analysis]
321 Lin J, Yang Q, Yan Z, Markowitz J, Wilder PT, Carrier F, Weber DJ. Inhibiting S100B restores p53 levels in primary malignant melanoma cancer cells. J Biol Chem. 2004;279:34071-34077. [PMID: 15178678 DOI: 10.1074/jbc.m405419200] [Cited by in Crossref: 94] [Cited by in F6Publishing: 52] [Article Influence: 5.2] [Reference Citation Analysis]
322 Lee W, Harvey TS, Yin Y, Yau P, Litchfield D, Arrowsmith CH. Solution structure of the tetrameric minimum transforming domain of p53. Nat Struct Biol 1994;1:877-90. [PMID: 7773777 DOI: 10.1038/nsb1294-877] [Cited by in Crossref: 195] [Cited by in F6Publishing: 205] [Article Influence: 7.2] [Reference Citation Analysis]
323 Kantarci N, Doruker P, Haliloglu T. Cooperative fluctuations point to the dimerization interface of p53 core domain. Biophys J 2006;91:421-32. [PMID: 16807229 DOI: 10.1529/biophysj.106.077800] [Cited by in Crossref: 11] [Cited by in F6Publishing: 11] [Article Influence: 0.7] [Reference Citation Analysis]
324 Glasfeld A, Koehler AN, Schumacher MA, Brennan RG. The role of lysine 55 in determining the specificity of the purine repressor for its operators through minor groove interactions. J Mol Biol 1999;291:347-61. [PMID: 10438625 DOI: 10.1006/jmbi.1999.2946] [Cited by in Crossref: 30] [Cited by in F6Publishing: 29] [Article Influence: 1.3] [Reference Citation Analysis]
325 Tsafou K, Tiwari PB, Forman-Kay JD, Metallo SJ, Toretsky JA. Targeting Intrinsically Disordered Transcription Factors: Changing the Paradigm. J Mol Biol 2018;430:2321-41. [PMID: 29655986 DOI: 10.1016/j.jmb.2018.04.008] [Cited by in Crossref: 48] [Cited by in F6Publishing: 44] [Article Influence: 12.0] [Reference Citation Analysis]
326 Xue B, Dunbrack RL, Williams RW, Dunker AK, Uversky VN. PONDR-FIT: a meta-predictor of intrinsically disordered amino acids. Biochim Biophys Acta 2010;1804:996-1010. [PMID: 20100603 DOI: 10.1016/j.bbapap.2010.01.011] [Cited by in Crossref: 685] [Cited by in F6Publishing: 634] [Article Influence: 57.1] [Reference Citation Analysis]
327 Gualberto A, Hixon ML, Finco TS, Perkins ND, Nabel GJ, Baldwin AS Jr. A proliferative p53-responsive element mediates tumor necrosis factor alpha induction of the human immunodeficiency virus type 1 long terminal repeat. Mol Cell Biol 1995;15:3450-9. [PMID: 7760842 DOI: 10.1128/MCB.15.6.3450] [Cited by in Crossref: 27] [Cited by in F6Publishing: 10] [Article Influence: 1.0] [Reference Citation Analysis]
328 Ueno M, Masutani H, Arai RJ, Yamauchi A, Hirota K, Sakai T, Inamoto T, Yamaoka Y, Yodoi J, Nikaido T. Thioredoxin-dependent redox regulation of p53-mediated p21 activation. J Biol Chem. 1999;274:35809-35815. [PMID: 10585464 DOI: 10.1074/jbc.274.50.35809] [Cited by in Crossref: 286] [Cited by in F6Publishing: 277] [Article Influence: 13.0] [Reference Citation Analysis]
329 Olive KP, Tuveson DA, Ruhe ZC, Yin B, Willis NA, Bronson RT, Crowley D, Jacks T. Mutant p53 gain of function in two mouse models of Li-Fraumeni syndrome. Cell. 2004;119:847-860. [PMID: 15607980 DOI: 10.1016/j.cell.2004.11.004] [Cited by in Crossref: 859] [Cited by in F6Publishing: 800] [Article Influence: 50.5] [Reference Citation Analysis]
330 Chen S, Wu JL, Liang Y, Tang YG, Song HX, Wu LL, Xing YF, Yan N, Li YT, Wang ZY, Xiao SJ, Lu X, Chen SJ, Lu M. Arsenic Trioxide Rescues Structural p53 Mutations through a Cryptic Allosteric Site. Cancer Cell 2021;39:225-239.e8. [PMID: 33357454 DOI: 10.1016/j.ccell.2020.11.013] [Cited by in Crossref: 16] [Cited by in F6Publishing: 13] [Article Influence: 8.0] [Reference Citation Analysis]
331 Wang XW, Harris CC. p53 tumor-suppressor gene: clues to molecular carcinogenesis. J Cell Physiol 1997;173:247-55. [PMID: 9365531 DOI: 10.1002/(SICI)1097-4652(199711)173:2<247::AID-JCP30>3.0.CO;2-A] [Cited by in Crossref: 50] [Cited by in F6Publishing: 12] [Article Influence: 2.0] [Reference Citation Analysis]
332 Arden N, Betenbaugh MJ. Regulating apoptosis in mammalian cell cultures. Cytotechnology 2006;50:77-92. [PMID: 19003072 DOI: 10.1007/s10616-006-9008-5] [Cited by in Crossref: 20] [Cited by in F6Publishing: 14] [Article Influence: 1.3] [Reference Citation Analysis]
333 Preuss U, Kreutzfeld R, Scheidtmann KH. Tumor-derived p53 mutant C174Y is a gain-of-function mutant which activates the fos promoter and enhances colony formation. Int J Cancer 2000;88:162-71. [PMID: 11004663 DOI: 10.1002/1097-0215(20001015)88:2<162::aid-ijc3>3.0.co;2-m] [Cited by in Crossref: 16] [Cited by in F6Publishing: 8] [Article Influence: 0.7] [Reference Citation Analysis]
334 Pan Y, Nussinov R. p53-Induced DNA bending: the interplay between p53-DNA and p53-p53 interactions. J Phys Chem B 2008;112:6716-24. [PMID: 18461991 DOI: 10.1021/jp800680w] [Cited by in Crossref: 26] [Cited by in F6Publishing: 25] [Article Influence: 1.9] [Reference Citation Analysis]
335 Dlakic M, Harrington RE. Bending and torsional flexibility of G/C-rich sequences as determined by cyclization assays. J Biol Chem 1995;270:29945-52. [PMID: 8530394 DOI: 10.1074/jbc.270.50.29945] [Cited by in Crossref: 54] [Cited by in F6Publishing: 51] [Article Influence: 2.1] [Reference Citation Analysis]
336 Knudsen TB. Cell Death. In: Kavlock RJ, Daston GP, editors. Drug Toxicity in Embryonic Development I. Berlin: Springer Berlin Heidelberg; 1997. pp. 211-44. [DOI: 10.1007/978-3-642-60445-4_8] [Cited by in Crossref: 11] [Cited by in F6Publishing: 10] [Article Influence: 0.4] [Reference Citation Analysis]
337 Tichý V, Navrátilová L, Adámik M, Fojta M, Brázdová M. Redox state of p63 and p73 core domains regulates sequence-specific DNA binding. Biochemical and Biophysical Research Communications 2013;433:445-9. [DOI: 10.1016/j.bbrc.2013.02.097] [Cited by in Crossref: 14] [Cited by in F6Publishing: 13] [Article Influence: 1.6] [Reference Citation Analysis]
338 Bateman E. Autoregulation of eukaryotic transcription factors. Prog Nucleic Acid Res Mol Biol 1998;60:133-68. [PMID: 9594574 DOI: 10.1016/s0079-6603(08)60892-2] [Cited by in Crossref: 38] [Cited by in F6Publishing: 25] [Article Influence: 1.6] [Reference Citation Analysis]
339 Barnas C, Martel-Planche G, Furukawa Y, Hollstein M, Montesano R, Hainaut P. Inactivation of the p53 protein in cell lines derived from human esophageal cancers. Int J Cancer 1997;71:79-87. [PMID: 9096669 DOI: 10.1002/(sici)1097-0215(19970328)71:1<79::aid-ijc14>3.0.co;2-4] [Cited by in Crossref: 48] [Cited by in F6Publishing: 25] [Article Influence: 1.9] [Reference Citation Analysis]
340 Grattan BJ, Freake HC. Zinc and cancer: implications for LIV-1 in breast cancer. Nutrients 2012;4:648-75. [PMID: 22852056 DOI: 10.3390/nu4070648] [Cited by in Crossref: 58] [Cited by in F6Publishing: 50] [Article Influence: 5.8] [Reference Citation Analysis]
341 Matsumoto M, Furihata M, Kurabayashi A, Sasaguri S, Araki K, Hayashi H, Ohtsuki Y. Prognostic significance of serine 392 phosphorylation in overexpressed p53 protein in human esophageal squamous cell carcinoma. Oncology. 2004;67:143-150. [PMID: 15539919 DOI: 10.1159/000081001] [Cited by in Crossref: 25] [Cited by in F6Publishing: 27] [Article Influence: 1.4] [Reference Citation Analysis]
342 Lam V, McPherson JP, Salmena L, Lees J, Chu W, Sexsmith E, Hedley DW, Freedman MH, Reed JC, Malkin D. p53 gene status and chemosensitivity of childhood acute lymphoblastic leukemia cells to adriamycin. Leuk Res. 1999;23:871-880. [PMID: 10573131 DOI: 10.1016/s0145-2126(99)00102-2] [Cited by in Crossref: 21] [Cited by in F6Publishing: 6] [Article Influence: 0.9] [Reference Citation Analysis]
343 Berghmans S, Murphey RD, Wienholds E, Neuberg D, Kutok JL, Fletcher CD, Morris JP, Liu TX, Schulte-Merker S, Kanki JP, Plasterk R, Zon LI, Look AT. tp53 mutant zebrafish develop malignant peripheral nerve sheath tumors. Proc Natl Acad Sci U S A 2005;102:407-12. [PMID: 15630097 DOI: 10.1073/pnas.0406252102] [Cited by in Crossref: 427] [Cited by in F6Publishing: 393] [Article Influence: 25.1] [Reference Citation Analysis]
344 Pearson GD, Merrill GF. Deletion of the Saccharomyces cerevisiae TRR1 gene encoding thioredoxin reductase inhibits p53-dependent reporter gene expression. J Biol Chem 1998;273:5431-4. [PMID: 9488661 DOI: 10.1074/jbc.273.10.5431] [Cited by in Crossref: 67] [Cited by in F6Publishing: 64] [Article Influence: 2.8] [Reference Citation Analysis]
345 Mathe E, Olivier M, Kato S, Ishioka C, Hainaut P, Tavtigian SV. Computational approaches for predicting the biological effect of p53 missense mutations: a comparison of three sequence analysis based methods. Nucleic Acids Res 2006;34:1317-25. [PMID: 16522644 DOI: 10.1093/nar/gkj518] [Cited by in Crossref: 211] [Cited by in F6Publishing: 202] [Article Influence: 13.2] [Reference Citation Analysis]
346 Joerger AC, Fersht AR. Structural biology of the tumor suppressor p53 and cancer-associated mutants. Adv Cancer Res 2007;97:1-23. [PMID: 17419939 DOI: 10.1016/S0065-230X(06)97001-8] [Cited by in Crossref: 59] [Cited by in F6Publishing: 33] [Article Influence: 4.5] [Reference Citation Analysis]
347 Petty TJ, Emamzadah S, Costantino L, Petkova I, Stavridi ES, Saven JG, Vauthey E, Halazonetis TD. An induced fit mechanism regulates p53 DNA binding kinetics to confer sequence specificity. EMBO J 2011;30:2167-76. [PMID: 21522129 DOI: 10.1038/emboj.2011.127] [Cited by in Crossref: 80] [Cited by in F6Publishing: 74] [Article Influence: 7.3] [Reference Citation Analysis]
348 Wang Y, Pascal LE, Zhong M, Ai J, Wang D, Jing Y, Pilch J, Song Q, Rigatti LH, Graham LE, Nelson JB, Parwani AV, Wang Z. Combined Loss of EAF2 and p53 Induces Prostate Carcinogenesis in Male Mice. Endocrinology 2017;158:4189-205. [PMID: 29029019 DOI: 10.1210/en.2017-00409] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 1.2] [Reference Citation Analysis]
349 Selivanova G, Ryabchenko L, Jansson E, Iotsova V, Wiman KG. Reactivation of mutant p53 through interaction of a C-terminal peptide with the core domain. Mol Cell Biol 1999;19:3395-402. [PMID: 10207063 DOI: 10.1128/MCB.19.5.3395] [Cited by in Crossref: 96] [Cited by in F6Publishing: 27] [Article Influence: 4.2] [Reference Citation Analysis]
350 Padlewska K, Ramoz N, Cassonnet P, Riou G, Barrois M, Majewski S, Croissant O, Jablonska S, Orth G. Mutation and Abnormal Expression of the p53 Gene in the Viral Skin Carcinogenesis of Epidermodysplasia Verruciformis. Journal of Investigative Dermatology 2001;117:935-42. [DOI: 10.1046/j.0022-202x.2001.01515.x] [Cited by in Crossref: 32] [Cited by in F6Publishing: 28] [Article Influence: 1.5] [Reference Citation Analysis]
351 El-Deiry WS. Insights into cancer therapeutic design based on p53 and TRAIL receptor signaling. Cell Death Differ. 2001;8:1066-1075. [PMID: 11687885 DOI: 10.1038/sj.cdd.4400943] [Cited by in Crossref: 93] [Cited by in F6Publishing: 83] [Article Influence: 4.7] [Reference Citation Analysis]
352 Bazan V, Agnese V, Corsale S, Calò V, Valerio MR, Latteri MA, Vieni S, Grassi N, Cicero G, Dardanoni G, Tomasino RM, Colucci G, Gebbia N, Russo A; Gruppo Oncologico dell'Italia Meridionale (GOIM). Specific TP53 and/or Ki-ras mutations as independent predictors of clinical outcome in sporadic colorectal adenocarcinomas: results of a 5-year Gruppo Oncologico dell'Italia Meridionale (GOIM) prospective study. Ann Oncol 2005;16 Suppl 4:iv50-55. [PMID: 15923430 DOI: 10.1093/annonc/mdi908] [Cited by in Crossref: 49] [Cited by in F6Publishing: 50] [Article Influence: 3.5] [Reference Citation Analysis]
353 Iijima H, Kasai N, Chiku H, Murakami S, Sugawara F, Sakaguchi K, Yoshida H, Mizushina Y. The inhibitory action of long-chain fatty acids on the DNA binding activity of p53. Lipids 2006;41:521-7. [DOI: 10.1007/s11745-006-5000-2] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 0.3] [Reference Citation Analysis]
354 Kaku S, Albor A, Kulesz-Martin M. Dissociation of DNA binding and in vitro transcriptional activities dependent on the C terminus of P53 proteins. Biochem Biophys Res Commun 2001;280:204-11. [PMID: 11162500 DOI: 10.1006/bbrc.2000.4060] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 0.1] [Reference Citation Analysis]
355 Tabori U, Shlien A, Baskin B, Levitt S, Ray P, Alon N, Hawkins C, Bouffet E, Pienkowska M, Lafay-Cousin L, Gozali A, Zhukova N, Shane L, Gonzalez I, Finlay J, Malkin D. TP53 alterations determine clinical subgroups and survival of patients with choroid plexus tumors. J Clin Oncol 2010;28:1995-2001. [PMID: 20308654 DOI: 10.1200/JCO.2009.26.8169] [Cited by in Crossref: 128] [Cited by in F6Publishing: 51] [Article Influence: 10.7] [Reference Citation Analysis]
356 Feuerborn A, Möritz C, Von Bonin F, Dobbelstein M, Trümper L, Stürzenhofecker B, Kube D. Dysfunctional p53 deletion mutants in cell lines derived from Hodgkin's lymphoma. Leuk Lymphoma 2006;47:1932-40. [PMID: 17065008 DOI: 10.1080/10428190600667721] [Cited by in Crossref: 24] [Cited by in F6Publishing: 16] [Article Influence: 1.5] [Reference Citation Analysis]
357 Saha T, Kar RK, Sa G. Structural and sequential context of p53: A review of experimental and theoretical evidence. Prog Biophys Mol Biol 2015;117:250-63. [PMID: 25550083 DOI: 10.1016/j.pbiomolbio.2014.12.002] [Cited by in Crossref: 39] [Cited by in F6Publishing: 35] [Article Influence: 4.9] [Reference Citation Analysis]
358 Hung J, Anderson R. p53: functions, mutations and sarcomas. Acta Orthop Scand Suppl 1997;273:68-73. [PMID: 9057590 DOI: 10.1080/17453674.1997.11744705] [Cited by in Crossref: 23] [Cited by in F6Publishing: 20] [Article Influence: 0.9] [Reference Citation Analysis]
359 Kraniak JM, Abrams J, Nowak JE, Tainsky MA. Antioxidant agents transiently inhibit aneuploidy progression in Li-Fraumeni cell strains. Mol Carcinog 2006;45:141-56. [PMID: 16385586 DOI: 10.1002/mc.20145] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 0.4] [Reference Citation Analysis]
360 Portis T, Grossman WJ, Harding JC, Hess JL, Ratner L. Analysis of p53 inactivation in a human T-cell leukemia virus type 1 Tax transgenic mouse model. J Virol 2001;75:2185-93. [PMID: 11160722 DOI: 10.1128/JVI.75.5.2185-2193.2001] [Cited by in Crossref: 18] [Cited by in F6Publishing: 13] [Article Influence: 0.9] [Reference Citation Analysis]
361 Eischen CM, Lozano G. The Mdm network and its regulation of p53 activities: a rheostat of cancer risk. Hum Mutat 2014;35:728-37. [PMID: 24488925 DOI: 10.1002/humu.22524] [Cited by in Crossref: 48] [Cited by in F6Publishing: 49] [Article Influence: 6.0] [Reference Citation Analysis]
362 Uversky VN, Oldfield CJ, Dunker AK. Showing your ID: intrinsic disorder as an ID for recognition, regulation and cell signaling. J Mol Recognit 2005;18:343-84. [PMID: 16094605 DOI: 10.1002/jmr.747] [Cited by in Crossref: 605] [Cited by in F6Publishing: 581] [Article Influence: 35.6] [Reference Citation Analysis]
363 Tripathi V, Kaur E, Kharat SS, Hussain M, Damodaran AP, Kulshrestha S, Sengupta S. Abrogation of FBW7α-dependent p53 degradation enhances p53's function as a tumor suppressor. J Biol Chem 2019;294:13224-32. [PMID: 31346036 DOI: 10.1074/jbc.AC119.008483] [Cited by in Crossref: 7] [Cited by in F6Publishing: 4] [Article Influence: 2.3] [Reference Citation Analysis]
364 Tu C, Tan YH, Shaw G, Zhou Z, Bai Y, Luo R, Ji X. Impact of low-frequency hotspot mutation R282Q on the structure of p53 DNA-binding domain as revealed by crystallography at 1.54 angstroms resolution. Acta Crystallogr D Biol Crystallogr 2008;64:471-7. [PMID: 18453682 DOI: 10.1107/S0907444908003338] [Cited by in Crossref: 8] [Cited by in F6Publishing: 4] [Article Influence: 0.6] [Reference Citation Analysis]
365 Ng HK, Lam PY. The molecular genetics of central nervous system tumors. Pathology 1998;30:196-202. [PMID: 9643506 DOI: 10.1080/00313029800169236] [Cited by in Crossref: 22] [Cited by in F6Publishing: 21] [Article Influence: 0.9] [Reference Citation Analysis]
366 Hu X, Chen H, Jin M, Wang X, Lee J, Xu W, Zhang R, Li S, Niu J. Molecular cytogenetic characterization of undifferentiated embryonal sarcoma of the liver: a case report and literature review. Mol Cytogenet 2012;5:26. [PMID: 22551002 DOI: 10.1186/1755-8166-5-26] [Cited by in Crossref: 11] [Cited by in F6Publishing: 9] [Article Influence: 1.1] [Reference Citation Analysis]
367 Harada K, Bando T, Yoshida H, Sato M. Characteristics of antitumour activity of cepharanthin against a human adenosquamous cell carcinoma cell line. Oral Oncol 2001;37:643-51. [PMID: 11590074 DOI: 10.1016/s1368-8375(00)00125-1] [Cited by in Crossref: 16] [Cited by in F6Publishing: 2] [Article Influence: 0.8] [Reference Citation Analysis]
368 Muller PA, Vousden KH. p53 mutations in cancer. Nat Cell Biol. 2013;15:2-8. [PMID: 23263379 DOI: 10.1038/ncb2641] [Cited by in Crossref: 1018] [Cited by in F6Publishing: 945] [Article Influence: 113.1] [Reference Citation Analysis]
369 Hsu S, Lin P, Chou C, Lee W. Progesterone up-regulates p27 through an increased binding of the progesterone receptor-A-p53 protein complex onto the non-canonical p53 binding motif in HUVEC. The Journal of Steroid Biochemistry and Molecular Biology 2019;185:163-71. [DOI: 10.1016/j.jsbmb.2018.08.011] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.7] [Reference Citation Analysis]
370 Vrba L, Junk DJ, Novak P, Futscher BW. p53 induces distinct epigenetic states at its direct target promoters. BMC Genomics 2008;9:486. [PMID: 18922183 DOI: 10.1186/1471-2164-9-486] [Cited by in Crossref: 37] [Cited by in F6Publishing: 37] [Article Influence: 2.6] [Reference Citation Analysis]
371 Jernvall P, Mäkinen M, Karttunen T, Mäkelä J, Vihko P. Conserved region mutations of the p53 gene are concentrated in distal colorectal cancers. Int J Cancer 1997;74:97-101. [PMID: 9036877 DOI: 10.1002/(sici)1097-0215(19970220)74:1<97::aid-ijc17>3.0.co;2-f] [Cited by in Crossref: 22] [Cited by in F6Publishing: 4] [Article Influence: 0.9] [Reference Citation Analysis]
372 Yang Q, Zhang R, Wang XW, Spillare EA, Linke SP, Subramanian D, Griffith JD, Li JL, Hickson ID, Shen JC, Loeb LA, Mazur SJ, Appella E, Brosh RM, Karmakar P, Bohr VA, Harris CC. The Processing of Holliday Junctions by BLM and WRN Helicases Is Regulated by p53. Journal of Biological Chemistry 2002;277:31980-7. [DOI: 10.1074/jbc.m204111200] [Cited by in Crossref: 74] [Cited by in F6Publishing: 38] [Article Influence: 3.7] [Reference Citation Analysis]
373 Janz C, Süsse S, Wiesmüller L. p53 and recombination intermediates: role of tetramerization at DNA junctions in complex formation and exonucleolytic degradation. Oncogene 2002;21:2130-40. [DOI: 10.1038/sj.onc.1205292] [Cited by in Crossref: 22] [Cited by in F6Publishing: 25] [Article Influence: 1.1] [Reference Citation Analysis]
374 Tan YS, Mhoumadi Y, Verma CS. Roles of computational modelling in understanding p53 structure, biology, and its therapeutic targeting. J Mol Cell Biol 2019;11:306-16. [PMID: 30726928 DOI: 10.1093/jmcb/mjz009] [Cited by in Crossref: 11] [Cited by in F6Publishing: 9] [Article Influence: 5.5] [Reference Citation Analysis]
375 Gilleran JA, Yu X, Blayney AJ, Bencivenga AF, Na B, Augeri DJ, Blanden AR, Kimball SD, Loh SN, Roberge JY, Carpizo DR. Benzothiazolyl and Benzoxazolyl Hydrazones Function as Zinc Metallochaperones to Reactivate Mutant p53. J Med Chem 2021;64:2024-45. [PMID: 33538587 DOI: 10.1021/acs.jmedchem.0c01360] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 3.0] [Reference Citation Analysis]
376 Sheng Y, Pero RW, Olsson AR, Bryngelsson C, Hua J. DNA repair enhancement by a combined supplement of carotenoids, nicotinamide, and zinc. Cancer Detect Prev 1998;22:284-92. [PMID: 9674871 DOI: 10.1046/j.1525-1500.1998.cdoa37.x] [Cited by in Crossref: 13] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
377 Nataraj AJ, Wolf P, Cerroni L, Ananthaswamy HN. p53 Mutation in Squamous Cell Carcinomas from Psoriasis Patients Treated with Psoralen + UVA (PUVA). Journal of Investigative Dermatology 1997;109:238-43. [DOI: 10.1111/1523-1747.ep12319764] [Cited by in Crossref: 55] [Cited by in F6Publishing: 45] [Article Influence: 2.2] [Reference Citation Analysis]
378 Yu J, Zhang L. The transcriptional targets of p53 in apoptosis control. Biochem Biophys Res Commun 2005;331:851-8. [PMID: 15865941 DOI: 10.1016/j.bbrc.2005.03.189] [Cited by in Crossref: 293] [Cited by in F6Publishing: 282] [Article Influence: 17.2] [Reference Citation Analysis]
379 Huber VJ, Arroll TW, Lum C, Goodman BA, Nakanishi H. (1-Benzimidazolonyl)alanine (Bia): preliminary investigations into a potential tryptophan mimetic. Tetrahedron Letters 2002;43:6729-33. [DOI: 10.1016/s0040-4039(02)01501-0] [Cited by in Crossref: 6] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
380 Robbins D, Cherian M, Wu J, Chen T. Human pregnane X receptor compromises the function of p53 and promotes malignant transformation. Cell Death Discov 2016;2:16023. [PMID: 27547448 DOI: 10.1038/cddiscovery.2016.23] [Cited by in Crossref: 15] [Cited by in F6Publishing: 15] [Article Influence: 2.5] [Reference Citation Analysis]
381 De Angeli C, Cuneo A, Aguiari G, Roberti MG, Piva N, Moretti S, Cavazzini P, Castoldi G, del Senno L. 5′ Region and Exon 7 Mutations of the TP53 Gene in Two Cases of B-Cell Prolymphocytic Leukemia. Cancer Genetics and Cytogenetics 1998;107:137-43. [DOI: 10.1016/s0165-4608(98)00101-0] [Cited by in Crossref: 2] [Article Influence: 0.1] [Reference Citation Analysis]
382 Ghosh A, Ganguly D. Structural modulation of p53TAD1-TAZ2 complex upon mutations and post-translational modification. J Biomol Struct Dyn 2021;:1-10. [PMID: 34787057 DOI: 10.1080/07391102.2021.2004235] [Reference Citation Analysis]
383 Balagurumoorthy P, Sakamoto H, Lewis MS, Zambrano N, Clore GM, Gronenborn AM, Appella E, Harrington RE. Four p53 DNA-binding domain peptides bind natural p53-response elements and bend the DNA. Proc Natl Acad Sci U S A 1995;92:8591-5. [PMID: 7567980 DOI: 10.1073/pnas.92.19.8591] [Cited by in Crossref: 93] [Cited by in F6Publishing: 90] [Article Influence: 3.4] [Reference Citation Analysis]
384 Hainaut P, Soussi T, Shomer B, Hollstein M, Greenblatt M, Hovig E, Harris CC, Montesano R. Database of p53 gene somatic mutations in human tumors and cell lines: updated compilation and future prospects. Nucleic Acids Res. 1997;25:151-157. [PMID: 9016527 DOI: 10.1093/nar/25.1.151] [Cited by in Crossref: 197] [Cited by in F6Publishing: 191] [Article Influence: 7.9] [Reference Citation Analysis]
385 Kim AL, Raffo AJ, Brandt-Rauf PW, Pincus MR, Monaco R, Abarzua P, Fine RL. Conformational and molecular basis for induction of apoptosis by a p53 C-terminal peptide in human cancer cells. J Biol Chem 1999;274:34924-31. [PMID: 10574967 DOI: 10.1074/jbc.274.49.34924] [Cited by in Crossref: 79] [Cited by in F6Publishing: 73] [Article Influence: 3.6] [Reference Citation Analysis]
386 Xia N, Liu L, Yi X, Wang J. Studies of interaction of tumor suppressor p53 with apo-MT using surface plasmon resonance. Anal Bioanal Chem 2009;395:2569-75. [DOI: 10.1007/s00216-009-3174-1] [Cited by in Crossref: 13] [Cited by in F6Publishing: 13] [Article Influence: 1.0] [Reference Citation Analysis]
387 Picksley SM, Lane DP. p53 and Rb: their cellular roles. Current Opinion in Cell Biology 1994;6:853-8. [DOI: 10.1016/0955-0674(94)90056-6] [Cited by in Crossref: 50] [Cited by in F6Publishing: 47] [Article Influence: 1.8] [Reference Citation Analysis]
388 Valdebenito-Maturana B, Reyes-Suarez JA, Henriquez J, Holmes DS, Quatrini R, Pohl E, Arenas-Salinas M. Mutantelec: An In Silico mutation simulation platform for comparative electrostatic potential profiling of proteins. J Comput Chem 2017;38:467-74. [PMID: 28114729 DOI: 10.1002/jcc.24712] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
389 Indukuri R, Hases L, Archer A, Williams C. Estrogen Receptor Beta Influences the Inflammatory p65 Cistrome in Colon Cancer Cells. Front Endocrinol (Lausanne) 2021;12:650625. [PMID: 33859619 DOI: 10.3389/fendo.2021.650625] [Reference Citation Analysis]
390 Annor GK, Elshabassy N, Lundine D, Conde DG, Xiao G, Ellison V, Bargonetti J. Oligomerization of Mutant p53 R273H is not Required for Gain-of-Function Chromatin Associated Activities. Front Cell Dev Biol 2021;9:772315. [PMID: 34881245 DOI: 10.3389/fcell.2021.772315] [Reference Citation Analysis]
391 Theocharis S, Margeli A, Koutselinis A. Metallothionein: A Multifunctional Protein from Toxicity to Cancer. Int J Biol Markers 2003;18:162-9. [DOI: 10.1177/172460080301800302] [Cited by in Crossref: 53] [Cited by in F6Publishing: 34] [Article Influence: 13.3] [Reference Citation Analysis]
392 Chatterjee M, Dass J. FP, Sengupta S. Nuclear stress bodies: Interaction of its components in oncogenic regulation. J Cell Biochem 2019;120:14700-10. [DOI: 10.1002/jcb.28731] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
393 Speiser P, Gharehbaghi-Schnell E, Eder S, Haid A, Kovarík J, Nenutil R, Sauter G, Schneeberger CH, Vojtesek B, Wiltschke CH, Zeillinger R. A constitutional de novo mutation in exon 8 of the p53 gene in a patient with multiple primary malignancies. Br J Cancer 1996;74:269-73. [PMID: 8688334 DOI: 10.1038/bjc.1996.350] [Cited by in Crossref: 9] [Cited by in F6Publishing: 9] [Article Influence: 0.3] [Reference Citation Analysis]
394 Fitzgerald AL, Osman AA, Xie TX, Patel A, Skinner H, Sandulache V, Myers JN. Reactive oxygen species and p21Waf1/Cip1 are both essential for p53-mediated senescence of head and neck cancer cells. Cell Death Dis 2015;6:e1678. [PMID: 25766317 DOI: 10.1038/cddis.2015.44] [Cited by in Crossref: 53] [Cited by in F6Publishing: 51] [Article Influence: 7.6] [Reference Citation Analysis]
395 Morandell D, Kaiser A, Herold S, Rostek U, Lechner S, Mitterberger MC, Jansen-Dürr P, Eilers M, Zwerschke W. The human papillomavirus type 16 E7 oncoprotein targets Myc-interacting zinc-finger protein-1. Virology 2012;422:242-53. [PMID: 22099967 DOI: 10.1016/j.virol.2011.10.027] [Cited by in Crossref: 12] [Cited by in F6Publishing: 10] [Article Influence: 1.1] [Reference Citation Analysis]
396 Liang Y, Dearnaley WJ, Alden NA, Solares MJ, Gilmore BL, Pridham KJ, Varano AC, Sheng Z, Alli E, Kelly DF. Correcting errors in the BRCA1 warning system. DNA Repair (Amst) 2019;73:120-8. [PMID: 30503669 DOI: 10.1016/j.dnarep.2018.11.009] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
397 Hsueh KW, Fu SL, Chang CB, Chang YL, Lin CH. A novel Aurora-A-mediated phosphorylation of p53 inhibits its interaction with MDM2. Biochim Biophys Acta 2013;1834:508-15. [PMID: 23201157 DOI: 10.1016/j.bbapap.2012.11.005] [Cited by in Crossref: 13] [Cited by in F6Publishing: 17] [Article Influence: 1.3] [Reference Citation Analysis]
398 Mazur DJ, Perrino FW. Structure and expression of the TREX1 and TREX2 3' --> 5' exonuclease genes. J Biol Chem 2001;276:14718-27. [PMID: 11278605 DOI: 10.1074/jbc.M010051200] [Cited by in Crossref: 50] [Cited by in F6Publishing: 36] [Article Influence: 2.4] [Reference Citation Analysis]
399 Lee JM, Bernstein A. Apoptosis, cancer and the p53 tumour suppressor gene. Cancer Metastasis Rev 1995;14:149-61. [PMID: 7554031 DOI: 10.1007/BF00665797] [Cited by in Crossref: 104] [Cited by in F6Publishing: 17] [Article Influence: 3.9] [Reference Citation Analysis]
400 Tidow H, Melero R, Mylonas E, Freund SM, Grossmann JG, Carazo JM, Svergun DI, Valle M, Fersht AR. Quaternary structures of tumor suppressor p53 and a specific p53 DNA complex. Proc Natl Acad Sci U S A 2007;104:12324-9. [PMID: 17620598 DOI: 10.1073/pnas.0705069104] [Cited by in Crossref: 144] [Cited by in F6Publishing: 138] [Article Influence: 9.6] [Reference Citation Analysis]
401 Collins K, Jacks T, Pavletich NP. The cell cycle and cancer. Proc Natl Acad Sci U S A 1997;94:2776-8. [PMID: 9096291 DOI: 10.1073/pnas.94.7.2776] [Cited by in Crossref: 242] [Cited by in F6Publishing: 217] [Article Influence: 9.7] [Reference Citation Analysis]
402 Walerych D, Pruszko M, Zyla L, Wezyk M, Gaweda-Walerych K, Zylicz A. Wild-type p53 oligomerizes more efficiently than p53 hot-spot mutants and overcomes mutant p53 gain-of-function via a "dominant-positive" mechanism. Oncotarget 2018;9:32063-80. [PMID: 30174797 DOI: 10.18632/oncotarget.25944] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 1.5] [Reference Citation Analysis]
403 Donzelli S, Biagioni F, Fausti F, Strano S, Fontemaggi G, Blandino G. Oncogenomic Approaches in Exploring Gain of Function of Mutant p53. Curr Genomics 2008;9:200-7. [PMID: 19440517 DOI: 10.2174/138920208784340713] [Cited by in Crossref: 15] [Cited by in F6Publishing: 15] [Article Influence: 1.4] [Reference Citation Analysis]
404 Marin JJ, Briz O, Monte MJ, Blazquez AG, Macias RI. Genetic variants in genes involved in mechanisms of chemoresistance to anticancer drugs. Curr Cancer Drug Targets. 2012;12:402-438. [PMID: 22229248 DOI: 10.1002/9780470015902.a0025217] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
405 Coffill CR, Lee AP, Siau JW, Chee SM, Joseph TL, Tan YS, Madhumalar A, Tay BH, Brenner S, Verma CS, Ghadessy FJ, Venkatesh B, Lane DP. The p53-Mdm2 interaction and the E3 ligase activity of Mdm2/Mdm4 are conserved from lampreys to humans. Genes Dev 2016;30:281-92. [PMID: 26798135 DOI: 10.1101/gad.274118.115] [Cited by in Crossref: 24] [Cited by in F6Publishing: 21] [Article Influence: 4.0] [Reference Citation Analysis]
406 Zhao Y, Chen XQ, Du JZ. Cellular adaptation to hypoxia and p53 transcription regulation. J Zhejiang Univ Sci B. 2009;10:404-410. [PMID: 19434769 DOI: 10.1631/jzus.b0820293] [Cited by in Crossref: 27] [Cited by in F6Publishing: 7] [Article Influence: 2.1] [Reference Citation Analysis]
407 Haug R, Kramer M, Richert C. Three-pronged probes: high-affinity DNA binding with cap, β-alanines and oligopyrrolamides. Chemistry 2013;19:15822-6. [PMID: 24222391 DOI: 10.1002/chem.201302972] [Cited by in Crossref: 9] [Cited by in F6Publishing: 7] [Article Influence: 1.1] [Reference Citation Analysis]
408 Cherny DI, Striker G, Subramaniam V, Jett SD, Paleček E, Jovin TM. DNA bending due to specific p53 and p53 core domain-DNA interactions visualized by electron microscopy. Journal of Molecular Biology 1999;294:1015-26. [DOI: 10.1006/jmbi.1999.3299] [Cited by in Crossref: 41] [Cited by in F6Publishing: 40] [Article Influence: 1.8] [Reference Citation Analysis]
409 Fulci G, Ishii N, Van Meir EG. p53 and brain tumors: from gene mutations to gene therapy. Brain Pathol 1998;8:599-613. [PMID: 9804370 DOI: 10.1111/j.1750-3639.1998.tb00187.x] [Cited by in Crossref: 46] [Cited by in F6Publishing: 38] [Article Influence: 2.0] [Reference Citation Analysis]
410 Hesketh R. P53. The Oncogene & Tumour Suppressor Gene Factsbook. Elsevier; 1997. pp. 446-63. [DOI: 10.1016/b978-012344548-3/50085-6] [Cited by in Crossref: 1] [Article Influence: 0.0] [Reference Citation Analysis]
411 An Z, Zhao K, Wei L, Wang Z, Li S, Wei L, Wei D. p53 gene cloning and response to hypoxia in the plateau zokor, Myospalax baileyi. Animal Biol 2018;68:289-308. [DOI: 10.1163/15707563-18000004] [Reference Citation Analysis]
412 Möller P. Pathophysiological aspects of tumor development. Stem Cells 1995;13 Suppl 1:240-7. [PMID: 7488952 DOI: 10.1002/stem.5530130729] [Cited by in Crossref: 1] [Article Influence: 0.0] [Reference Citation Analysis]
413 Li X, Coffino P. High-risk human papillomavirus E6 protein has two distinct binding sites within p53, of which only one determines degradation. J Virol 1996;70:4509-16. [DOI: 10.1128/jvi.70.7.4509-4516.1996] [Cited by in Crossref: 128] [Cited by in F6Publishing: 53] [Article Influence: 4.9] [Reference Citation Analysis]
414 Fen CX, Coomber DW, Lane DP, Ghadessy FJ. Directed evolution of p53 variants with altered DNA-binding specificities by in vitro compartmentalization. J Mol Biol 2007;371:1238-48. [PMID: 17610896 DOI: 10.1016/j.jmb.2007.05.099] [Cited by in Crossref: 15] [Cited by in F6Publishing: 14] [Article Influence: 1.0] [Reference Citation Analysis]
415 Keegan, Lunec, Neal. p53 and p53-regulated genes in bladder cancer. BJU Int 1998;82:710-20. [DOI: 10.1046/j.1464-410x.1998.00822.x] [Cited by in Crossref: 27] [Cited by in F6Publishing: 4] [Article Influence: 1.1] [Reference Citation Analysis]
416 Chen F. Reactive Oxygen Species in the Activation and Regulation of Intracellular Signaling Events. In: Vallyathan V, Shi X, Castranova V, editors. Oxygen/Nitrogen Radicals. CRC Press; 2004. pp. 59-90. [DOI: 10.1201/b14147-4] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.2] [Reference Citation Analysis]
417 Hinow P, Rogers CE, Barbieri CE, Pietenpol JA, Kenworthy AK, DiBenedetto E. The DNA binding activity of p53 displays reaction-diffusion kinetics. Biophys J 2006;91:330-42. [PMID: 16603489 DOI: 10.1529/biophysj.105.078303] [Cited by in Crossref: 58] [Cited by in F6Publishing: 53] [Article Influence: 3.6] [Reference Citation Analysis]
418 Todorova TA, Jordanov SH, Stancheva GS, Chalakov IJ, Melnicharov MB, Kunev KV, Mitev VI, Kaneva RP, Goranova TE. Mutational Status of CDKN2A and TP53 Genes in Laryngeal Squamous Cell Carcinoma. Pathol Oncol Res 2015;21:413-21. [PMID: 25149524 DOI: 10.1007/s12253-014-9836-0] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 0.5] [Reference Citation Analysis]
419 Zhang H, Yang X, Wang K, Tan W, Li H, Zuo X, Wen J. On-chip oligonucleotide ligation assay using one-dimensional microfluidic beads array for the detection of low-abundant DNA point mutations. Biosensors and Bioelectronics 2008;23:945-51. [DOI: 10.1016/j.bios.2007.09.012] [Cited by in Crossref: 20] [Cited by in F6Publishing: 18] [Article Influence: 1.4] [Reference Citation Analysis]
420 Bayle JH, Elenbaas B, Levine AJ. The carboxyl-terminal domain of the p53 protein regulates sequence-specific DNA binding through its nonspecific nucleic acid-binding activity. Proc Natl Acad Sci U S A 1995;92:5729-33. [PMID: 7777576 DOI: 10.1073/pnas.92.12.5729] [Cited by in Crossref: 63] [Cited by in F6Publishing: 70] [Article Influence: 2.3] [Reference Citation Analysis]
421 Vaishnavi K, Saxena N, Shah N, Singh R, Manjunath K, Uthayakumar M, Kanaujia SP, Kaul SC, Sekar K, Wadhwa R. Differential activities of the two closely related withanolides, Withaferin A and Withanone: bioinformatics and experimental evidences. PLoS One 2012;7:e44419. [PMID: 22973447 DOI: 10.1371/journal.pone.0044419] [Cited by in F6Publishing: 57] [Reference Citation Analysis]
422 Garg A, Hazra JP, Sannigrahi MK, Rakshit S, Sinha S. Variable Mutations at the p53-R273 Oncogenic Hotspot Position Leads to Altered Properties. Biophys J 2020;118:720-8. [PMID: 31952808 DOI: 10.1016/j.bpj.2019.12.015] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 1.3] [Reference Citation Analysis]
423 Yolcu E, Sayan BS, Yağci T, Cetin-atalay R, Soussi T, Yurdusev N, Ozturk M. A monoclonal antibody against DNA binding helix of p53 protein. Oncogene 2001;20:1398-401. [DOI: 10.1038/sj.onc.1204240] [Cited by in Crossref: 3] [Cited by in F6Publishing: 5] [Article Influence: 0.1] [Reference Citation Analysis]
424 Lin Z, Yang W, Zhang G, Liu Q, Qiu B, Cai Z, Chen G. An ultrasensitive colorimeter assay strategy for p53 mutation assisted by nicking endonuclease signal amplification. Chem Commun 2011;47:9069. [DOI: 10.1039/c1cc13146j] [Cited by in Crossref: 42] [Cited by in F6Publishing: 40] [Article Influence: 3.8] [Reference Citation Analysis]
425 Liang S, Gong X, Zhang G, Huang G, Lu Y, Li Y. The lncRNA XIST interacts with miR-140/miR-124/iASPP axis to promote pancreatic carcinoma growth. Oncotarget 2017;8:113701-18. [PMID: 29371940 DOI: 10.18632/oncotarget.22555] [Cited by in Crossref: 17] [Cited by in F6Publishing: 15] [Article Influence: 3.4] [Reference Citation Analysis]
426 Deppert W. Binding of MAR-DNA elements by mutant p53: Possible implications for its oncogenic functions. J Cell Biochem 1996;62:172-80. [DOI: 10.1002/(sici)1097-4644(199608)62:2<172::aid-jcb5>3.0.co;2-p] [Cited by in Crossref: 28] [Cited by in F6Publishing: 9] [Article Influence: 1.1] [Reference Citation Analysis]
427 Warren RS, Atreya CE, Niedzwiecki D, Weinberg VK, Donner DB, Mayer RJ, Goldberg RM, Compton CC, Zuraek MB, Ye C. Association of TP53 mutational status and gender with survival after adjuvant treatment for stage III colon cancer: results of CALGB 89803. Clin Cancer Res. 2013;19:5777-5787. [PMID: 23983256 DOI: 10.1158/1078-0432.ccr-13-0351] [Cited by in Crossref: 27] [Cited by in F6Publishing: 19] [Article Influence: 3.0] [Reference Citation Analysis]
428 Ganguly D, Chen J. Modulation of the disordered conformational ensembles of the p53 transactivation domain by cancer-associated mutations. PLoS Comput Biol 2015;11:e1004247. [PMID: 25897952 DOI: 10.1371/journal.pcbi.1004247] [Cited by in Crossref: 23] [Cited by in F6Publishing: 22] [Article Influence: 3.3] [Reference Citation Analysis]
429 Klein C, Planker E, Diercks T, Kessler H, Künkele K, Lang K, Hansen S, Schwaiger M. NMR Spectroscopy Reveals the Solution Dimerization Interface of p53 Core Domains Bound to Their Consensus DNA. Journal of Biological Chemistry 2001;276:49020-7. [DOI: 10.1074/jbc.m107516200] [Cited by in Crossref: 63] [Cited by in F6Publishing: 26] [Article Influence: 3.0] [Reference Citation Analysis]
430 Fimognari C, Lenzi M, Sciuscio D, Cantelli-Forti G, Hrelia P. Combination of doxorubicin and sulforaphane for reversing doxorubicin-resistant phenotype in mouse fibroblasts with p53Ser220 mutation. Ann N Y Acad Sci 2007;1095:62-9. [PMID: 17404018 DOI: 10.1196/annals.1397.008] [Cited by in Crossref: 23] [Cited by in F6Publishing: 18] [Article Influence: 1.5] [Reference Citation Analysis]
431 Maruyama H, Yasui T, Ishikawa-Fujiwara T, Morii E, Yamamoto Y, Yoshii T, Takenaka Y, Nakahara S, Todo T, Hongyo T, Inohara H. Human papillomavirus and p53 mutations in head and neck squamous cell carcinoma among Japanese population. Cancer Sci 2014;105:409-17. [PMID: 24521534 DOI: 10.1111/cas.12369] [Cited by in Crossref: 54] [Cited by in F6Publishing: 44] [Article Influence: 6.8] [Reference Citation Analysis]
432 Kaneko K, Kurahashi T, Makino R, Konishi K, Ito H, Katagiri A, Kumekawa Y, Hirayama Y, Yoneyama K, Kushima M, Kusano M, Tajiri H, Rembacken BJ, Mitamura K, Imawari M. Pathological features and genetic alterations in colorectal carcinomas with characteristics of nonpolypoid growth. Br J Cancer 2004;91:312-8. [PMID: 15213719 DOI: 10.1038/sj.bjc.6601965] [Cited by in Crossref: 9] [Cited by in F6Publishing: 10] [Article Influence: 0.5] [Reference Citation Analysis]
433 Jurneczko E, Cruickshank F, Porrini M, Clarke DJ, Campuzano IDG, Morris M, Nikolova PV, Barran PE. Probing the Conformational Diversity of Cancer-Associated Mutations in p53 with Ion-Mobility Mass Spectrometry. Angew Chem 2013;125:4466-70. [DOI: 10.1002/ange.201210015] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 0.3] [Reference Citation Analysis]
434 Huyen Y, Jeffrey PD, Derry WB, Rothman JH, Pavletich NP, Stavridi ES, Halazonetis TD. Structural differences in the DNA binding domains of human p53 and its C. elegans ortholog Cep-1. Structure 2004;12:1237-43. [PMID: 15242600 DOI: 10.1016/j.str.2004.05.007] [Cited by in Crossref: 35] [Cited by in F6Publishing: 37] [Article Influence: 2.1] [Reference Citation Analysis]
435 Melero R, Rajagopalan S, Lázaro M, Joerger AC, Brandt T, Veprintsev DB, Lasso G, Gil D, Scheres SH, Carazo JM, Fersht AR, Valle M. Electron microscopy studies on the quaternary structure of p53 reveal different binding modes for p53 tetramers in complex with DNA. Proc Natl Acad Sci U S A 2011;108:557-62. [PMID: 21178074 DOI: 10.1073/pnas.1015520107] [Cited by in Crossref: 51] [Cited by in F6Publishing: 51] [Article Influence: 4.3] [Reference Citation Analysis]
436 Menendez D, Inga A, Jordan JJ, Resnick MA. Changing the p53 master regulatory network: ELEMENTary, my dear Mr Watson. Oncogene 2007;26:2191-201. [PMID: 17401428 DOI: 10.1038/sj.onc.1210277] [Cited by in Crossref: 26] [Cited by in F6Publishing: 24] [Article Influence: 1.7] [Reference Citation Analysis]
437 Kuriyan J, Thanos D. Structure of the NF-kappa B transcription factor: a holistic interaction with DNA. Structure 1995;3:135-41. [PMID: 7735829 DOI: 10.1016/s0969-2126(01)00143-5] [Cited by in Crossref: 12] [Cited by in F6Publishing: 6] [Article Influence: 0.4] [Reference Citation Analysis]
438 Kim HC, Huibregtse JM. Polyubiquitination by HECT E3s and the determinants of chain type specificity. Mol Cell Biol 2009;29:3307-18. [PMID: 19364824 DOI: 10.1128/MCB.00240-09] [Cited by in Crossref: 169] [Cited by in F6Publishing: 124] [Article Influence: 13.0] [Reference Citation Analysis]
439 Ikeda J, Tada M, Ishii N, Saya H, Tsuchiya K, Okaichi K, Mishima K, Sawamura Y, Fulci G, Liu TJ, Van Meir EG. Restoration of endogenous wild-type p53 activity in a glioblastoma cell line with intrinsic temperature-sensitive p53 induces growth arrest but not apoptosis. Int J Cancer 2001;94:35-43. [PMID: 11668476 DOI: 10.1002/ijc.1431] [Cited by in Crossref: 11] [Cited by in F6Publishing: 11] [Article Influence: 0.5] [Reference Citation Analysis]
440 Krüger A, Stier A, Fischbach A, Bürkle A, Hauser K, Mangerich A. Interactions of p53 with poly(ADP-ribose) and DNA induce distinct changes in protein structure as revealed by ATR-FTIR spectroscopy. Nucleic Acids Res 2019;47:4843-58. [PMID: 30892621 DOI: 10.1093/nar/gkz175] [Cited by in Crossref: 9] [Cited by in F6Publishing: 9] [Article Influence: 3.0] [Reference Citation Analysis]
441 Hainaut P, Mann K. Zinc Binding and Redox Control of p53 Structure and Function. Antioxidants & Redox Signaling 2001;3:611-23. [DOI: 10.1089/15230860152542961] [Cited by in Crossref: 123] [Cited by in F6Publishing: 109] [Article Influence: 5.9] [Reference Citation Analysis]
442 Wilhelm MT, Méndez-vidal C, Wiman KG. Identification of functional p53-binding motifs in the mouse wig-1 promoter. FEBS Letters 2002;524:69-72. [DOI: 10.1016/s0014-5793(02)03004-1] [Cited by in Crossref: 11] [Cited by in F6Publishing: 9] [Article Influence: 0.6] [Reference Citation Analysis]
443 Yourtee D, Emery J, Smith RE, Hodgson B. Stereolithographic models of biopolymers. Journal of Molecular Graphics and Modelling 2000;18:26-8. [DOI: 10.1016/s1093-3263(00)00029-2] [Cited by in Crossref: 7] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
444 Li B, Kittrell FS, Medina D, Rosen JM. Delay of dimethylbenz[a]anthracene-induced mammary tumorigenesis in transgenic mice by apoptosis induced by an unusual mutant p53 protein. Mol Carcinog 1995;14:75-83. [DOI: 10.1002/mc.2940140203] [Cited by in Crossref: 17] [Cited by in F6Publishing: 18] [Article Influence: 0.6] [Reference Citation Analysis]
445 Hardcastle IR. Targeting the MDM2–p53 Protein–Protein Interaction. Cancer Drug Design and Discovery. Elsevier; 2014. pp. 391-426. [DOI: 10.1016/b978-0-12-396521-9.00013-9] [Cited by in Crossref: 2] [Article Influence: 0.3] [Reference Citation Analysis]
446 Gaiddon C, Lokshin M, Ahn J, Zhang T, Prives C. A subset of tumor-derived mutant forms of p53 down-regulate p63 and p73 through a direct interaction with the p53 core domain. Mol Cell Biol. 2001;21:1874-1887. [PMID: 11238924 DOI: 10.1128/mcb.21.5.1874-1887.2001] [Cited by in Crossref: 312] [Cited by in F6Publishing: 174] [Article Influence: 14.9] [Reference Citation Analysis]
447 Bristow RG, Benchimol S, Hill RP. The p53 gene as a modifier of intrinsic radiosensitivity: implications for radiotherapy. Radiotherapy and Oncology 1996;40:197-223. [DOI: 10.1016/0167-8140(96)01806-3] [Cited by in Crossref: 121] [Cited by in F6Publishing: 104] [Article Influence: 4.7] [Reference Citation Analysis]
448 Kasparkova J, Fojta M, Farrell N, Brabec V. Differential recognition by the tumor suppressor protein p53 of DNA modified by the novel antitumor trinuclear platinum drug BBR3464 and cisplatin. Nucleic Acids Res 2004;32:5546-52. [PMID: 15486204 DOI: 10.1093/nar/gkh896] [Cited by in Crossref: 17] [Cited by in F6Publishing: 17] [Article Influence: 0.9] [Reference Citation Analysis]
449 Lee JM, Lee YC, Yang SY, Shi WL, Lee CJ, Luh SP, Chen CJ, Hsieh CY, Wu MT. Genetic polymorphisms of p53 and GSTP1, but not NAT2,are associated with susceptibility to squamous-cell carcinoma of the esophagus. Int J Cancer. 2000;89:458-464. [PMID: 11008209 DOI: 10.1002/1097-0215(20000920)89:5%3C458::AID-IJC10%3E3.0.CO;2-R] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
450 Murakami S, Yokomizo H, Matsushita S, Ogawa M, Nishimura Y. Binding of mutated Ras- and p53-derived peptides to HLA-DR molecules. Immunol Lett 1996;49:149-53. [PMID: 8739309 DOI: 10.1016/0165-2478(96)02495-9] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.1] [Reference Citation Analysis]
451 Bazan V, Bruno L, Augello C, Agnese V, Calò V, Corsale S, Gargano G, Terrasi M, Schirò V, Di Fede G, Adamo V, Intrivici C, Crosta A, Rinaldi G, Latteri F, Dardanoni G, Grassi N, Valerio MR, Colucci G, Macaluso M, Russo A; Gruppo Oncologico dell'Italia Meridionale. Molecular detection of TP53, Ki-Ras and p16INK4A promoter methylation in plasma of patients with colorectal cancer and its association with prognosis. Results of a 3-year GOIM (Gruppo Oncologico dell'Italia Meridionale) prospective study. Ann Oncol 2006;17 Suppl 7:vii84-90. [PMID: 16760301 DOI: 10.1093/annonc/mdl958] [Cited by in Crossref: 34] [Cited by in F6Publishing: 33] [Article Influence: 2.4] [Reference Citation Analysis]
452 Ryan KM, Vousden KH. Characterization of structural p53 mutants which show selective defects in apoptosis but not cell cycle arrest. Mol Cell Biol 1998;18:3692-8. [PMID: 9632751 DOI: 10.1128/MCB.18.7.3692] [Cited by in Crossref: 118] [Cited by in F6Publishing: 40] [Article Influence: 4.9] [Reference Citation Analysis]
453 van Slooten HJ, van De Vijver MJ, Borresen AL, Eyfjörd JE, Valgardsdóttir R, Scherneck S, Nesland JM, Devilee P, Cornelisse CJ, van Dierendonck JH. Mutations in exons 5-8 of the p53 gene, independent of their type and location, are associated with increased apoptosis and mitosis in invasive breast carcinoma. J Pathol 1999;189:504-13. [PMID: 10629550 DOI: 10.1002/(SICI)1096-9896(199912)189:4<504::AID-PATH483>3.0.CO;2-A] [Cited by in Crossref: 17] [Cited by in F6Publishing: 6] [Article Influence: 0.8] [Reference Citation Analysis]
454 Merino EJ, Boal AK, Barton JK. Biological contexts for DNA charge transport chemistry. Curr Opin Chem Biol 2008;12:229-37. [PMID: 18314014 DOI: 10.1016/j.cbpa.2008.01.046] [Cited by in Crossref: 103] [Cited by in F6Publishing: 87] [Article Influence: 7.4] [Reference Citation Analysis]
455 Mao Y, Luo C, Ouyang Q. Studies of temperature-dependent electronic transduction on DNA hairpin loop sensor. Nucleic Acids Res 2003;31:e108. [PMID: 12954784 DOI: 10.1093/nar/gng108] [Cited by in Crossref: 68] [Cited by in F6Publishing: 57] [Article Influence: 3.8] [Reference Citation Analysis]
456 Li H, Zhang J, Tong JHM, Chan AWH, Yu J, Kang W, To KF. Targeting the Oncogenic p53 Mutants in Colorectal Cancer and Other Solid Tumors. Int J Mol Sci 2019;20:E5999. [PMID: 31795192 DOI: 10.3390/ijms20235999] [Cited by in Crossref: 26] [Cited by in F6Publishing: 29] [Article Influence: 8.7] [Reference Citation Analysis]
457 Xirodimas DP, Scheffner M. Ubiquitin Family Members in the Regulation of the Tumor Suppressor p53. In: Groettrup M, editor. Conjugation and Deconjugation of Ubiquitin Family Modifiers. New York: Springer; 2010. pp. 116-35. [DOI: 10.1007/978-1-4419-6676-6_10] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 0.3] [Reference Citation Analysis]
458 Sogame N, Kim M, Abrams JM. Drosophila p53 preserves genomic stability by regulating cell death. Proc Natl Acad Sci U S A 2003;100:4696-701. [PMID: 12672954 DOI: 10.1073/pnas.0736384100] [Cited by in Crossref: 110] [Cited by in F6Publishing: 119] [Article Influence: 5.8] [Reference Citation Analysis]
459 Lowry DF, Stancik A, Shrestha RM, Daughdrill GW. Modeling the accessible conformations of the intrinsically unstructured transactivation domain of p53. Proteins 2008;71:587-98. [PMID: 17972286 DOI: 10.1002/prot.21721] [Cited by in Crossref: 38] [Cited by in F6Publishing: 35] [Article Influence: 2.7] [Reference Citation Analysis]
460 De Grandis V, Bizzarri AR, Cannistraro S. Docking study and free energy simulation of the complex between p53 DNA-binding domain and azurin. J Mol Recognit 2007;20:215-26. [PMID: 17703463 DOI: 10.1002/jmr.840] [Cited by in Crossref: 45] [Cited by in F6Publishing: 43] [Article Influence: 3.0] [Reference Citation Analysis]
461 Zelazny E, Li B, Anagnostopoulos AM, Coleman A, Perkins AS. Cooperating oncogenic events in murine mammary tumorigenesis: assessment of ErbB2, mutant p53, and mouse mammary tumor virus. Exp Mol Pathol 2001;70:183-93. [PMID: 11417997 DOI: 10.1006/exmp.2001.2357] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 0.3] [Reference Citation Analysis]
462 Lee KC, Goh WL, Xu M, Kua N, Lunny D, Wong JS, Coomber D, Vojtesek B, Lane EB, Lane DP. Detection of the p53 response in zebrafish embryos using new monoclonal antibodies. Oncogene 2008;27:629-40. [PMID: 17684488 DOI: 10.1038/sj.onc.1210695] [Cited by in Crossref: 52] [Cited by in F6Publishing: 54] [Article Influence: 3.5] [Reference Citation Analysis]
463 Shatnawi A, Abu Rabe DI, Frigo DE. Roles of the tumor suppressor inhibitor of growth family member 4 (ING4) in cancer. Adv Cancer Res 2021;152:225-62. [PMID: 34353439 DOI: 10.1016/bs.acr.2021.05.004] [Reference Citation Analysis]
464 Barker FG, Israel MA. The Molecular Biology of Brain Tumors. Neurologic Clinics 1995;13:701-21. [DOI: 10.1016/s0733-8619(18)30014-8] [Cited by in Crossref: 4] [Article Influence: 0.1] [Reference Citation Analysis]
465 Cui F, Zhurkin VB. Rotational positioning of nucleosomes facilitates selective binding of p53 to response elements associated with cell cycle arrest. Nucleic Acids Res 2014;42:836-47. [PMID: 24153113 DOI: 10.1093/nar/gkt943] [Cited by in Crossref: 37] [Cited by in F6Publishing: 30] [Article Influence: 4.1] [Reference Citation Analysis]
466 Kim E, Deppert W. Interactions of mutant p53 with DNA: guilt by association. Oncogene 2007;26:2185-90. [PMID: 17401427 DOI: 10.1038/sj.onc.1210312] [Cited by in Crossref: 21] [Cited by in F6Publishing: 22] [Article Influence: 1.4] [Reference Citation Analysis]
467 Sarin H. Conserved molecular mechanisms underlying the effects of small molecule xenobiotic chemotherapeutics on cells. Mol Clin Oncol 2016;4:326-68. [PMID: 26998284 DOI: 10.3892/mco.2015.714] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 0.6] [Reference Citation Analysis]
468 Rivera A, Maxwell SA. The p53-induced gene-6 (proline oxidase) mediates apoptosis through a calcineurin-dependent pathway. J Biol Chem 2005;280:29346-54. [PMID: 15914462 DOI: 10.1074/jbc.M504852200] [Cited by in Crossref: 120] [Cited by in F6Publishing: 56] [Article Influence: 7.1] [Reference Citation Analysis]
469 Weidman MK, Yalamanchili P, Ng B, Tsai W, Dasgupta A. Poliovirus 3C protease-mediated degradation of transcriptional activator p53 requires a cellular activity. Virology 2001;291:260-71. [PMID: 11878895 DOI: 10.1006/viro.2001.1215] [Cited by in Crossref: 40] [Cited by in F6Publishing: 39] [Article Influence: 2.0] [Reference Citation Analysis]
470 Xiao M, An Y, Wang F, Yao C, Zhang C, Xin J, Duan Y, Zhao X, Fang N, Ji S. A chimeric protein PTEN-L-p53 enters U251 cells to repress proliferation and invasion. Exp Cell Res 2018;369:234-42. [PMID: 29802838 DOI: 10.1016/j.yexcr.2018.05.023] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
471 Murata H, Sakaguchi M, Futami J, Kitazoe M, Maeda T, Doura H, Kosaka M, Tada H, Seno M, Huh N, Yamada H. Denatured and Reversibly Cationized p53 Readily Enters Cells and Simultaneously Folds to the Functional Protein in the Cells. Biochemistry 2006;45:6124-32. [DOI: 10.1021/bi052642a] [Cited by in Crossref: 17] [Cited by in F6Publishing: 16] [Article Influence: 1.1] [Reference Citation Analysis]
472 Fojta M, Pivonkova H, Brazdova M, Nemcova K, Palecek J, Vojtesek B. Investigations of the supercoil-selective DNA binding of wild type p53 suggest a novel mechanism for controlling p53 function: Redox and antibody modulation of p53-scDNA binding. European Journal of Biochemistry 2004;271:3865-76. [DOI: 10.1111/j.1432-1033.2004.04323.x] [Cited by in Crossref: 33] [Cited by in F6Publishing: 33] [Article Influence: 1.8] [Reference Citation Analysis]
473 Yip YL, Zoete V, Scheib H, Michielin O. Structural assessment of single amino acid mutations: application to TP53 function. Hum Mutat 2006;27:926-37. [PMID: 16917930 DOI: 10.1002/humu.20379] [Cited by in Crossref: 11] [Cited by in F6Publishing: 11] [Article Influence: 0.7] [Reference Citation Analysis]
474 Göhler T, Reimann M, Cherny D, Walter K, Warnecke G, Kim E, Deppert W. Specific interaction of p53 with target binding sites is determined by DNA conformation and is regulated by the C-terminal domain. J Biol Chem 2002;277:41192-203. [PMID: 12171916 DOI: 10.1074/jbc.M202344200] [Cited by in Crossref: 57] [Cited by in F6Publishing: 26] [Article Influence: 2.9] [Reference Citation Analysis]
475 Giel-Pietraszuk M, Hoffmann M, Dolecka S, Rychlewski J, Barciszewski J. Palindromes in proteins. J Protein Chem 2003;22:109-13. [PMID: 12760415 DOI: 10.1023/a:1023454111924] [Cited by in Crossref: 11] [Cited by in F6Publishing: 1] [Article Influence: 0.6] [Reference Citation Analysis]
476 Zhai W, Comai L. Repression of RNA polymerase I transcription by the tumor suppressor p53. Mol Cell Biol 2000;20:5930-8. [PMID: 10913176 DOI: 10.1128/MCB.20.16.5930-5938.2000] [Cited by in Crossref: 188] [Cited by in F6Publishing: 117] [Article Influence: 8.5] [Reference Citation Analysis]
477 Zhou B, Wu Q, Chen G, Zhang T, Zhao Y. NOP14 promotes proliferation and metastasis of pancreatic cancer cells. Cancer Letters 2012;322:195-203. [DOI: 10.1016/j.canlet.2012.03.010] [Cited by in Crossref: 14] [Cited by in F6Publishing: 13] [Article Influence: 1.4] [Reference Citation Analysis]
478 Yakovleva T, Kolesnikova L, Vukojević V, Gileva I, Tan-No K, Austen M, Lüscher B, Ekström TJ, Terenius L, Bakalkin G. YY1 binding to a subset of p53 DNA-target sites regulates p53-dependent transcription. Biochem Biophys Res Commun 2004;318:615-24. [PMID: 15120643 DOI: 10.1016/j.bbrc.2004.04.065] [Cited by in Crossref: 33] [Cited by in F6Publishing: 34] [Article Influence: 1.8] [Reference Citation Analysis]
479 Patel S, George R, Autore F, Fraternali F, Ladbury JE, Nikolova PV. Molecular interactions of ASPP1 and ASPP2 with the p53 protein family and the apoptotic promoters PUMA and Bax. Nucleic Acids Res 2008;36:5139-51. [PMID: 18676979 DOI: 10.1093/nar/gkn490] [Cited by in Crossref: 33] [Cited by in F6Publishing: 34] [Article Influence: 2.4] [Reference Citation Analysis]
480 Murata J, Tada M, Iggo RD, Sawamura Y, Shinohe Y, Abe H. Nitric oxide as a carcinogen: analysis by yeast functional assay of inactivating p53 mutations induced by nitric oxide. Mutat Res 1997;379:211-8. [PMID: 9357550 DOI: 10.1016/s0027-5107(97)00149-8] [Cited by in Crossref: 46] [Cited by in F6Publishing: 9] [Article Influence: 1.8] [Reference Citation Analysis]
481 Godek KM, Venere M, Wu Q, Mills KD, Hickey WF, Rich JN, Compton DA. Chromosomal Instability Affects the Tumorigenicity of Glioblastoma Tumor-Initiating Cells. Cancer Discov 2016;6:532-45. [PMID: 27001151 DOI: 10.1158/2159-8290.CD-15-1154] [Cited by in Crossref: 31] [Cited by in F6Publishing: 23] [Article Influence: 5.2] [Reference Citation Analysis]
482 Sedlacek Z, Kodet R, Kriz V, Seemanova E, Vodvarka P, Wilgenbus P, Mares J, Poustka A, Goetz P. Two Li-Fraumeni syndrome families with novel germline p53 mutations: loss of the wild-type p53 allele in only 50% of tumours. Br J Cancer 1998;77:1034-9. [PMID: 9569035 DOI: 10.1038/bjc.1998.172] [Cited by in Crossref: 35] [Cited by in F6Publishing: 29] [Article Influence: 1.5] [Reference Citation Analysis]
483 Elgavish A, Wood PA, Pinkert CA, Eltoum IE, Cartee T, Wilbanks J, Mentor-Marcel R, Tian L, Scroggins SE. Transgenic mouse with human mutant p53 expression in the prostate epithelium. Prostate 2004;61:26-34. [PMID: 15287091 DOI: 10.1002/pros.20071] [Cited by in Crossref: 14] [Cited by in F6Publishing: 10] [Article Influence: 0.8] [Reference Citation Analysis]
484 Kastan MB, Canman CE, Leonard CJ. P53, cell cycle control and apoptosis: implications for cancer. Cancer Metastasis Rev. 1995;14:3-15. [PMID: 7606818 DOI: 10.1007/bf00690207] [Cited by in Crossref: 299] [Cited by in F6Publishing: 91] [Article Influence: 11.1] [Reference Citation Analysis]
485 Chumakov PM. Versatile functions of p53 protein in multicellular organisms. Biochemistry (Mosc) 2007;72:1399-421. [PMID: 18282133 DOI: 10.1134/s0006297907130019] [Cited by in Crossref: 45] [Cited by in F6Publishing: 21] [Article Influence: 3.2] [Reference Citation Analysis]
486 Norberg T, Lennerstrand J, Inganäs M, Bergh J. Comparison between p53 protein measurements using the luminometric immunoassay and immunohistochemistry with detection ofp53 gene mutations using cDNA sequencing in human breast tumors. Int J Cancer 1998;79:376-83. [DOI: 10.1002/(sici)1097-0215(19980821)79:4<376::aid-ijc12>3.0.co;2-3] [Cited by in Crossref: 36] [Cited by in F6Publishing: 16] [Article Influence: 1.5] [Reference Citation Analysis]
487 Kageyama S, Komatsu M. Impaired G1-arrest, autophagy, and apoptosis in Atg7-knockout mice. Circ Res 2012;111:962-4. [PMID: 23023507 DOI: 10.1161/CIRCRESAHA.112.280768] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.3] [Reference Citation Analysis]
488 Zhang Q, Bykov VJN, Wiman KG, Zawacka-Pankau J. APR-246 reactivates mutant p53 by targeting cysteines 124 and 277. Cell Death Dis. 2018;9:439. [PMID: 29670092 DOI: 10.1038/s41419-018-0463-7] [Cited by in Crossref: 79] [Cited by in F6Publishing: 76] [Article Influence: 19.8] [Reference Citation Analysis]
489 Strano S, Dell'Orso S, Di Agostino S, Fontemaggi G, Sacchi A, Blandino G. Mutant p53: an oncogenic transcription factor. Oncogene. 2007;26:2212-2219. [PMID: 17401430 DOI: 10.1038/sj.onc.1210296] [Cited by in Crossref: 176] [Cited by in F6Publishing: 161] [Article Influence: 11.7] [Reference Citation Analysis]
490 Sun PD, Foster CE, Boyington JC. Overview of protein structural and functional folds. Curr Protoc Protein Sci 2004;Chapter 17:Unit 17.1. [PMID: 18429251 DOI: 10.1002/0471140864.ps1701s35] [Cited by in Crossref: 4] [Cited by in F6Publishing: 2] [Article Influence: 0.3] [Reference Citation Analysis]
491 Arbely E, Natan E, Brandt T, Allen MD, Veprintsev DB, Robinson CV, Chin JW, Joerger AC, Fersht AR. Acetylation of lysine 120 of p53 endows DNA-binding specificity at effective physiological salt concentration. Proc Natl Acad Sci U S A 2011;108:8251-6. [PMID: 21525412 DOI: 10.1073/pnas.1105028108] [Cited by in Crossref: 65] [Cited by in F6Publishing: 64] [Article Influence: 5.9] [Reference Citation Analysis]
492 Wu H, Hyun J, Martinez-Yamout MA, Park SJ, Dyson HJ. Characterization of an Hsp90-Independent Interaction between Co-Chaperone p23 and Transcription Factor p53. Biochemistry 2018;57:935-44. [PMID: 29334217 DOI: 10.1021/acs.biochem.7b01076] [Cited by in Crossref: 7] [Cited by in F6Publishing: 6] [Article Influence: 1.8] [Reference Citation Analysis]
493 Rhodes D, Schwabe JW. Signal transduction: Fast lane to transcriptional activation. Current Biology 1998;8:R765-7. [DOI: 10.1016/s0960-9822(07)00481-2] [Cited by in Crossref: 3] [Article Influence: 0.1] [Reference Citation Analysis]
494 Miosge LA, Field MA, Sontani Y, Cho V, Johnson S, Palkova A, Balakishnan B, Liang R, Zhang Y, Lyon S, Beutler B, Whittle B, Bertram EM, Enders A, Goodnow CC, Andrews TD. Comparison of predicted and actual consequences of missense mutations. Proc Natl Acad Sci U S A 2015;112:E5189-98. [PMID: 26269570 DOI: 10.1073/pnas.1511585112] [Cited by in Crossref: 137] [Cited by in F6Publishing: 118] [Article Influence: 19.6] [Reference Citation Analysis]
495 Gu J, Wang B, Liu Y, Zhong L, Tang Y, Guo H, Jiang T, Wang L, Li Y, Cai L. Murine double minute 2 siRNA and wild-type p53 gene therapy interact positively with zinc on prostate tumours in vitro and in vivo. Eur J Cancer 2014;50:1184-94. [PMID: 24447832 DOI: 10.1016/j.ejca.2013.12.027] [Cited by in Crossref: 15] [Cited by in F6Publishing: 14] [Article Influence: 1.9] [Reference Citation Analysis]
496 Alam S, Kelleher SL. Cellular mechanisms of zinc dysregulation: a perspective on zinc homeostasis as an etiological factor in the development and progression of breast cancer. Nutrients. 2012;4:875-903. [PMID: 23016122 DOI: 10.3390/nu4080875] [Cited by in Crossref: 79] [Cited by in F6Publishing: 72] [Article Influence: 7.9] [Reference Citation Analysis]
497 Cobbs CS, Samanta M, Harkins LE, Gillespie GY, Merrick BA, MacMillan-Crow LA. Evidence for peroxynitrite-mediated modifications to p53 in human gliomas: possible functional consequences. Arch Biochem Biophys 2001;394:167-72. [PMID: 11594730 DOI: 10.1006/abbi.2001.2540] [Cited by in Crossref: 51] [Cited by in F6Publishing: 47] [Article Influence: 2.4] [Reference Citation Analysis]
498 Santi R, Cetica V, Franchi A, Pepi M, Cesinaro AM, Miracco C, Paglierani M, De Giorgi V, Delfino C, Difonzo EM, Pimpinelli N, Bianchi S, Sardi I, Santucci M, Massi D. Tumour suppressor gene TP53 mutations in atypical vascular lesions of breast skin following radiotherapy. Histopathology 2011;58:455-66. [PMID: 21323968 DOI: 10.1111/j.1365-2559.2011.03770.x] [Cited by in Crossref: 21] [Cited by in F6Publishing: 13] [Article Influence: 1.9] [Reference Citation Analysis]
499 Chiba I, Muthumala M, Yamazaki Y, Uz Zaman A, Iizuka T, Amemiya A, Shibata T, Kashiwazaki H, Sugiura C, Fukuda H. Characteristics of mutations in thep53 gene of oral squamous-cell carcinomas associated with betel-quid chewing in Sri Lanka. Int J Cancer 1998;77:839-42. [DOI: 10.1002/(sici)1097-0215(19980911)77:6<839::aid-ijc7>3.0.co;2-v] [Cited by in Crossref: 24] [Cited by in F6Publishing: 8] [Article Influence: 1.0] [Reference Citation Analysis]
500 Shaminie J, Peh S, Tan J. p53 alterations in sequential biopsies of Asian follicular lymphoma: a study of immunohistochemical staining pattern and gene mutations by PCR-SSCP in paraffin-embedded tissues. Pathology 2005;37:39-44. [DOI: 10.1080/00313020400011334] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 0.2] [Reference Citation Analysis]
501 Olotu FA, Soliman MES. From mutational inactivation to aberrant gain-of-function: Unraveling the structural basis of mutant p53 oncogenic transition. J Cell Biochem 2018;119:2646-52. [PMID: 29058783 DOI: 10.1002/jcb.26430] [Cited by in Crossref: 26] [Cited by in F6Publishing: 21] [Article Influence: 5.2] [Reference Citation Analysis]
502 Lee H, Mok KH, Muhandiram R, Park KH, Suk JE, Kim DH, Chang J, Sung YC, Choi KY, Han KH. Local structural elements in the mostly unstructured transcriptional activation domain of human p53. J Biol Chem 2000;275:29426-32. [PMID: 10884388 DOI: 10.1074/jbc.M003107200] [Cited by in Crossref: 237] [Cited by in F6Publishing: 115] [Article Influence: 10.8] [Reference Citation Analysis]
503 Jost CA, Marin MC, Kaelin WG. p73 is a simian [correction of human] p53-related protein that can induce apoptosis. Nature. 1997;389:191-194. [PMID: 9296498 DOI: 10.1038/38298] [Cited by in Crossref: 653] [Cited by in F6Publishing: 681] [Article Influence: 26.1] [Reference Citation Analysis]
504 Han CW, Lee HN, Jeong MS, Park SY, Jang SB. Structural basis of the p53 DNA binding domain and PUMA complex. Biochem Biophys Res Commun 2021;548:39-46. [PMID: 33631672 DOI: 10.1016/j.bbrc.2021.02.049] [Reference Citation Analysis]
505 Daya-grosjean L, Dumaz N, Sarasin A. The specificity of p53 mutation spectra in sunlight induced human cancers. Journal of Photochemistry and Photobiology B: Biology 1995;28:115-24. [DOI: 10.1016/1011-1344(95)07130-t] [Cited by in Crossref: 108] [Cited by in F6Publishing: 17] [Article Influence: 4.0] [Reference Citation Analysis]
506 Hebert-Magee S, Yu H, Behring M, Jadhav T, Shanmugam C, Frost A, Eltoum IE, Varambally S, Manne U. The combined survival effect of codon 72 polymorphisms and p53 somatic mutations in breast cancer depends on race and molecular subtype. PLoS One 2019;14:e0211734. [PMID: 30730944 DOI: 10.1371/journal.pone.0211734] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 1.3] [Reference Citation Analysis]
507 Millward H, Samowitz W, Wittwer CT, Bernard PS. Homogeneous Amplification and Mutation Scanning of the p53 Gene Using Fluorescent Melting Curves. Clinical Chemistry 2002;48:1321-8. [DOI: 10.1093/clinchem/48.8.1321] [Cited by in Crossref: 21] [Cited by in F6Publishing: 13] [Article Influence: 1.1] [Reference Citation Analysis]
508 Robbins P. p53 and Breast Cancer. Int J Surg Pathol 1996;4:93-110. [DOI: 10.1177/106689699600400206] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 0.8] [Reference Citation Analysis]
509 Qin K, Hou H, Liang Y, Zhang X. Prognostic value of TP53 concurrent mutations for EGFR- TKIs and ALK-TKIs based targeted therapy in advanced non-small cell lung cancer: a meta-analysis. BMC Cancer 2020;20:328. [PMID: 32299384 DOI: 10.1186/s12885-020-06805-5] [Cited by in Crossref: 16] [Cited by in F6Publishing: 16] [Article Influence: 8.0] [Reference Citation Analysis]
510 Zaffaroni N, Benini E, Gornati D, Bearzatto A, Silvestrini R. Lack of a correlation between p53 protein expression and radiation response in human tumor primary cultures. Stem Cells 1995;13:77-85. [DOI: 10.1002/stem.5530130110] [Cited by in Crossref: 9] [Cited by in F6Publishing: 6] [Article Influence: 0.3] [Reference Citation Analysis]
511 Garcia PB, Attardi LD. Illuminating p53 function in cancer with genetically engineered mouse models. Semin Cell Dev Biol 2014;27:74-85. [PMID: 24394915 DOI: 10.1016/j.semcdb.2013.12.014] [Cited by in Crossref: 38] [Cited by in F6Publishing: 32] [Article Influence: 4.8] [Reference Citation Analysis]
512 Sidles JA, Garbini JL, Bruland KJ, Rugar D, Züger O, Hoen S, Yannoni CS. Magnetic resonance force microscopy. Rev Mod Phys 1995;67:249-65. [DOI: 10.1103/revmodphys.67.249] [Cited by in Crossref: 371] [Cited by in F6Publishing: 1] [Article Influence: 13.7] [Reference Citation Analysis]
513 Ahmadi S, Saffari M, Modarressi MH, Shirkoohi R, Jamalian M, Teimori H. Dysregulation of miR-638 in Breast Cancer Patients and Bioinformatics Investigation of Its Target Genes in Apoptosis, Angiogenesis and Autophagy Pathways. Int J Cancer Manag 2019;12. [DOI: 10.5812/ijcm.88829] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
514 Piccinin S, Tonin E, Sessa S, Demontis S, Rossi S, Pecciarini L, Zanatta L, Pivetta F, Grizzo A, Sonego M, Rosano C, Tos A, Doglioni C, Maestro R. A “Twist box” Code of p53 Inactivation: Twist box:p53 Interaction Promotes p53 Degradation. Cancer Cell 2012;22:404-15. [DOI: 10.1016/j.ccr.2012.08.003] [Cited by in Crossref: 84] [Cited by in F6Publishing: 84] [Article Influence: 8.4] [Reference Citation Analysis]
515 Nagaich AK, Appella E, Harrington RE. DNA bending is essential for the site-specific recognition of DNA response elements by the DNA binding domain of the tumor suppressor protein p53. J Biol Chem 1997;272:14842-9. [PMID: 9169453 DOI: 10.1074/jbc.272.23.14842] [Cited by in Crossref: 69] [Cited by in F6Publishing: 74] [Article Influence: 2.8] [Reference Citation Analysis]
516 Fujita H, Senju S, Yokomizo H, Saya H, Ogawa M, Matsushita S, Nishimura Y. Evidence that HLA class II-restricted human CD4+ T cells specific to p53 self peptides respond to p53 proteins of both wild and mutant forms. Eur J Immunol 1998;28:305-16. [DOI: 10.1002/(sici)1521-4141(199801)28:01<305::aid-immu305>3.0.co;2-3] [Cited by in Crossref: 36] [Cited by in F6Publishing: 8] [Article Influence: 1.5] [Reference Citation Analysis]
517 Sasaki DY, Alam TM. Solid-State 31 P NMR Study of Phosphonate Binding Sites in Guanidine-Functionalized, Molecular Imprinted Silica Xerogels. Chem Mater 2000;12:1400-7. [DOI: 10.1021/cm990737r] [Cited by in Crossref: 44] [Cited by in F6Publishing: 38] [Article Influence: 2.0] [Reference Citation Analysis]
518 Soussi T. p53 alterations in human cancer: more questions than answers. Oncogene. 2007;26:2145-2156. [PMID: 17401423 DOI: 10.1038/sj.onc.1210280] [Cited by in Crossref: 157] [Cited by in F6Publishing: 146] [Article Influence: 10.5] [Reference Citation Analysis]
519 Shapiro L, Kwong PD, Fannon AM, Colman DR, Hendrickson WA. Considerations on the folding topology and evolutionary origin of cadherin domains. Proc Natl Acad Sci U S A 1995;92:6793-7. [PMID: 7624321 DOI: 10.1073/pnas.92.15.6793] [Cited by in Crossref: 65] [Cited by in F6Publishing: 59] [Article Influence: 2.4] [Reference Citation Analysis]
520 Puca R, Nardinocchi L, Givol D, D'Orazi G. Regulation of p53 activity by HIPK2: molecular mechanisms and therapeutical implications in human cancer cells. Oncogene 2010;29:4378-87. [PMID: 20514025 DOI: 10.1038/onc.2010.183] [Cited by in Crossref: 85] [Cited by in F6Publishing: 86] [Article Influence: 7.1] [Reference Citation Analysis]
521 Kamata H, Hirata H. Redox regulation of cellular signalling. Cell Signal. 1999;11:1-14. [PMID: 10206339 DOI: 10.1016/s0898-6568(98)00037-0] [Cited by in Crossref: 804] [Cited by in F6Publishing: 241] [Article Influence: 35.0] [Reference Citation Analysis]
522 Hainaut P, Butcher S, Milner J. Temperature sensitivity for conformation is an intrinsic property of wild-type p53. Br J Cancer 1995;71:227-31. [PMID: 7841034 DOI: 10.1038/bjc.1995.48] [Cited by in Crossref: 38] [Cited by in F6Publishing: 40] [Article Influence: 1.4] [Reference Citation Analysis]
523 Shi R, Mullins EA, Shen XX, Lay KT, Yuen PK, David SS, Rokas A, Eichman BF. Selective base excision repair of DNA damage by the non-base-flipping DNA glycosylase AlkC. EMBO J 2018;37:63-74. [PMID: 29054852 DOI: 10.15252/embj.201797833] [Cited by in Crossref: 8] [Cited by in F6Publishing: 9] [Article Influence: 1.6] [Reference Citation Analysis]
524 Tan Y, Luo R. Structural and functional implications of p53 missense cancer mutations. PMC Biophys 2009;2:5. [PMID: 19558684 DOI: 10.1186/1757-5036-2-5] [Cited by in Crossref: 9] [Cited by in F6Publishing: 14] [Article Influence: 0.7] [Reference Citation Analysis]
525 Kubicka S, Trautwein C, Schrem H, Tillmann H, Manns M. Low incidence of p53 mutations in European hepatocellular carcinomas with heterogeneous mutation as a rare event. J Hepatol. 1995;23:412-419. [PMID: 8655958 DOI: 10.1016/0168-8278(95)80199-5] [Cited by in Crossref: 22] [Cited by in F6Publishing: 19] [Article Influence: 0.8] [Reference Citation Analysis]
526 Xue Y, Wang S, Feng X. Effect of Metal Ion on the Structural Stability of Tumour Suppressor Protein p53 DNA-Binding Domain. Journal of Biochemistry 2009;146:193-200. [DOI: 10.1093/jb/mvp055] [Cited by in Crossref: 13] [Cited by in F6Publishing: 12] [Article Influence: 1.0] [Reference Citation Analysis]
527 Cimino F, Esposito F, Ammendola R, Russo T. Gene Regulation by Reactive Oxygen Species. Elsevier; 1997. pp. 123-48. [DOI: 10.1016/s0070-2137(97)80005-2] [Cited by in Crossref: 67] [Cited by in F6Publishing: 5] [Article Influence: 2.7] [Reference Citation Analysis]
528 Dridi W, Krabchi K, Gadji M, Lavoie J, Bronsard M, Fetni R, Drouin R. Activité dominante négative des protéines p53 mutées. Med Sci (Paris) 2006;22:301-7. [DOI: 10.1051/medsci/2006223301] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 0.3] [Reference Citation Analysis]
529 Chang F, Lai M. VARIOUS FORMS OF MUTANT p53 CONFER SENSITIVITY TO CISPLATIN AND DOXORUBICIN IN BLADDER CANCER CELLS. Journal of Urology 2001;166:304-10. [DOI: 10.1016/s0022-5347(05)66150-2] [Cited by in Crossref: 27] [Article Influence: 1.3] [Reference Citation Analysis]
530 Yakovleva T, Pramanik A, Terenius L, Ekström T, Bakalkin G. p53 latency – out of the blind alley. Trends in Biochemical Sciences 2002;27:612-8. [DOI: 10.1016/s0968-0004(02)02209-0] [Cited by in Crossref: 19] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
531 Martin AC, Facchiano AM, Cuff AL, Hernandez-boussard T, Olivier M, Hainaut P, Thornton JM. Integrating mutation data and structural analysis of the TP53 tumor-suppressor protein. Hum Mutat 2002;19:149-64. [DOI: 10.1002/humu.10032] [Cited by in Crossref: 88] [Cited by in F6Publishing: 87] [Article Influence: 4.4] [Reference Citation Analysis]
532 Ho Y, Cheng H, Wang Y, Lin J. p53 gene mutational spectra in hepatocellular carcinomas induced by 2-acetylaminofluorene andN-nitroso-2-acetylaminofluorene in rats. Mol Carcinog 1995;13:182-90. [DOI: 10.1002/mc.2940130308] [Cited by in Crossref: 14] [Cited by in F6Publishing: 14] [Article Influence: 0.5] [Reference Citation Analysis]
533 Dixit U, Liu Z, Pandey AK, Kothari R, Pandey VN. Fuse binding protein antagonizes the transcription activity of tumor suppressor protein p53. BMC Cancer 2014;14:925. [PMID: 25487856 DOI: 10.1186/1471-2407-14-925] [Cited by in Crossref: 18] [Cited by in F6Publishing: 18] [Article Influence: 2.3] [Reference Citation Analysis]
534 Subekti DRG, Murata A, Itoh Y, Fukuchi S, Takahashi H, Kanbayashi S, Takahashi S, Kamagata K. The Disordered Linker in p53 Participates in Nonspecific Binding to and One-Dimensional Sliding along DNA Revealed by Single-Molecule Fluorescence Measurements. Biochemistry 2017;56:4134-44. [DOI: 10.1021/acs.biochem.7b00292] [Cited by in Crossref: 20] [Cited by in F6Publishing: 15] [Article Influence: 4.0] [Reference Citation Analysis]
535 Orgad S, Dimant H, Dor-On E, Azriel-Rosenfeld R, Benhar I, Solomon B. TAR1, a human anti-p53 single-chain antibody, restores tumor suppressor function to mutant p53 variants. J Immunother 2010;33:146-54. [PMID: 20139776 DOI: 10.1097/CJI.0b013e3181be14dc] [Cited by in Crossref: 2] [Article Influence: 0.2] [Reference Citation Analysis]
536 Harvey M, Vogel H, Morris D, Bradley A, Bernstein A, Donehower LA. A mutant p53 transgene accelerates tumour development in heterozygous but not nullizygous p53–deficient mice. Nat Genet 1995;9:305-11. [DOI: 10.1038/ng0395-305] [Cited by in Crossref: 149] [Cited by in F6Publishing: 137] [Article Influence: 5.5] [Reference Citation Analysis]
537 Finianos A, Matar CF, Taher A. Hepatocellular Carcinoma in β-Thalassemia Patients: Review of the Literature with Molecular Insight into Liver Carcinogenesis. Int J Mol Sci 2018;19:E4070. [PMID: 30562917 DOI: 10.3390/ijms19124070] [Cited by in Crossref: 7] [Cited by in F6Publishing: 9] [Article Influence: 1.8] [Reference Citation Analysis]
538 Lim JH, Latysheva NS, Iggo RD, Barker D. Cluster Analysis of p53 Binding Site Sequences Reveals Subsets with Different Functions. Cancer Inform 2016;15:199-209. [PMID: 27812278 DOI: 10.4137/CIN.S39968] [Reference Citation Analysis]
539 Gabizon R, Mor M, Rosenberg MM, Britan L, Hayouka Z, Kotler M, Shalev DE, Friedler A. Using peptides to study the interaction between the p53 tetramerization domain and HIV-1 Tat. Biopolymers 2008;90:105-16. [PMID: 18189286 DOI: 10.1002/bip.20919] [Cited by in Crossref: 14] [Cited by in F6Publishing: 13] [Article Influence: 1.0] [Reference Citation Analysis]
540 Bisht G, Rayamajhi S. ZnO Nanoparticles: A Promising Anticancer Agent. Nanobiomedicine (Rij) 2016;3:9. [PMID: 29942384 DOI: 10.5772/63437] [Cited by in Crossref: 123] [Cited by in F6Publishing: 82] [Article Influence: 20.5] [Reference Citation Analysis]
541 Tang Y, Yao Y, Wei G. Unraveling the Allosteric Mechanism of Four Cancer-related Mutations in the Disruption of p53-DNA Interaction. J Phys Chem B 2021;125:10138-48. [PMID: 34403252 DOI: 10.1021/acs.jpcb.1c05638] [Reference Citation Analysis]
542 Bykov VJ, Wiman KG. Novel cancer therapy by reactivation of the p53 apoptosis pathway. Ann Med. 2003;35:458-465. [PMID: 14649328 DOI: 10.1080/07853890310017152] [Cited by in Crossref: 34] [Cited by in F6Publishing: 32] [Article Influence: 1.9] [Reference Citation Analysis]
543 Joerger AC, Fersht AR. The tumor suppressor p53: from structures to drug discovery. Cold Spring Harb Perspect Biol 2010;2:a000919. [PMID: 20516128 DOI: 10.1101/cshperspect.a000919] [Cited by in Crossref: 176] [Cited by in F6Publishing: 167] [Article Influence: 14.7] [Reference Citation Analysis]
544 Millau JF, Bandele OJ, Perron J, Bastien N, Bouchard EF, Gaudreau L, Bell DA, Drouin R. Formation of stress-specific p53 binding patterns is influenced by chromatin but not by modulation of p53 binding affinity to response elements. Nucleic Acids Res 2011;39:3053-63. [PMID: 21177650 DOI: 10.1093/nar/gkq1209] [Cited by in Crossref: 10] [Cited by in F6Publishing: 9] [Article Influence: 0.8] [Reference Citation Analysis]
545 Harris CR, Dewan A, Zupnick A, Normart R, Gabriel A, Prives C, Levine AJ, Hoh J. p53 responsive elements in human retrotransposons. Oncogene 2009;28:3857-65. [PMID: 19718052 DOI: 10.1038/onc.2009.246] [Cited by in Crossref: 62] [Cited by in F6Publishing: 61] [Article Influence: 4.8] [Reference Citation Analysis]
546 Zakrzewska K, Lavery R. Modelling Protein-DNA Interactions. Computational Molecular Biology. Elsevier; 1999. pp. 441-83. [DOI: 10.1016/s1380-7323(99)80087-9] [Cited by in Crossref: 6] [Article Influence: 0.3] [Reference Citation Analysis]
547 Gottlieb TM, Oren M. p53 in growth control and neoplasia. Biochim Biophys Acta 1996;1287:77-102. [PMID: 8672531 DOI: 10.1016/0304-419x(95)00019-c] [Cited by in Crossref: 64] [Cited by in F6Publishing: 106] [Article Influence: 2.5] [Reference Citation Analysis]
548 Riley T, Sontag E, Chen P, Levine A. Transcriptional control of human p53-regulated genes. Nat Rev Mol Cell Biol 2008;9:402-12. [PMID: 18431400 DOI: 10.1038/nrm2395] [Cited by in Crossref: 1277] [Cited by in F6Publishing: 1214] [Article Influence: 91.2] [Reference Citation Analysis]
549 Wallentine BD, Wang Y, Tretyachenko-Ladokhina V, Tan M, Senear DF, Luecke H. Structures of oncogenic, suppressor and rescued p53 core-domain variants: mechanisms of mutant p53 rescue. Acta Crystallogr D Biol Crystallogr 2013;69:2146-56. [PMID: 24100332 DOI: 10.1107/S0907444913020830] [Cited by in Crossref: 6] [Cited by in F6Publishing: 2] [Article Influence: 0.7] [Reference Citation Analysis]
550 Bykov VJN, Eriksson SE, Bianchi J, Wiman KG. Targeting mutant p53 for efficient cancer therapy. Nat Rev Cancer 2018;18:89-102. [PMID: 29242642 DOI: 10.1038/nrc.2017.109] [Cited by in Crossref: 318] [Cited by in F6Publishing: 314] [Article Influence: 63.6] [Reference Citation Analysis]
551 Wang W, Hu Y. Small molecule agents targeting the p53-MDM2 pathway for cancer therapy: p53-MDM2 PATHWAY FOR CANCER THERAPY. Med Res Rev 2012;32:1159-96. [DOI: 10.1002/med.20236] [Cited by in Crossref: 55] [Cited by in F6Publishing: 50] [Article Influence: 5.0] [Reference Citation Analysis]
552 Wieczorek AM, Waterman JL, Waterman MJ, Halazonetis TD. Structure–based rescue of common tumor–derived p53 mutants. Nat Med 1996;2:1143-6. [DOI: 10.1038/nm1096-1143] [Cited by in Crossref: 58] [Cited by in F6Publishing: 58] [Article Influence: 2.2] [Reference Citation Analysis]
553 Ozaki T, Nakagawara A. p53: the attractive tumor suppressor in the cancer research field. J Biomed Biotechnol 2011;2011:603925. [PMID: 21188172 DOI: 10.1155/2011/603925] [Cited by in Crossref: 53] [Cited by in F6Publishing: 59] [Article Influence: 4.4] [Reference Citation Analysis]
554 Degtjarik O, Golovenko D, Diskin-Posner Y, Abrahmsén L, Rozenberg H, Shakked Z. Structural basis of reactivation of oncogenic p53 mutants by a small molecule: methylene quinuclidinone (MQ). Nat Commun 2021;12:7057. [PMID: 34862374 DOI: 10.1038/s41467-021-27142-6] [Reference Citation Analysis]
555 Gholami A, Fridgen TD. The unimolecular chemistry of [Zn(amino acid)2-H]+ in the gas phase: H2 elimination when the amino acid is a secondary amine. Phys Chem Chem Phys 2014;16:3134-43. [PMID: 24402409 DOI: 10.1039/c3cp53716a] [Cited by in Crossref: 6] [Article Influence: 0.8] [Reference Citation Analysis]
556 Mckinney K, Prives C. Regulation of p53 DNA Binding. In: Hainaut P, Wiman KG, editors. 25 Years of p53 Research. Dordrecht: Springer Netherlands; 2007. pp. 27-51. [DOI: 10.1007/978-1-4020-2922-6_2] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 0.3] [Reference Citation Analysis]
557 Hayman L, Chaudhry WR, Revin VV, Zhelev N, Bourdon J. What is the potential of p53 isoforms as a predictive biomarker in the treatment of cancer? Expert Review of Molecular Diagnostics 2019;19:149-59. [DOI: 10.1080/14737159.2019.1563484] [Cited by in Crossref: 6] [Cited by in F6Publishing: 7] [Article Influence: 2.0] [Reference Citation Analysis]
558 Tajima S, Zhuang WZ, Kato MV, Okada K, Ikawa Y, Aida Y. Function and Conformation of Wild-Type p53 Protein Are Influenced by Mutations in Bovine Leukemia Virus-Induced B-Cell Lymphosarcoma. Virology 1998;243:235-46. [DOI: 10.1006/viro.1998.9051] [Cited by in Crossref: 20] [Cited by in F6Publishing: 8] [Article Influence: 0.8] [Reference Citation Analysis]
559 Barrow LL, van Bokhoven H, Daack-Hirsch S, Andersen T, van Beersum SE, Gorlin R, Murray JC. Analysis of the p63 gene in classical EEC syndrome, related syndromes, and non-syndromic orofacial clefts. J Med Genet 2002;39:559-66. [PMID: 12161593 DOI: 10.1136/jmg.39.8.559] [Cited by in Crossref: 73] [Cited by in F6Publishing: 59] [Article Influence: 3.7] [Reference Citation Analysis]
560 Chen GG, Merchant JL, Lai PB, Ho RL, Hu X, Okada M, Huang SF, Chui AK, Law DJ, Li YG. Mutation of p53 in recurrent hepatocellular carcinoma and its association with the expression of ZBP-89. Am J Pathol. 2003;162:1823-1829. [PMID: 12759240 DOI: 10.1016/s0002-9440(10)64317-9] [Cited by in Crossref: 31] [Cited by in F6Publishing: 20] [Article Influence: 1.6] [Reference Citation Analysis]
561 Luo T, Yu W, Yuan Z, Deng Y, Zhao Y, Yuan W, Xiao J, Wang Y, Luo N, Mo X, Li Y, Liu M, Wu X. A novel mutation of p63 in a Chinese family with inherited syndactyly and adactylism. Mutat Res 2008;637:182-9. [PMID: 17915261 DOI: 10.1016/j.mrfmmm.2007.08.010] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.2] [Reference Citation Analysis]
562 Ma J, Fu Y, Tu YY, Liu Y, Tan YR, Ju WT, Pickering CR, Myers JN, Zhang ZY, Zhong LP. Mutation allele frequency threshold does not affect prognostic analysis using next-generation sequencing in oral squamous cell carcinoma. BMC Cancer 2018;18:758. [PMID: 30041611 DOI: 10.1186/s12885-018-4481-8] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 1.5] [Reference Citation Analysis]
563 Römer L, Klein C, Dehner A, Kessler H, Buchner J. p53 – ein natürlicher Krebskiller: Einsichten in die Struktur und Therapiekonzepte. Angew Chem 2006;118:6590-611. [DOI: 10.1002/ange.200600611] [Cited by in Crossref: 10] [Cited by in F6Publishing: 10] [Article Influence: 0.6] [Reference Citation Analysis]
564 Cai BH, Chao CF, Huang HC, Lee HY, Kannagi R, Chen JY. Roles of p53 Family Structure and Function in Non-Canonical Response Element Binding and Activation. Int J Mol Sci 2019;20:E3681. [PMID: 31357595 DOI: 10.3390/ijms20153681] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 2.7] [Reference Citation Analysis]
565 Mann K, Hainaut P. Aminothiol WR1065 induces differential gene expression in the presence of wild-type p53. Oncogene 2005;24:3964-75. [DOI: 10.1038/sj.onc.1208563] [Cited by in Crossref: 15] [Cited by in F6Publishing: 12] [Article Influence: 0.9] [Reference Citation Analysis]
566 Loging WT, Reisman D. Inhibition of the putative tumor suppressor gene TIMP-3 by tumor-derived p53 mutants and wild type p53. Oncogene 1999;18:7608-15. [PMID: 10602522 DOI: 10.1038/sj.onc.1203135] [Cited by in Crossref: 27] [Cited by in F6Publishing: 28] [Article Influence: 1.2] [Reference Citation Analysis]
567 Danziger SA, Zeng J, Wang Y, Brachmann RK, Lathrop RH. Choosing where to look next in a mutation sequence space: Active Learning of informative p53 cancer rescue mutants. Bioinformatics 2007;23:i104-14. [PMID: 17646286 DOI: 10.1093/bioinformatics/btm166] [Cited by in Crossref: 32] [Cited by in F6Publishing: 11] [Article Influence: 2.1] [Reference Citation Analysis]
568 Cuff AL, Janes RW, Martin AC. Analysing the ability to retain sidechain hydrogen-bonds in mutant proteins. Bioinformatics 2006;22:1464-70. [DOI: 10.1093/bioinformatics/btl120] [Cited by in Crossref: 10] [Cited by in F6Publishing: 8] [Article Influence: 0.6] [Reference Citation Analysis]
569 Ziegler A, Jonason A, Simon J, Leffell D, Brash DE. Tumor Suppressor Gene Mutations and Photocarcinogenesis. Photochem Photobiol 1996;63:432-5. [DOI: 10.1111/j.1751-1097.1996.tb03064.x] [Cited by in Crossref: 38] [Cited by in F6Publishing: 34] [Article Influence: 1.5] [Reference Citation Analysis]
570 Gorgoulis VG, Zacharatos P, Kotsinas A, Kletsas D, Mariatos G, Zoumpourlis V, Ryan KM, Kittas C, Papavassiliou AG. p53 activates ICAM-1 (CD54) expression in an NF-kappaB-independent manner. EMBO J 2003;22:1567-78. [PMID: 12660163 DOI: 10.1093/emboj/cdg157] [Cited by in Crossref: 67] [Cited by in F6Publishing: 62] [Article Influence: 3.5] [Reference Citation Analysis]
571 Young KH, Weisenburger DD, Dave BJ, Smith L, Sanger W, Iqbal J, Campo E, Delabie J, Gascoyne RD, Ott G, Rimsza L, Müller-Hermelink HK, Jaffe ES, Rosenwald A, Staudt LM, Chan WC, Greiner TC. Mutations in the DNA-binding codons of TP53, which are associated with decreased expression of TRAILreceptor-2, predict for poor survival in diffuse large B-cell lymphoma. Blood 2007;110:4396-405. [PMID: 17881637 DOI: 10.1182/blood-2007-02-072082] [Cited by in Crossref: 72] [Cited by in F6Publishing: 71] [Article Influence: 4.8] [Reference Citation Analysis]
572 Shao JC, Wu JF, Wang DB, Qin R, Zhang H. Relationship between the expression of human telomerase reverse transcriptase gene and cell cycle regulators in gastric cancer and its significance. World J Gastroenterol 2003; 9(3): 427-431 [PMID: 12632490 DOI: 10.3748/wjg.v9.i3.427] [Cited by in CrossRef: 12] [Cited by in F6Publishing: 11] [Article Influence: 0.6] [Reference Citation Analysis]
573 Janus F, Albrechtsen N, Knippschild U, Wiesmüller L, Grosse F, Deppert W. Different regulation of the p53 core domain activities 3'-to-5' exonuclease and sequence-specific DNA binding. Mol Cell Biol 1999;19:2155-68. [PMID: 10022902 DOI: 10.1128/MCB.19.3.2155] [Cited by in Crossref: 25] [Cited by in F6Publishing: 9] [Article Influence: 1.1] [Reference Citation Analysis]
574 Wong P, Verselis SJ, Garber JE, Schneider K, DiGianni L, Stockwell DH, Li FP, Syngal S. Prevalence of early onset colorectal cancer in 397 patients with classic Li-Fraumeni syndrome. Gastroenterology 2006;130:73-9. [PMID: 16401470 DOI: 10.1053/j.gastro.2005.10.014] [Cited by in Crossref: 80] [Cited by in F6Publishing: 67] [Article Influence: 5.0] [Reference Citation Analysis]
575 Nelsons HC, Bestor TH. Base eversion and shuffling by DNA methyltransferases. Chemistry & Biology 1996;3:419-23. [DOI: 10.1016/s1074-5521(96)90089-7] [Cited by in Crossref: 9] [Article Influence: 0.3] [Reference Citation Analysis]
576 Anderson CL, Routes TC, Eckhardt LL, Delisle BP, January CT, Kamp TJ. A rapid solubility assay of protein domain misfolding for pathogenicity assessment of rare DNA sequence variants. Genet Med 2020;22:1642-52. [PMID: 32475984 DOI: 10.1038/s41436-020-0842-1] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
577 Ng JW, Lama D, Lukman S, Lane DP, Verma CS, Sim AY. R248Q mutation--Beyond p53-DNA binding. Proteins 2015;83:2240-50. [PMID: 26442703 DOI: 10.1002/prot.24940] [Cited by in Crossref: 16] [Cited by in F6Publishing: 16] [Article Influence: 2.3] [Reference Citation Analysis]
578 Bhattacharjee S, Sengupta J. Hidden electrostatic energy contributions define dynamic allosteric communications within p53 during molecular recognition. Biophys J 2021;120:4512-24. [PMID: 34478701 DOI: 10.1016/j.bpj.2021.08.037] [Reference Citation Analysis]
579 Klosterman S, Choi J, Hadwiger L. Programmed cell death is not mediated by a p53 homolog in Pisum sativum. Physiological and Molecular Plant Pathology 2000;56:197-206. [DOI: 10.1006/pmpp.2000.0267] [Cited by in Crossref: 6] [Cited by in F6Publishing: 3] [Article Influence: 0.3] [Reference Citation Analysis]
580 Lanni C, Racchi M, Memo M, Govoni S, Uberti D. p53 at the crossroads between cancer and neurodegeneration. Free Radic Biol Med 2012;52:1727-33. [PMID: 22387179 DOI: 10.1016/j.freeradbiomed.2012.02.034] [Cited by in Crossref: 59] [Cited by in F6Publishing: 62] [Article Influence: 5.9] [Reference Citation Analysis]
581 Rauf SM, Ismael M, Sahu KK, Suzuki A, Koyama M, Tsuboi H, Hatakeyama N, Endou A, Takaba H, Del Carpio CA, Kubo M, Miyamoto A. The effect of R249S carcinogenic and H168R-R249S suppressor mutations on p53-DNA interaction, a multi scale computational study. Comput Biol Med 2010;40:498-508. [PMID: 20403587 DOI: 10.1016/j.compbiomed.2010.03.004] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 0.3] [Reference Citation Analysis]
582 Ishiguro N, Furuoka H, Matsui T, Horiuchi M, Shinagawa M, Asahina M, Okada K. p53 mutation as a potential cellular factor for tumor development in enzootic bovine leukosis. Veterinary Immunology and Immunopathology 1997;55:351-8. [DOI: 10.1016/s0165-2427(96)05721-2] [Cited by in Crossref: 16] [Cited by in F6Publishing: 5] [Article Influence: 0.6] [Reference Citation Analysis]
583 Gonzalez-fernandez F, Kaltreider SA, Patnaik BD, Retief JD, Bao Y, Newman S, Stoler MH, Levine PA. Sebaceous carcinoma. Ophthalmology 1998;105:497-506. [DOI: 10.1016/s0161-6420(98)93034-2] [Cited by in Crossref: 54] [Cited by in F6Publishing: 9] [Article Influence: 2.3] [Reference Citation Analysis]
584 Reaz S, Mossalam M, Okal A, Lim CS. A single mutant, A276S of p53, turns the switch to apoptosis. Mol Pharm 2013;10:1350-9. [PMID: 23402381 DOI: 10.1021/mp300598k] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 0.7] [Reference Citation Analysis]
585 Kobren SN, Chazelle B, Singh M. PertInInt: An Integrative, Analytical Approach to Rapidly Uncover Cancer Driver Genes with Perturbed Interactions and Functionalities. Cell Syst 2020;11:63-74.e7. [PMID: 32711844 DOI: 10.1016/j.cels.2020.06.005] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
586 Cachot J, Galgani F, Vincent F. cDNA cloning and expression analysis of flounder p53 tumour suppressor gene. Comp Biochem Physiol B Biochem Mol Biol 1998;121:235-42. [PMID: 9972298 DOI: 10.1016/s0305-0491(98)10133-5] [Cited by in Crossref: 21] [Cited by in F6Publishing: 1] [Article Influence: 0.9] [Reference Citation Analysis]
587 Zhao L, Zhao X, Wu X, Tang W. Association of p53 Arg72Pro polymorphism with esophageal cancer: a meta-analysis based on 14 case-control studies. Genet Test Mol Biomarkers 2013;17:721-6. [PMID: 23844939 DOI: 10.1089/gtmb.2013.0103] [Cited by in Crossref: 11] [Cited by in F6Publishing: 8] [Article Influence: 1.2] [Reference Citation Analysis]
588 Deng J, Dayam R, Neamati N. Patented small molecule inhibitors of p53–MDM2 interaction. Expert Opinion on Therapeutic Patents 2006;16:165-88. [DOI: 10.1517/13543776.16.2.165] [Cited by in Crossref: 14] [Cited by in F6Publishing: 13] [Article Influence: 0.9] [Reference Citation Analysis]
589 Shenk JL, Fisher CJ, Chen SY, Zhou XF, Tillman K, Shemshedini L. p53 represses androgen-induced transactivation of prostate-specific antigen by disrupting hAR amino- to carboxyl-terminal interaction. J Biol Chem 2001;276:38472-9. [PMID: 11504717 DOI: 10.1074/jbc.M103652200] [Cited by in Crossref: 72] [Cited by in F6Publishing: 38] [Article Influence: 3.4] [Reference Citation Analysis]
590 Pan Y, Nussinov R. Preferred drifting along the DNA major groove and cooperative anchoring of the p53 core domain: mechanisms and scenarios. J Mol Recognit 2010;23:232-40. [PMID: 19856322 DOI: 10.1002/jmr.990] [Cited by in F6Publishing: 2] [Reference Citation Analysis]
591 Wang Y, Suh YA, Fuller MY, Jackson JG, Xiong S, Terzian T, Quintás-Cardama A, Bankson JA, El-Naggar AK, Lozano G. Restoring expression of wild-type p53 suppresses tumor growth but does not cause tumor regression in mice with a p53 missense mutation. J Clin Invest 2011;121:893-904. [PMID: 21285512 DOI: 10.1172/JCI44504] [Cited by in Crossref: 84] [Cited by in F6Publishing: 66] [Article Influence: 7.6] [Reference Citation Analysis]
592 Shapiro L. Finding function through structural genomics. Current Opinion in Biotechnology;11:31-5. [DOI: 10.1016/s0958-1669(99)00064-6] [Cited by in Crossref: 45] [Cited by in F6Publishing: 16] [Article Influence: 2.0] [Reference Citation Analysis]
593 Boysen M, Kityk R, Mayer MP. Hsp70- and Hsp90-Mediated Regulation of the Conformation of p53 DNA Binding Domain and p53 Cancer Variants. Molecular Cell 2019;74:831-843.e4. [DOI: 10.1016/j.molcel.2019.03.032] [Cited by in Crossref: 29] [Cited by in F6Publishing: 26] [Article Influence: 9.7] [Reference Citation Analysis]
594 Rivlin N, Brosh R, Oren M, Rotter V. Mutations in the p53 Tumor Suppressor Gene: Important Milestones at the Various Steps of Tumorigenesis. Genes Cancer. 2011;2:466-474. [PMID: 21779514 DOI: 10.1177/1947601911408889] [Cited by in Crossref: 449] [Cited by in F6Publishing: 414] [Article Influence: 40.8] [Reference Citation Analysis]
595 Strano S, Dell'Orso S, Mongiovi AM, Monti O, Lapi E, Di Agostino S, Fontemaggi G, Blandino G. Mutant p53 proteins: between loss and gain of function. Head Neck 2007;29:488-96. [PMID: 17123310 DOI: 10.1002/hed.20531] [Cited by in Crossref: 37] [Cited by in F6Publishing: 31] [Article Influence: 2.5] [Reference Citation Analysis]
596 Martinelli AHS, Lopes FC, John EBO, Carlini CR, Ligabue-Braun R. Modulation of Disordered Proteins with a Focus on Neurodegenerative Diseases and Other Pathologies. Int J Mol Sci 2019;20:E1322. [PMID: 30875980 DOI: 10.3390/ijms20061322] [Cited by in Crossref: 20] [Cited by in F6Publishing: 16] [Article Influence: 6.7] [Reference Citation Analysis]
597 Ishimaru D, Maia LF, Maiolino LM, Quesado PA, Lopez PC, Almeida FC, Valente AP, Silva JL. Conversion of wild-type p53 core domain into a conformation that mimics a hot-spot mutant. J Mol Biol 2003;333:443-51. [PMID: 14529628 DOI: 10.1016/j.jmb.2003.08.026] [Cited by in Crossref: 31] [Cited by in F6Publishing: 31] [Article Influence: 1.6] [Reference Citation Analysis]
598 Gualberto A, Aldape K, Kozakiewicz K, Tlsty TD. An oncogenic form of p53 confers a dominant, gain-of-function phenotype that disrupts spindle checkpoint control. Proc Natl Acad Sci U S A 1998;95:5166-71. [PMID: 9560247 DOI: 10.1073/pnas.95.9.5166] [Cited by in Crossref: 165] [Cited by in F6Publishing: 165] [Article Influence: 6.9] [Reference Citation Analysis]
599 Ma B, Pan Y, Gunasekaran K, Keskin O, Venkataraghavan RB, Levine AJ, Nussinov R. The contribution of the Trp/Met/Phe residues to physical interactions of p53 with cellular proteins. Phys Biol 2005;2:S56-66. [DOI: 10.1088/1478-3975/2/2/s06] [Cited by in Crossref: 10] [Cited by in F6Publishing: 4] [Article Influence: 0.6] [Reference Citation Analysis]
600 Bazan V, Migliavacca M, Tubiolo C, Macaluso M, Zanna I, Corsale S, Amato A, Calò V, Dardanoni G, Morello V, La Farina M, Albanese I, Tomasino RM, Gebbia N, Russo A. Have p53 gene mutations and protein expression a different biological significance in colorectal cancer? J Cell Physiol 2002;191:237-46. [PMID: 12064467 DOI: 10.1002/jcp.10088] [Cited by in Crossref: 16] [Cited by in F6Publishing: 15] [Article Influence: 0.8] [Reference Citation Analysis]
601 Xu H, el-Gewely MR. P53-responsive genes and the potential for cancer diagnostics and therapeutics development. Biotechnol Annu Rev 2001;7:131-64. [PMID: 11686042 DOI: 10.1016/s1387-2656(01)07035-1] [Cited by in Crossref: 25] [Cited by in F6Publishing: 10] [Article Influence: 1.3] [Reference Citation Analysis]
602 Wery JP, Schevitz RW. New trends in macromolecular X-ray crystallography. Curr Opin Chem Biol 1997;1:365-9. [PMID: 9667874 DOI: 10.1016/s1367-5931(97)80075-0] [Cited by in Crossref: 7] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
603 Chen Y, Chen PL, Lee WH. Hot-spot p53 mutants interact specifically with two cellular proteins during progression of the cell cycle. Mol Cell Biol 1994;14:6764-72. [PMID: 7935394 DOI: 10.1128/mcb.14.10.6764-6772.1994] [Cited by in Crossref: 1] [Cited by in F6Publishing: 7] [Article Influence: 0.0] [Reference Citation Analysis]
604 Bykov V, Selivanova G, Wiman K. Small molecules that reactivate mutant p53. European Journal of Cancer 2003;39:1828-34. [DOI: 10.1016/s0959-8049(03)00454-4] [Cited by in Crossref: 91] [Cited by in F6Publishing: 25] [Article Influence: 4.8] [Reference Citation Analysis]
605 Hensey C, Gautier J. Regulation of cell cycle progression following DNA damage. In: Meijer L, Guidet S, Tung HYL, editors. Progress in Cell Cycle Research. Boston: Springer US; 1995. pp. 149-62. [DOI: 10.1007/978-1-4615-1809-9_12] [Cited by in Crossref: 7] [Cited by in F6Publishing: 8] [Article Influence: 0.3] [Reference Citation Analysis]
606 Dickerson RE, Chiu TK. Helix bending as a factor in protein/DNA recognition. Biopolymers 1997;44:361-403. [DOI: 10.1002/(sici)1097-0282(1997)44:4<361::aid-bip4>3.0.co;2-x] [Cited by in Crossref: 89] [Cited by in F6Publishing: 39] [Article Influence: 3.6] [Reference Citation Analysis]
607 Cheng Z, Zhu S, Wang L, Liu F, Tian H, Pengsakul T, Wang Y. Identification and characterisation of Emp53, the homologue of human tumor suppressor p53, from Echinococcus multilocularis: its role in apoptosis and the oxidative stress response. International Journal for Parasitology 2015;45:517-26. [DOI: 10.1016/j.ijpara.2015.02.010] [Cited by in Crossref: 10] [Cited by in F6Publishing: 11] [Article Influence: 1.4] [Reference Citation Analysis]
608 Brachmann RK, Vidal M, Boeke JD. Dominant-negative p53 mutations selected in yeast hit cancer hot spots. Proc Natl Acad Sci U S A 1996;93:4091-5. [PMID: 8633021 DOI: 10.1073/pnas.93.9.4091] [Cited by in Crossref: 98] [Cited by in F6Publishing: 105] [Article Influence: 3.8] [Reference Citation Analysis]
609 Ríos-Tamayo R, Lupiañez CB, Campa D, Hielscher T, Weinhold N, Martínez-López J, Jerez A, Landi S, Jamroziak K, Dumontet C, Wątek M, Lesueur F, Reis RM, Marques H, Jurczyszyn A, Vogel U, Buda G, García-Sanz R, Orciuolo E, Petrini M, Vangsted AJ, Gemignani F, Försti A, Goldschmidt H, Hemminki K, Canzian F, Jurado M, Sainz J. A common variant within the HNF1B gene is associated with overall survival of multiple myeloma patients: results from the IMMEnSE consortium and meta-analysis. Oncotarget 2016;7:59029-48. [PMID: 27437873 DOI: 10.18632/oncotarget.10665] [Cited by in Crossref: 10] [Cited by in F6Publishing: 9] [Article Influence: 2.5] [Reference Citation Analysis]
610 Gini B, Thomas N, Blakely CM. Impact of concurrent genomic alterations in epidermal growth factor receptor (EGFR)-mutated lung cancer. J Thorac Dis 2020;12:2883-95. [PMID: 32642201 DOI: 10.21037/jtd.2020.03.78] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 2.0] [Reference Citation Analysis]
611 Iseki A, Kambe F, Okumura K, Hayakawa T, Seo H. Regulation of thyroid follicular cell function by intracellular redox-active copper. Endocrinology 2000;141:4373-82. [PMID: 11108245 DOI: 10.1210/endo.141.12.7835] [Cited by in Crossref: 11] [Cited by in F6Publishing: 11] [Article Influence: 0.5] [Reference Citation Analysis]
612 Elledge RM, Lee W. Life and death by P53. Bioessays 1995;17:923-30. [DOI: 10.1002/bies.950171105] [Cited by in Crossref: 64] [Cited by in F6Publishing: 62] [Article Influence: 2.4] [Reference Citation Analysis]
613 Zhang X, Diao S, Rao Q, Xing H, Liu H, Liao X, Wang M, Wang J. Identification of a Novel Isoform of iASPP and its Interaction with p53. Journal of Molecular Biology 2007;368:1162-71. [DOI: 10.1016/j.jmb.2007.03.001] [Cited by in Crossref: 13] [Cited by in F6Publishing: 13] [Article Influence: 0.9] [Reference Citation Analysis]
614 Mayer S, Rüdiger S, Ang HC, Joerger AC, Fersht AR. Correlation of levels of folded recombinant p53 in escherichia coli with thermodynamic stability in vitro. J Mol Biol 2007;372:268-76. [PMID: 17631895 DOI: 10.1016/j.jmb.2007.06.044] [Cited by in Crossref: 72] [Cited by in F6Publishing: 68] [Article Influence: 4.8] [Reference Citation Analysis]
615 Parks D, Bolinger R, Mann K. Redox state regulates binding of p53 to sequence-specific DNA, but not to non-specific or mismatched DNA. Nucleic Acids Res 1997;25:1289-95. [PMID: 9092641 DOI: 10.1093/nar/25.6.1289] [Cited by in Crossref: 64] [Cited by in F6Publishing: 59] [Article Influence: 2.6] [Reference Citation Analysis]
616 Cordani M, Butera G, Pacchiana R, Donadelli M. Molecular interplay between mutant p53 proteins and autophagy in cancer cells. Biochim Biophys Acta Rev Cancer 2017;1867:19-28. [PMID: 27871965 DOI: 10.1016/j.bbcan.2016.11.003] [Cited by in Crossref: 34] [Cited by in F6Publishing: 45] [Article Influence: 5.7] [Reference Citation Analysis]
617 Mitra N, Dey S. Biochemical characterization of mono ADP ribosyl transferase activity of human sirtuin SIRT7 and its regulation. Arch Biochem Biophys 2020;680:108226. [PMID: 31843644 DOI: 10.1016/j.abb.2019.108226] [Cited by in Crossref: 4] [Cited by in F6Publishing: 2] [Article Influence: 1.3] [Reference Citation Analysis]
618 Mirzayans R, Andrais B, Scott A, Murray D. New insights into p53 signaling and cancer cell response to DNA damage: implications for cancer therapy. J Biomed Biotechnol. 2012;2012:170325. [PMID: 22911014 DOI: 10.1155/2012/170325] [Cited by in Crossref: 138] [Cited by in F6Publishing: 138] [Article Influence: 13.8] [Reference Citation Analysis]
619 Ma B, Levine AJ. Probing potential binding modes of the p53 tetramer to DNA based on the symmetries encoded in p53 response elements. Nucleic Acids Res 2007;35:7733-47. [PMID: 17986463 DOI: 10.1093/nar/gkm890] [Cited by in Crossref: 25] [Cited by in F6Publishing: 22] [Article Influence: 1.7] [Reference Citation Analysis]
620 Follis AV, Llambi F, Ou L, Baran K, Green DR, Kriwacki RW. The DNA-binding domain mediates both nuclear and cytosolic functions of p53. Nat Struct Mol Biol 2014;21:535-43. [PMID: 24814347 DOI: 10.1038/nsmb.2829] [Cited by in Crossref: 57] [Cited by in F6Publishing: 53] [Article Influence: 7.1] [Reference Citation Analysis]
621 Haugen BR, Woodmansee WW, Mcdermott MT. Towards improving the utility of fine-needle aspiration biopsy for the diagnosis of thyroid tumours: FNA diagnosis of thyroid tumours. Clinical Endocrinology 2002;56:281-90. [DOI: 10.1046/j.1365-2265.2002.01500.x] [Cited by in Crossref: 66] [Cited by in F6Publishing: 51] [Article Influence: 3.3] [Reference Citation Analysis]
622 Shi T, van Soest DMK, Polderman PE, Burgering BMT, Dansen TB. DNA damage and oxidant stress activate p53 through differential upstream signaling pathways. Free Radic Biol Med 2021;172:298-311. [PMID: 34144191 DOI: 10.1016/j.freeradbiomed.2021.06.013] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
623 Voeltzel T, Morel AP, Rostan MC, Ji J, Chiodino C, Ponchel F, Vigouroux J, Caron De Fromentel C, Soussi T, Ozturk M. A New Set of Monoclonal Antibodies Directed to Proline-Rich and Central Regions of p53. Hybridoma and Hybridomics 2004;23:287-92. [DOI: 10.1089/hyb.2004.23.287] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
624 Lee J, Lee Y, Yang S, Shi W, Lee C, Luh S, Chen C, Hsieh C, Wu M. Genetic polymorphisms ofp53 andGSTP1,but notNAT2,are associated with susceptibility to squamous-cell carcinoma of the esophagus. Int J Cancer 2000;89:458-64. [DOI: 10.1002/1097-0215(20000920)89:5<458::aid-ijc10>3.0.co;2-r] [Cited by in Crossref: 75] [Cited by in F6Publishing: 22] [Article Influence: 3.4] [Reference Citation Analysis]
625 Peng YC, Kuo F, Breiding DE, Wang YF, Mansur CP, Androphy EJ. AMF1 (GPS2) modulates p53 transactivation. Mol Cell Biol 2001;21:5913-24. [PMID: 11486030 DOI: 10.1128/MCB.21.17.5913-5924.2001] [Cited by in Crossref: 41] [Cited by in F6Publishing: 23] [Article Influence: 2.0] [Reference Citation Analysis]
626 Vautier G, Bomford AB, Portmann BC, Metivier E, Williams R, Ryder SD. p53 mutations in British patients with hepatocellular carcinoma: Clustering in genetic hemochromatosis. Gastroenterology 1999;117:154-60. [DOI: 10.1016/s0016-5085(99)70562-7] [Cited by in Crossref: 62] [Cited by in F6Publishing: 9] [Article Influence: 2.7] [Reference Citation Analysis]
627 Li Y, Cui K, Zhang Q, Li X, Lin X, Tang Y, Prochownik EV, Li Y. FBXL6 degrades phosphorylated p53 to promote tumor growth. Cell Death Differ 2021;28:2112-25. [PMID: 33568778 DOI: 10.1038/s41418-021-00739-6] [Reference Citation Analysis]
628 Porrello A, Soddu S, Zbilut JP, Crescenzi M, Giuliani A. Discrimination of single amino acid mutations of the p53 protein by means of deterministic singularities of recurrence quantification analysis. Proteins 2004;55:743-55. [DOI: 10.1002/prot.20075] [Cited by in Crossref: 14] [Cited by in F6Publishing: 12] [Article Influence: 0.8] [Reference Citation Analysis]
629 Roy B, Beamon J, Balint E, Reisman D. Transactivation of the human p53 tumor suppressor gene by c-Myc/Max contributes to elevated mutant p53 expression in some tumors. Mol Cell Biol 1994;14:7805-15. [PMID: 7969121 DOI: 10.1128/mcb.14.12.7805-7815.1994] [Cited by in Crossref: 76] [Article Influence: 2.7] [Reference Citation Analysis]
630 Shikama N, Lee CW, France S, Delavaine L, Lyon J, Krstic-Demonacos M, La Thangue NB. A novel cofactor for p300 that regulates the p53 response. Mol Cell 1999;4:365-76. [PMID: 10518217 DOI: 10.1016/s1097-2765(00)80338-x] [Cited by in Crossref: 149] [Cited by in F6Publishing: 78] [Article Influence: 6.5] [Reference Citation Analysis]
631 Naletova I, Satriano C, Curci A, Margiotta N, Natile G, Arena G, La Mendola D, Nicoletti VG, Rizzarelli E. Cytotoxic phenanthroline derivatives alter metallostasis and redox homeostasis in neuroblastoma cells. Oncotarget 2018;9:36289-316. [PMID: 30555630 DOI: 10.18632/oncotarget.26346] [Cited by in Crossref: 11] [Cited by in F6Publishing: 10] [Article Influence: 2.8] [Reference Citation Analysis]
632 Yue WW, Froese DS, Brennan PE. The role of protein structural analysis in the next generation sequencing era. Top Curr Chem 2014;336:67-98. [PMID: 22610134 DOI: 10.1007/128_2012_326] [Cited by in Crossref: 9] [Cited by in F6Publishing: 8] [Article Influence: 1.1] [Reference Citation Analysis]
633 Wölcke J, Reimann M, Klumpp M, Göhler T, Kim E, Deppert W. Analysis of p53 "latency" and "activation" by fluorescence correlation spectroscopy. Evidence for different modes of high affinity DNA binding. J Biol Chem 2003;278:32587-95. [PMID: 12813031 DOI: 10.1074/jbc.M303615200] [Cited by in Crossref: 28] [Cited by in F6Publishing: 5] [Article Influence: 1.5] [Reference Citation Analysis]
634 Würl P, Taubert H, Bache M, Kroll J, Meye A, Berger D, Siermann A, Holzhausen HJ, Hinze R, Schmidt H, Rath FW. Frequent occurrence of p53 mutations in rhabdomyosarcoma and leiomyosarcoma, but not in fibrosarcoma and malignant neural tumors. Int J Cancer 1996;69:317-23. [PMID: 8797875 DOI: 10.1002/(SICI)1097-0215(19960822)69:4<317::AID-IJC14>3.0.CO;2-2] [Cited by in Crossref: 25] [Cited by in F6Publishing: 8] [Article Influence: 1.0] [Reference Citation Analysis]
635 Semenza JC, Weasel LH. Molecular epidemiology in environmental health: the potential of tumor suppressor gene p53 as a biomarker. Environ Health Perspect 1997;105 Suppl 1:155-63. [PMID: 9114284 DOI: 10.1289/ehp.97105s1155] [Cited by in Crossref: 13] [Cited by in F6Publishing: 10] [Article Influence: 0.5] [Reference Citation Analysis]
636 Li D, Zhao R, Lilyestrom W, Gai D, Zhang R, DeCaprio JA, Fanning E, Jochimiak A, Szakonyi G, Chen XS. Structure of the replicative helicase of the oncoprotein SV40 large tumour antigen. Nature 2003;423:512-8. [PMID: 12774115 DOI: 10.1038/nature01691] [Cited by in Crossref: 224] [Cited by in F6Publishing: 223] [Article Influence: 11.8] [Reference Citation Analysis]
637 Yuan X, Jia X, Li H, Yu X, Wu Y. Red-emitting p53-protected gold nanoclusters and their screening of anti-tumor agents from Chinese medicine. RSC Adv 2017;7:34276-82. [DOI: 10.1039/c7ra05630c] [Cited by in Crossref: 1] [Article Influence: 0.2] [Reference Citation Analysis]
638 Landré V, Revi B, Mir MG, Verma C, Hupp TR, Gilbert N, Ball KL. Regulation of transcriptional activators by DNA-binding domain ubiquitination. Cell Death Differ 2017;24:903-16. [PMID: 28362432 DOI: 10.1038/cdd.2017.42] [Cited by in Crossref: 14] [Cited by in F6Publishing: 11] [Article Influence: 2.8] [Reference Citation Analysis]
639 Li Y, Bhuiyan M, Vaitkevicius VK, Sarkar FH. Molecular analysis of the p53 gene in pancreatic adenocarcinoma. Diagn Mol Pathol. 1998;7:4-9. [PMID: 9646028 DOI: 10.1097/00019606-199802000-00002] [Cited by in Crossref: 10] [Cited by in F6Publishing: 10] [Article Influence: 0.4] [Reference Citation Analysis]
640 Young KH, Leroy K, Møller MB, Colleoni GW, Sánchez-Beato M, Kerbauy FR, Haioun C, Eickhoff JC, Young AH, Gaulard P, Piris MA, Oberley TD, Rehrauer WM, Kahl BS, Malter JS, Campo E, Delabie J, Gascoyne RD, Rosenwald A, Rimsza L, Huang J, Braziel RM, Jaffe ES, Wilson WH, Staudt LM, Vose JM, Chan WC, Weisenburger DD, Greiner TC. Structural profiles of TP53 gene mutations predict clinical outcome in diffuse large B-cell lymphoma: an international collaborative study. Blood 2008;112:3088-98. [PMID: 18559976 DOI: 10.1182/blood-2008-01-129783] [Cited by in Crossref: 117] [Cited by in F6Publishing: 112] [Article Influence: 8.4] [Reference Citation Analysis]
641 Mann K. Methods for the study of redox-mediated changes in p53 structure and function. Methods Mol Biol 2008;476:117-38. [PMID: 19157013 DOI: 10.1007/978-1-59745-129-1_9] [Reference Citation Analysis]
642 Butturini E, Butera G, Pacchiana R, Carcereri de Prati A, Mariotto S, Donadelli M. Redox Sensitive Cysteine Residues as Crucial Regulators of Wild-Type and Mutant p53 Isoforms. Cells 2021;10:3149. [PMID: 34831372 DOI: 10.3390/cells10113149] [Reference Citation Analysis]
643 Chrisanthar R, Knappskog S, Løkkevik E, Anker G, Østenstad B, Lundgren S, Berge EO, Risberg T, Mjaaland I, Maehle L, Engebretsen LF, Lillehaug JR, Lønning PE. CHEK2 mutations affecting kinase activity together with mutations in TP53 indicate a functional pathway associated with resistance to epirubicin in primary breast cancer. PLoS One 2008;3:e3062. [PMID: 18725978 DOI: 10.1371/journal.pone.0003062] [Cited by in Crossref: 58] [Cited by in F6Publishing: 55] [Article Influence: 4.1] [Reference Citation Analysis]
644 Vainer R, Cohen S, Shahar A, Zarivach R, Arbely E. Structural Basis for p53 Lys120-Acetylation-Dependent DNA-Binding Mode. Journal of Molecular Biology 2016;428:3013-25. [DOI: 10.1016/j.jmb.2016.06.009] [Cited by in Crossref: 19] [Cited by in F6Publishing: 17] [Article Influence: 3.2] [Reference Citation Analysis]
645 Thomas M, Kalita A, Labrecque S, Pim D, Banks L, Matlashewski G. Two polymorphic variants of wild-type p53 differ biochemically and biologically. Mol Cell Biol 1999;19:1092-100. [PMID: 9891044 DOI: 10.1128/MCB.19.2.1092] [Cited by in Crossref: 460] [Cited by in F6Publishing: 178] [Article Influence: 20.0] [Reference Citation Analysis]
646 Gorina S, Pavletich NP. Structure of the p53 tumor suppressor bound to the ankyrin and SH3 domains of 53BP2. Science. 1996;274:1001-1005. [PMID: 8875926 DOI: 10.1126/science.274.5289.1001] [Cited by in Crossref: 370] [Cited by in F6Publishing: 365] [Article Influence: 14.2] [Reference Citation Analysis]
647 Martin TG, Bharat TA, Joerger AC, Bai XC, Praetorius F, Fersht AR, Dietz H, Scheres SH. Design of a molecular support for cryo-EM structure determination. Proc Natl Acad Sci U S A 2016;113:E7456-63. [PMID: 27821763 DOI: 10.1073/pnas.1612720113] [Cited by in Crossref: 74] [Cited by in F6Publishing: 57] [Article Influence: 12.3] [Reference Citation Analysis]
648 Huang C, Kohno N, Inufusa H, Kodama K, Taki T, Miyake M. Overexpression of bax associated with mutations in the loop-sheet-helix motif of p53. Am J Pathol 1999;155:955-65. [PMID: 10487853 DOI: 10.1016/s0002-9440(10)65195-4] [Cited by in Crossref: 16] [Cited by in F6Publishing: 4] [Article Influence: 0.7] [Reference Citation Analysis]
649 Wu Y, Huang H, Miner Z, Kulesz-Martin M. Activities and response to DNA damage of latent and active sequence-specific DNA binding forms of mouse p53. Proc Natl Acad Sci U S A 1997;94:8982-7. [PMID: 9256421 DOI: 10.1073/pnas.94.17.8982] [Cited by in Crossref: 12] [Cited by in F6Publishing: 16] [Article Influence: 0.5] [Reference Citation Analysis]
650 Bullock AN, Henckel J, Fersht AR. Quantitative analysis of residual folding and DNA binding in mutant p53 core domain: definition of mutant states for rescue in cancer therapy. Oncogene 2000;19:1245-56. [PMID: 10713666 DOI: 10.1038/sj.onc.1203434] [Cited by in Crossref: 270] [Cited by in F6Publishing: 260] [Article Influence: 12.3] [Reference Citation Analysis]
651 Brandt T, Petrovich M, Joerger AC, Veprintsev DB. Conservation of DNA-binding specificity and oligomerisation properties within the p53 family. BMC Genomics 2009;10:628. [PMID: 20030809 DOI: 10.1186/1471-2164-10-628] [Cited by in Crossref: 57] [Cited by in F6Publishing: 55] [Article Influence: 4.4] [Reference Citation Analysis]
652 Loh SN. Follow the Mutations: Toward Class-Specific, Small-Molecule Reactivation of p53. Biomolecules 2020;10:E303. [PMID: 32075132 DOI: 10.3390/biom10020303] [Cited by in Crossref: 12] [Cited by in F6Publishing: 11] [Article Influence: 6.0] [Reference Citation Analysis]
653 Ma W, Yang D, Gu Y, Guo X, Zhao W, Guo Z. Finding disease-specific coordinated functions by multi-function genes: insight into the coordination mechanisms in diseases. Genomics 2009;94:94-100. [PMID: 19427897 DOI: 10.1016/j.ygeno.2009.05.001] [Cited by in Crossref: 16] [Cited by in F6Publishing: 12] [Article Influence: 1.2] [Reference Citation Analysis]
654 Hollstein M, Shomer B, Greenblatt M, Soussi T, Hovig E, Montesano R, Harris CC. Somatic point mutations in the p53 gene of human tumors and cell lines: updated compilation. Nucleic Acids Res 1996;24:141-6. [PMID: 8594564 DOI: 10.1093/nar/24.1.141] [Cited by in Crossref: 306] [Cited by in F6Publishing: 287] [Article Influence: 11.8] [Reference Citation Analysis]
655 Ryk C, Berggren P, Kumar R, Hemminki K, Larsson P, Steineck G, Lambert B, Hou SM. Influence of GSTM1, GSTT1, GSTP1 and NAT2 genotypes on the p53 mutational spectrum in bladder tumours. Int J Cancer 2005;113:761-8. [PMID: 15499621 DOI: 10.1002/ijc.20650] [Cited by in Crossref: 17] [Cited by in F6Publishing: 18] [Article Influence: 1.0] [Reference Citation Analysis]
656 Rahnamoun H, Lu H, Duttke SH, Benner C, Glass CK, Lauberth SM. Mutant p53 shapes the enhancer landscape of cancer cells in response to chronic immune signaling. Nat Commun 2017;8:754. [PMID: 28963538 DOI: 10.1038/s41467-017-01117-y] [Cited by in Crossref: 34] [Cited by in F6Publishing: 36] [Article Influence: 6.8] [Reference Citation Analysis]
657 Choisy-rossi C, Reisdorf P, Yonish-rouach E. Mechanisms of p53-induced apoptosis: in search of genes which are regulated during p53-mediated cell death. Toxicology Letters 1998;102-103:491-6. [DOI: 10.1016/s0378-4274(98)00238-0] [Cited by in Crossref: 18] [Cited by in F6Publishing: 10] [Article Influence: 0.8] [Reference Citation Analysis]
658 Stengel A, Schnittger S, Weissmann S, Kuznia S, Kern W, Kohlmann A, Haferlach T, Haferlach C. TP53 mutations occur in 15.7% of ALL and are associated with MYC-rearrangement, low hypodiploidy, and a poor prognosis. Blood 2014;124:251-8. [PMID: 24829203 DOI: 10.1182/blood-2014-02-558833] [Cited by in Crossref: 70] [Cited by in F6Publishing: 72] [Article Influence: 8.8] [Reference Citation Analysis]
659 Gavrin LK, Denny RA, Saiah E. Small Molecules That Target Protein Misfolding. J Med Chem 2012;55:10823-43. [DOI: 10.1021/jm301182j] [Cited by in Crossref: 31] [Cited by in F6Publishing: 29] [Article Influence: 3.1] [Reference Citation Analysis]
660 Bochkareva E, Kaustov L, Ayed A, Yi GS, Lu Y, Pineda-Lucena A, Liao JC, Okorokov AL, Milner J, Arrowsmith CH, Bochkarev A. Single-stranded DNA mimicry in the p53 transactivation domain interaction with replication protein A. Proc Natl Acad Sci U S A 2005;102:15412-7. [PMID: 16234232 DOI: 10.1073/pnas.0504614102] [Cited by in Crossref: 204] [Cited by in F6Publishing: 199] [Article Influence: 12.0] [Reference Citation Analysis]
661 Hamroun D, Kato S, Ishioka C, Claustres M, Béroud C, Soussi T. The UMD TP53 database and website: update and revisions. Hum Mutat 2006;27:14-20. [DOI: 10.1002/humu.20269] [Cited by in Crossref: 100] [Cited by in F6Publishing: 86] [Article Influence: 6.3] [Reference Citation Analysis]
662 Saadi S, Saari N, Ghazali HM, Mohammed AS, Abdul-hamid A, Nacer NE, Anwar F. Lipopeptides in promoting signals at surface/interface of micelles: Their roles in repairing cellular and nuclear damages. Food Bioscience 2022;46:101522. [DOI: 10.1016/j.fbio.2021.101522] [Reference Citation Analysis]
663 Brázda V, Coufal J. Recognition of Local DNA Structures by p53 Protein. Int J Mol Sci 2017;18:E375. [PMID: 28208646 DOI: 10.3390/ijms18020375] [Cited by in Crossref: 24] [Cited by in F6Publishing: 22] [Article Influence: 4.8] [Reference Citation Analysis]
664 Lago CU, Sung HJ, Ma W, Wang PY, Hwang PM. p53, aerobic metabolism, and cancer. Antioxid Redox Signal 2011;15:1739-48. [PMID: 20919942 DOI: 10.1089/ars.2010.3650] [Cited by in Crossref: 39] [Cited by in F6Publishing: 31] [Article Influence: 3.5] [Reference Citation Analysis]
665 Chen L, Rashid F, Shah A, Awan HM, Wu M, Liu A, Wang J, Zhu T, Luo Z, Shan G. The isolation of an RNA aptamer targeting to p53 protein with single amino acid mutation. Proc Natl Acad Sci U S A 2015;112:10002-7. [PMID: 26216949 DOI: 10.1073/pnas.1502159112] [Cited by in Crossref: 66] [Cited by in F6Publishing: 62] [Article Influence: 9.4] [Reference Citation Analysis]
666 Welin M, Kosinska U, Mikkelsen NE, Carnrot C, Zhu C, Wang L, Eriksson S, Munch-Petersen B, Eklund H. Structures of thymidine kinase 1 of human and mycoplasmic origin. Proc Natl Acad Sci U S A 2004;101:17970-5. [PMID: 15611477 DOI: 10.1073/pnas.0406332102] [Cited by in Crossref: 85] [Cited by in F6Publishing: 81] [Article Influence: 4.7] [Reference Citation Analysis]
667 Wang G, Huang CH, Zhao Y, Cai L, Wang Y, Xiu SJ, Jiang ZW, Yang S, Zhao XT, Huang W, Gu JR. Genetic aberration in primary hepatocellular carcinoma: correlation between p53 gene mutation and loss-of-hetero- zygosity on chromosome 16q21-q23 and 9p21-p23. Cell Res 2000;10:311-23. [DOI: 10.1038/sj.cr.7290058] [Cited by in Crossref: 26] [Cited by in F6Publishing: 26] [Article Influence: 1.2] [Reference Citation Analysis]
668 Approved by the Commission in May 1997. Genetic susceptibility to cancer: ICRP Publication 79. Ann ICRP 1998;28:1-157. [DOI: 10.1016/s0146-6435(98)00007-3] [Cited by in Crossref: 26] [Article Influence: 4.3] [Reference Citation Analysis]
669 Malcikova J, Tichy B, Damborsky J, Kabathova J, Trbusek M, Mayer J, Pospisilova S. Analysis of the DNA-binding activity of p53 mutants using functional protein microarrays and its relationship to transcriptional activation. Biol Chem 2010;391:197-205. [PMID: 20128691 DOI: 10.1515/bc.2010.027] [Cited by in Crossref: 11] [Cited by in F6Publishing: 9] [Article Influence: 0.9] [Reference Citation Analysis]
670 Sahu G, Wang D, Chen CB, Zhurkin VB, Harrington RE, Appella E, Hager GL, Nagaich AK. p53 binding to nucleosomal DNA depends on the rotational positioning of DNA response element. J Biol Chem 2010;285:1321-32. [PMID: 19887449 DOI: 10.1074/jbc.M109.081182] [Cited by in Crossref: 40] [Cited by in F6Publishing: 29] [Article Influence: 3.1] [Reference Citation Analysis]
671 Prabakaran P, Siebers JG, Ahmad S, Gromiha MM, Singarayan MG, Sarai A. Classification of Protein-DNA Complexes Based on Structural Descriptors. Structure 2006;14:1355-67. [DOI: 10.1016/j.str.2006.06.018] [Cited by in Crossref: 33] [Cited by in F6Publishing: 29] [Article Influence: 2.1] [Reference Citation Analysis]
672 Oh JH, Ku JL, Yoon KA, Kwon HJ, Kim WH, Park HS, Yeo KS, Song SY, Chung JK, Park JG. Establishment and characterization of 12 human colorectal-carcinoma cell lines. Int J Cancer 1999;81:902-10. [PMID: 10362137 DOI: 10.1002/(sici)1097-0215(19990611)81:6<902::aid-ijc11>3.0.co;2-t] [Cited by in Crossref: 31] [Cited by in F6Publishing: 13] [Article Influence: 1.3] [Reference Citation Analysis]
673 Matsumura I, Ellington AD. In vitro evolution of thermostable p53 variants. Protein Sci 1999;8:731-40. [PMID: 10211819 DOI: 10.1110/ps.8.4.731] [Cited by in Crossref: 22] [Cited by in F6Publishing: 22] [Article Influence: 1.0] [Reference Citation Analysis]
674 Zhang X, Sjöblom T. Targeting Loss of Heterozygosity: A Novel Paradigm for Cancer Therapy. Pharmaceuticals (Basel) 2021;14:57. [PMID: 33450833 DOI: 10.3390/ph14010057] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
675 Kim DH, Han KH. Target-binding behavior of IDPs via pre-structured motifs. Prog Mol Biol Transl Sci 2021;183:187-247. [PMID: 34656329 DOI: 10.1016/bs.pmbts.2021.07.031] [Reference Citation Analysis]
676 Kuykendall A, Duployez N, Boissel N, Lancet JE, Welch JS. Acute Myeloid Leukemia: The Good, the Bad, and the Ugly. American Society of Clinical Oncology Educational Book 2018. [DOI: 10.1200/edbk_199519] [Cited by in Crossref: 29] [Cited by in F6Publishing: 12] [Article Influence: 7.3] [Reference Citation Analysis]
677 Li J, Xuan Z, Liu C. Long non-coding RNAs and complex human diseases. Int J Mol Sci 2013;14:18790-808. [PMID: 24036441 DOI: 10.3390/ijms140918790] [Cited by in Crossref: 113] [Cited by in F6Publishing: 108] [Article Influence: 12.6] [Reference Citation Analysis]
678 Warren AJ. Eukaryotic transcription factors. Current Opinion in Structural Biology 2002;12:107-14. [DOI: 10.1016/s0959-440x(02)00296-8] [Cited by in Crossref: 40] [Cited by in F6Publishing: 15] [Article Influence: 2.0] [Reference Citation Analysis]
679 Zeng X, Levine AJ, Lu H. Non-p53 p53RE binding protein, a human transcription factor functionally analogous to P53. Proc Natl Acad Sci U S A 1998;95:6681-6. [PMID: 9618472 DOI: 10.1073/pnas.95.12.6681] [Cited by in Crossref: 23] [Cited by in F6Publishing: 25] [Article Influence: 1.0] [Reference Citation Analysis]
680 Backvall H, Stromberg S, Gustafsson A, Asplund A, Sivertsson A, Lundeberg J, Ponten F. Mutation spectra of epidermal p53 clones adjacent to basal cell carcinoma and squamous cell carcinoma. Exp Dermatol 2004;13:643-50. [DOI: 10.1111/j.0906-6705.2004.00211.x] [Cited by in Crossref: 25] [Cited by in F6Publishing: 27] [Article Influence: 1.4] [Reference Citation Analysis]
681 Munch-Petersen HD, Asmar F, Dimopoulos K, Areškevičiūtė A, Brown P, Girkov MS, Pedersen A, Sjö LD, Heegaard S, Broholm H, Kristensen LS, Ralfkiaer E, Grønbæk K. TP53 hotspot mutations are predictive of survival in primary central nervous system lymphoma patients treated with combination chemotherapy. Acta Neuropathol Commun 2016;4:40. [PMID: 27101868 DOI: 10.1186/s40478-016-0307-6] [Cited by in Crossref: 10] [Cited by in F6Publishing: 11] [Article Influence: 1.7] [Reference Citation Analysis]
682 Okorokov AL, Milner J. An ATP/ADP-dependent molecular switch regulates the stability of p53-DNA complexes. Mol Cell Biol 1999;19:7501-10. [PMID: 10523638 DOI: 10.1128/MCB.19.11.7501] [Cited by in Crossref: 27] [Cited by in F6Publishing: 12] [Article Influence: 1.2] [Reference Citation Analysis]
683 Laptenko O, Beckerman R, Freulich E, Prives C. p53 binding to nucleosomes within the p21 promoter in vivo leads to nucleosome loss and transcriptional activation. Proc Natl Acad Sci U S A 2011;108:10385-90. [PMID: 21606339 DOI: 10.1073/pnas.1105680108] [Cited by in Crossref: 63] [Cited by in F6Publishing: 60] [Article Influence: 5.7] [Reference Citation Analysis]
684 Villiard E, Brinkmann H, Moiseeva O, Mallette FA, Ferbeyre G, Roy S. Urodele p53 tolerates amino acid changes found in p53 variants linked to human cancer. BMC Evol Biol 2007;7:180. [PMID: 17903248 DOI: 10.1186/1471-2148-7-180] [Cited by in Crossref: 38] [Cited by in F6Publishing: 35] [Article Influence: 2.5] [Reference Citation Analysis]
685 Mulder FA, Ayed A, Yang D, Arrowsmith CH, Kay LE. Assignment of 1H(N), 15N, 13C(alpha), 13CO and 13C(beta) resonances in a 67 kDa p53 dimer using 4D-TROSY NMR spectroscopy. J Biomol NMR 2000;18:173-6. [PMID: 11101222 DOI: 10.1023/a:1008317825976] [Cited by in Crossref: 19] [Cited by in F6Publishing: 12] [Article Influence: 0.9] [Reference Citation Analysis]
686 Chene P, Jahnke W. Oligomerization of p53 upon cooperative DNA binding: towards a structural understanding of p53 function. Angew Chem Int Ed Engl 2002;41:1702-4. [PMID: 19750689 DOI: 10.1002/1521-3773(20020517)41:10<1702::aid-anie1702>3.0.co;2-3] [Cited by in Crossref: 4] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
687 Arold S, Franken P, Strub M, Hoh F, Benichou S, Benarous R, Dumas C. The crystal structure of HIV-1 Nef protein bound to the Fyn kinase SH3 domain suggests a role for this complex in altered T cell receptor signaling. Structure 1997;5:1361-72. [DOI: 10.1016/s0969-2126(97)00286-4] [Cited by in Crossref: 159] [Cited by in F6Publishing: 88] [Article Influence: 6.4] [Reference Citation Analysis]
688 Park YR, Kim YM, Lee SW, Lee HY, Lee GE, Lee JE, Kim YT. Optimization to detect TP53 mutations in circulating cell-free tumor DNA from patients with serous epithelial ovarian cancer. Obstet Gynecol Sci 2018;61:328-36. [PMID: 29780774 DOI: 10.5468/ogs.2018.61.3.328] [Cited by in Crossref: 14] [Cited by in F6Publishing: 14] [Article Influence: 3.5] [Reference Citation Analysis]
689 Hollstein M, Hergenhahn M, Yang Q, Bartsch H, Wang Z, Hainaut P. New approaches to understanding p53 gene tumor mutation spectra. Mutation Research/Fundamental and Molecular Mechanisms of Mutagenesis 1999;431:199-209. [DOI: 10.1016/s0027-5107(99)00162-1] [Cited by in Crossref: 140] [Cited by in F6Publishing: 44] [Article Influence: 6.1] [Reference Citation Analysis]
690 Sykes SM, Stanek TJ, Frank A, Murphy ME, McMahon SB. Acetylation of the DNA binding domain regulates transcription-independent apoptosis by p53. J Biol Chem 2009;284:20197-205. [PMID: 19494119 DOI: 10.1074/jbc.M109.026096] [Cited by in Crossref: 48] [Cited by in F6Publishing: 35] [Article Influence: 3.7] [Reference Citation Analysis]
691 Inga A, Storici F, Darden TA, Resnick MA. Differential transactivation by the p53 transcription factor is highly dependent on p53 level and promoter target sequence. Mol Cell Biol 2002;22:8612-25. [PMID: 12446780 DOI: 10.1128/MCB.22.24.8612-8625.2002] [Cited by in Crossref: 137] [Cited by in F6Publishing: 80] [Article Influence: 7.2] [Reference Citation Analysis]
692 Saghiri MA, Asatourian A, Orangi J, Sorenson CM, Sheibani N. Functional role of inorganic trace elements in angiogenesis-Part II: Cr, Si, Zn, Cu, and S. Crit Rev Oncol Hematol 2015;96:143-55. [PMID: 26088455 DOI: 10.1016/j.critrevonc.2015.05.011] [Cited by in Crossref: 71] [Cited by in F6Publishing: 65] [Article Influence: 10.1] [